Join Clinical Trials for Acne and Other Skin Disorders

All Categories Medical Conditions » Skin Disorders

A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)

Condition: Psoriasis
Interventions: Drug: 80 mg ixekizumab Dosing Regimen; Drug: 50 mg etanercept; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2012
Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus

Condition: Skin Infection
Intervention: Drug: CG400549
Sponsors: CrystalGenomics, Inc.; CrystalGenomics, Inc.
Not yet recruiting - verified May 2012
An Observational Pilot Study Evaluating The Feasibility of Conducting Genomewide Association Studies Utilizing Subject-Provided Information in Subjects With Metastatic Breast Cancer Treated With Avastin (Bevacizumab)

Condition: Breast Cancer
Intervention:
Sponsors: Genentech; Genentech; 23andMe, Inc.
Recruiting - verified May 2012
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer

Condition: Breast Cancer
Intervention: Drug: enzalutamide
Sponsors: Medivation, Inc.; Medivation, Inc.; Astellas Pharma Inc
Recruiting - verified May 2012
Phase I Study of LJM716 in Combination With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast Cancer

Condition: Advanced HER2-positive Breast Cancer
Interventions: Drug: LJM716; Drug: Trastuzumab
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012
Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: PLX3397; Drug: Eribulin
Sponsors: University of California, San Francisco; Hope Rugo, MD; Susan G. Komen Breast Cancer Foundation; Plexxikon, Inc.; Eisai Inc.
Not yet recruiting - verified May 2012
Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer

Conditions: Lung Cancer; Non Small Cell Lung Cancer (NSCLC); Breast Cancer; ER+ Breast Cancer
Interventions: Drug: entinostat; Drug: entinostat; Drug: Erlotinib; Drug: Erlotinib; Drug: Exemestane; Drug: Exemestane
Sponsors: Syndax Pharmaceuticals; Syndax Pharmaceuticals
Recruiting - verified May 2012
A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer

Conditions: HER2 + Breast Cancer; HER2 + Gastric Cancer; Squamous Cell Carcinoma of Head and Neck
Intervention: Drug: LJM716
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012
Prospective Chart-Review: Impact of Combination - Digital Breast Tomosynthesis + Digital Mammography

Condition: Breast Cancer
Intervention:
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center
Recruiting - verified May 2012
Treatment of Staphylococcus Aureus Colonization in Hand Eczema

Conditions: Hand Eczema; Foot Eczema
Interventions: Drug: Retapamulin 1% ointment; Drug: Placebo
Sponsors: Mount Sinai School of Medicine; Gary Goldenberg
Recruiting - verified May 2012
Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2

Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Eribulin; Drug: 5-Fluorouracil; Drug: Epirubicin; Drug: Cyclophosphamide; Drug: Doxorubicin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Eisai Inc.
Not yet recruiting - verified May 2012
Use of Epidermal Expansion System for Epidermal Grafting on Hypopigmented Skin and Surgical Wounds

Conditions: Surgical Wound; Hypo-pigmented Skin
Intervention: Device: Momelan Technologies Epidermal Graft Harvesting System
Sponsors: Momelan Technologies; Momelan Technologies
Recruiting - verified May 2012
Ulthera® System for the Treatment of Moderate to Severe Facial Acne

Condition: Facial Acne
Intervention: Device: Ulthera System Treatment
Sponsors: Ulthera, Inc; Ulthera, Inc
Recruiting - verified May 2012
Enhancing Hair Density With Platelet Rich Fibrin Matrix (PRFM)

Condition: Alopecia
Intervention: Biological: PRFM treatment
Sponsors: The New York Eye & Ear Infirmary; The New York Eye & Ear Infirmary
Recruiting - verified May 2012
Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Glycopyrrolate (AIDES-G)

Conditions: Hyperhydrosis; Depression
Intervention: Drug: Glycopyrrolate
Sponsors: Thomas Jefferson University; Thomas Jefferson University
Recruiting - verified April 2012
Prospective Trial of Two Prone Breast Radiotherapy Techniques With Randomization to Concurrent Versus Weekly Boost

Condition: Breast Cancer
Intervention: Other: Radiation Therapy
Sponsors: New York University School of Medicine; New York University School of Medicine
Recruiting - verified May 2012
Cancer and Mindfulness-Based Cancer Recovery After Chemotherapy

Conditions: Cancer Survivor; Breast Cancer; Colorectal Cancer; Gynecological Cancer; Ovarian Cancer; Uterine Cancer
Intervention: Behavioral: Mindfulness Based Cancer Recovery
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Not yet recruiting - verified May 2012
Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra® & Compare Both to a Vehicle Control in Treatment of Interdigital Tinea Pedis

Condition: Tinea Pedis
Interventions: Drug: Butenafine HCl Cream, 1%; Drug: Lotrimin Ultra®; Drug: Butenafine Vehicle
Sponsors: Taro Pharmaceuticals USA; Taro Pharmaceuticals USA
Recruiting - verified April 2012
Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis

Condition: Tinea Pedis
Interventions: Drug: Naftifine HCl Cream 1%; Drug: Naftin® (Naftifine HCl) Cream 1%; Drug: Placebo topical cream
Sponsors: Taro Pharmaceuticals USA; Taro Pharmaceuticals USA
Not yet recruiting - verified April 2012
Safety Study of Topical Compound 31543 (Calcitriol, USP) in Patients Receiving Chemotherapy for Breast Cancer

Conditions: Alopecia; Breast Cancer
Intervention: Drug: compound 31543 Calcitriol
Sponsors: Berg Pharma,LLC; Berg Pharma,LLC
Not yet recruiting - verified April 2012
The Ultrasound Study of Tamoxifen

Condition: Breast Neoplasms
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012
Erlotinib Hydrochloride and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed By Surgery

Conditions: Squamous Cell Carcinoma of the Skin; Stage I Squamous Cell Carcinoma of the Hypopharynx; Stage I Squamous Cell Carcinoma of the Larynx; Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage I Squamous Cell Carcinoma of the Oropharynx; Stage I Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage I Verrucous Carcinoma of the Larynx; Stage I Verrucous Carcinoma of the Oral Cavity; Stage II Squamous Cell Carcinoma of the Hypopharynx; Stage II Squamous Cell Carcinoma of the Larynx; Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage II Squamous Cell Carcinoma of the Oropharynx; Stage II Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage II Verrucous Carcinoma of the Oral Cavity
Interventions: Drug: erlotinib hydrochloride; Procedure: therapeutic conventional surgery
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified April 2012
Home-Based Symptom Management Via Reflexology for Breast Cancer Patients

Condition: Breast Cancer
Intervention: Other: Reflexology
Sponsors: Michigan State University; Michigan State University; National Cancer Institute (NCI)
Recruiting - verified April 2012
Dynamic Plantar Microvascular Skin Response to Compressive Loads in At-risk Diabetic and Healthy Control: a Pilot Study

Condition: Foot Ulcer, Diabetic
Intervention:
Sponsors: Temple University; Temple University
Recruiting - verified June 2011
Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer

Condition: Pancreatic Ductal Adenocarcinoma
Intervention: Drug: Doxorubicin-EMCH
Sponsors: CytRx; CytRx
Not yet recruiting - verified May 2012
Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis

Condition: Psoriasis
Interventions: Drug: BI 655066 (high medium i.v. dose); Drug: BI 655066 (very low i.v. dose); Drug: BI 655066 (low i.v. dose); Drug: BI 655066 (low medium i.v. dose); Drug: BI 655066 (low s.c. dose); Drug: BI 655066 (high i.v. dose); Drug: BI 655066 (very high i.v. dose); Drug: Placebo, i.v.; Drug: BI 655066 (high s.c. dose); Drug: Placebo, s.c.
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012
Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction

Conditions: Breast Cancer; Pain, Postoperative; BRCA1 Mutation; BRCA2 Mutation; Breast Diseases; Neoplasms
Interventions: Drug: Botulinum Toxin Type A; Drug: Sodium Chloride Solution
Sponsors: Mayo Clinic; Mayo Clinic
Not yet recruiting - verified May 2012
Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis

Conditions: Chemical Injuries; Unspecified Complication of Corneal Transplant; Autoimmune Diseases; Ocular Cicatricial Pemphigoid; Stevens Johnson Syndrome; Lupus Erythematosus, Systemic; Rheumatoid Arthritis; Other Autoimmune Diseases
Intervention: Drug: Riboflavin
Sponsors: Massachusetts Eye and Ear Infirmary; Massachusetts Eye and Ear Infirmary
Recruiting - verified April 2012
A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route

Condition: Hereditary Angioedema Types I and II
Interventions: Biological: C1-esterase inhibitor - single intravenous dose; Biological: C1-esterase inhibitor - subcutaneous low dose; Biological: C1-esterase inhibitor - subcutaneous medium dose; Biological: C1-esterase inhibitor - subcutaneous high dose
Sponsors: CSL Behring; CSL Behring; Parexel
Recruiting - verified May 2012
National Breast Cancer and Lymphedema Registry

Conditions: Breast Cancer; Lymphedema
Intervention:
Sponsors: Stanford University; Stanley Rockson
Recruiting - verified April 2012
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Conditions: Dose Escalation; Safety; Preliminary Efficacy; Advanced Solid Tumors; Metastatic Breast Cancer; Advanced Pancreatic Adenocarcinoma; Metastatic Colorectal Cancer; Recurrent Glioblastoma Multiforme
Intervention: Drug: LDE225 and BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012
Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: tivantinib; Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: mutation analysis; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Dana-Farber Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified April 2012
Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old

Condition: Herpes Labialis
Intervention: Drug: acyclovir/hydrocortisone cream
Sponsors: Meda Pharmaceuticals; Meda Pharmaceuticals; TKL Research, Inc.
Recruiting - verified April 2012
Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea Tarda

Condition: Porphyria Cutanea Tarda
Interventions: Drug: Hydroxychloroquine; Procedure: Phlebotomy
Sponsors: The University of Texas, Galveston; The University of Texas, Galveston
Recruiting - verified April 2012
Topical Sodium Thiosulfate and Fractional Carbon Dioxide Laser in Treating Dermatomyositis Associated Calcinosis

Condition: Dermatomyositis Associated Superficial Calcinosis
Interventions: Device: Fractional Carbon Dioxide (FCO2) Laser (Candela QuadraLase (TM)); Drug: Sodium thiosulfate
Sponsors: George Washington University; George Washington University
Not yet recruiting - verified April 2012
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Condition: Breast Cancer
Interventions: Drug: BKM120; Drug: Paclitaxel; Drug: BKM120 matching placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012
Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer

Condition: Cancer
Interventions: Behavioral: survey, questionaire; Behavioral: survey, questionaire
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; St. Jude Children's Research Hospital; University of Colorado Cancer Center, Denver, CO; Dana-Farber Cancer Institute; University of Chicago
Recruiting - verified April 2012
Phase 2 Study of HL-009 Liposomal Gel to Treat Mild to Moderate Atopic Dermatitis

Condition: Mild to Moderate Atopic Dermatitis
Intervention: Drug: HL-009 Liposomal Gel
Sponsors: HanAll BioPharma Co., Ltd.; HanAll BioPharma Co., Ltd.
Recruiting - verified March 2012
Exercise in Breast Cancer Survivors

Conditions: Breast Cancer; Obesity
Intervention: Behavioral: Exercise
Sponsors: University of Mississippi Medical Center; University of Mississippi Medical Center
Recruiting - verified April 2012
To Evaluate the Safety, Tolerability and Efficacy of Calcipotriene Foam, 0.005%, Versus Vehicle Foam in Pediatric Subjects (Ages 2-11) With Plaque Psoriasis

Condition: Psoriasis
Interventions: Drug: STF 115469 Foam; Drug: Vehicle Foam
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified May 2012
Breast MRI for Newly Diagnosed Breast Cancer:Impact on Re-excision Lumpectomy

Condition: Breast Cancer
Intervention: Other: MRI
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Recruiting - verified March 2012
A Comparison of Recall Rates Between Conventional 2d Mammography and 2d Plus 3d (Tomosynthesis) Mammography in a Screening Population

Condition: Breast Cancer
Intervention:
Sponsors: Rose Imaging Specialists, P.A.; Rose Imaging Specialists, P.A.; Hologic, Inc.
Recruiting - verified March 2012
Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing

Conditions: Cutaneous Lymphoma; Other Skin Disorders; Mycosis Fungoides
Intervention:
Sponsors: Stanford University; Stanford University
Not yet recruiting - verified March 2012
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: trastuzumab [Herceptin]; Drug: pertuzumab; Drug: trastuzumab [Herceptin]; Drug: vinorelbine
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified April 2012
A Phase 1, Open-label, Multicenter, Safety and Pharmacokinetic Study of EDI200

Condition: X-linked Hypohidrotic Ectodermal Dysplasia
Intervention: Drug: EDI200
Sponsors: Edimer Pharmaceuticals; Edimer Pharmaceuticals
Not yet recruiting - verified March 2012
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax

Condition: Breast Cancer
Interventions: Drug: Herceptin; Drug: NeuVax vaccine; Drug: GM-CSF
Sponsors: San Antonio Military Medical Center; COL George Peoples, MD, FACS; Genentech; Galena Biopharma, Inc.
Not yet recruiting - verified April 2012
Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors

Condition: Advanced Solid Tumors, Excluding Breast Cancer
Interventions: Drug: caffeine; Drug: diclofenac; Drug: omeprazole; Drug: midazolam; Drug: TKI258
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012
Wound Fluid Protease Levels During Use of Novel Wound Dressing

Condition: Venous Stasis Ulcers
Intervention: Device: Novel Dressing
Sponsors: Hollister Incorporated; Hollister Incorporated
Recruiting - verified March 2012
Ruxolitinib in Patients With Breast Cancer

Condition: Breast Cancer
Intervention: Drug: Ruxolitinib
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Not yet recruiting - verified March 2012
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease

Conditions: Scleroderma, Systemic; Sclerosis, Systemic; Systemic Scleroderma; Systemic Sclerosis
Interventions: Drug: Pomalidomide (CC-4047); Drug: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Not yet recruiting - verified April 2012
A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis

Condition: Psoriasis
Interventions: Drug: Ustekinumab 45 mg; Drug: Ustekinumab 90 mg; Drug: Placebo
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified May 2012
Trial Comparing the Effects of Intermittent Vismodegib Versus Photodynamic Therapy in Patients With Multiple Basal Cell Carcinomas

Conditions: Basal Cell Nevus Syndrome; Gorlin's Syndrome
Interventions: Drug: GDC-0449; Procedure: Aminolevulinic acid %20 topical solution + blue light
Sponsors: Children's Hospital & Research Center Oakland; Children's Hospital & Research Center Oakland; Genentech
Not yet recruiting - verified March 2012
To Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Calcipotriene 0.005%, Applied Under Maximal Use Conditions in 12-16 Year Olds With Plaque Psoriasis

Condition: Psoriasis
Intervention: Drug: calcipotriene
Sponsors: GlaxoSmithKline; Stiefel, a GSK Company; GlaxoSmithKline
Recruiting - verified April 2012
Use of Artefill® for Moderate to Severe Atrophic Acne Scar Correction

Condition: Acne Scarring of the Face
Interventions: Drug: Normal Saline; Device: Artefill
Sponsors: Suneva Medical, Inc.; Suneva Medical, Inc.
Recruiting - verified March 2012
An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psoriasis

Condition: Moderate to Severe Plaque Psoriasis
Intervention: Other: No intervention
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified May 2012
Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Disseminated Neuroblastoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Plasma Cell Neoplasm; Poor Prognosis Metastatic Gestational Trophoblastic Tumor; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Neuroblastoma; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage II Ovarian Epithelial Cancer; Stage II Ovarian Germ Cell Tumor; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Malignant Testicular Germ Cell Tumor; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Ovarian Epithelial Cancer; Stage III Ovarian Germ Cell Tumor; Stage III Small Lymphocytic Lymphoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Breast Cancer; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Small Lymphocytic Lymphoma
Interventions: Procedure: management of therapy complications; Procedure: musculoskeletal complications management/prevention
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Not yet recruiting - verified May 2012
A Study to Evaluate the Effectiveness of STELARA ™ (USTEKINUMAB) in the Treatment of Scalp Psoriasis

Conditions: Scalp Psoriasis; Plaque Psoriasis
Interventions: Drug: Ustekinumab; Drug: Placebo
Sponsors: Yamauchi, Paul Steven, M.D., Ph.D.; Paul Steven Yamauchi, MD, PhD; Janssen Services, LLC
Not yet recruiting - verified March 2012
Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast Cancer

Condition: Breast Neoplasms
Interventions: Drug: lapatinib ditosylate; Biological: trastuzumab
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Not yet recruiting - verified March 2012
Grafix® DFU: Open-Label Extension Option to Evaluate Safety & Efficacy of Grafix® for Chronic Diabetic Foot Ulcers

Condition: Diabetic Foot Ulcers
Interventions: Other: Tissue; Other: Control
Sponsors: Osiris Therapeutics; Osiris Therapeutics
Recruiting - verified May 2012
The Use of Laser-Assisted Indocyanine Green Dye Angiography to Predict Mastectomy Skin Flap Viability

Conditions: Breast Cancer; Breast Reconstruction; Mastectomy
Intervention: Device: Laser-Assisted ICG Dye Angiography (SPY System)
Sponsors: Stony Brook University; Stony Brook University
Recruiting - verified March 2012
Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies

Conditions: Malignant Solid Tumour; Breast Cancer Nos Metastatic Recurrent; Neuropathy
Intervention: Drug: Eribulin in Combination w/ Cyclophosphamide
Sponsors: University of California, San Francisco; University of California, San Francisco; Eisai Inc.
Not yet recruiting - verified March 2012
IN-BALANCE VLU Inflammation, Bacteria, & Angiogenesis Effects in Launching Venous Leg Ulcer Healing

Condition: Venous Leg Ulcers
Intervention: Device: MIST Therapy
Sponsors: Celleration, Inc.; Celleration, Inc.
Not yet recruiting - verified March 2012
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: AC regimen; Drug: TAC regimen; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified May 2012
Prontosan Versus Saline in the Cleansing of Chronic Leg Ulcers in Diabetic Patients

Condition: Diabetic Complications
Interventions: Device: Prontosan; Device: Saline
Sponsors: B. Braun Medical Inc.; B. Braun Medical Inc.
Recruiting - verified May 2012
Human Amniotic Membrane Grafting and Standard of Care Versus Standard of Care Alone in the Treatment of Venous Leg Ulcers

Condition: Venous Leg Ulcer
Interventions: Other: 1 application of EpiFix; Other: 2 applications of EpiFix; Other: Standard of care
Sponsors: MiMedx Group, Inc.; MiMedx Group, Inc.
Recruiting - verified March 2012
Cancer Symptom Data From Multiple Treatment Centers

Conditions: Breast Cancer; Colon Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011
Comparative Study of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers

Condition: Diabetic Foot Ulcer
Interventions: Other: Standard of care; Other: Applications of EpiFix
Sponsors: MiMedx Group, Inc.; MiMedx Group, Inc.
Recruiting - verified March 2012
Immune Reactions in Contact Dermatitis Affected Skin

Condition: Allergic Contact Dermatitis
Intervention: Other: Patch tests
Sponsors: Rockefeller University; Rockefeller University
Recruiting - verified March 2012
IL1-TRAP, Rilonacept, in Systemic Sclerosis

Conditions: Scleroderma; Systemic Sclerosis; Diffuse Scleroderma; Diffuse Systemic Sclerosis
Interventions: Drug: Rilonacept; Drug: Placebo
Sponsors: Boston University; Boston University; Regeneron Pharmaceuticals
Recruiting - verified February 2012
Targeted Intraoperative Radiotherapy United States (TARGIT-US) Registry Trial

Conditions: Malignant Neoplasm of Breast; Breast Radiotherapy; Breast Diseases; Ductal Breast Carcinoma; Intraoperative Radiotherapy
Intervention: Radiation: Intraoperative radiation therapy (IORT)
Sponsors: University of California, San Francisco; University of California, San Francisco; H. Lee Moffitt Cancer Center and Research Institute; Northwestern University; Los Angeles Women's Health Clinic of California Hospital and Medical Center
Not yet recruiting - verified April 2012
ARQ197 in Metastatic Triple-Negative Breast Cancer

Condition: Breast Cancer
Intervention: Drug: ARQ 197
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Not yet recruiting - verified March 2012
Collection of FUJIFILM's 3Dimensional Mammograms

Condition: Breast Cancer
Interventions: Device: 3Dimensional Mammography; Device: 2D FFDM
Sponsors: Fujifilm Medical Systems USA, Inc.; Fujifilm Medical Systems USA, Inc.
Recruiting - verified March 2012
Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer

Condition: Early Stage Breast Cancer
Intervention: Drug: Denosumab
Sponsors: University of California, San Francisco; Hope Rugo, MD; University of California, San Francisco; Amgen
Not yet recruiting - verified March 2012
Prophylactic Treatment of Sleep/Fatigue Before and During Chemotherapy

Condition: Stage, Breast Cancer
Interventions: Behavioral: Brief behavioral treatment for insomnia and bright light; Behavioral: treatment as usual
Sponsors: University of California, San Diego; University of California, San Diego
Not yet recruiting - verified February 2012
Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa

Condition: Dystrophic Epidermolysis Bullosa
Intervention: Drug: Granulocyte Colony Stimulating Factor (GCSF)
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified February 2012
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Fulvestrant; Drug: Ganetespib
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Not yet recruiting - verified March 2012
Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients

Condition: Psoriasis, Plaque-type Psoriasis
Interventions: Drug: secukinumab; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Clinical Diagnosis of Acute Porphyria

Conditions: Hereditary Coproporphyria (HCP); Acute Intermittent Porphyria (AIP); Variegate Porphyria (VP)
Intervention:
Sponsors: University of California, San Francisco; University of California, San Francisco; University of Texas; University of Alabama at Birmingham; Mount Sinai School of Medicine; University of Utah; Carolinas Medical Center; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Rare Diseases Clinical Research Network
Recruiting - verified March 2012
Impact of Body Weight on Pharmacokinetic Analysis of Doxorubicin + Cyclophosphamide in Breast Cancer

Condition: Breast Cancer
Intervention:
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center; Texas Tech University Health Sciences Center
Not yet recruiting - verified January 2012
Evaluation of a Staphylococcus Eradication Protocol for Patients Who Present to the Emergency Department With Cutaneous Abscess

Condition: Cutaneous Abscess
Interventions: Drug: Chlorhexidine gluconate; Drug: Mupirocin
Sponsors: Tufts Medical Center; Tufts Medical Center
Recruiting - verified March 2012
A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp

Condition: Actinic Keratosis
Interventions: Procedure: Cryotherapy; Drug: Vehicle; Drug: Ingenol metabute
Sponsors: LEO Pharma; LEO Pharma
Recruiting - verified March 2012
Longitudinal Study of the Porphyrias

Conditions: Acute Porphyrias; Cutaneous Porphyrias
Intervention:
Sponsors: Mount Sinai School of Medicine; Mount Sinai School of Medicine
Recruiting - verified March 2012
Vascular Inflammation in Psoriasis Trial (The VIP Trial)

Conditions: Psoriasis; Cardiovascular Disease
Interventions: Drug: Adalimumab (Humira); Drug: Placebo Injection; Other: NB-UVB phototherapy
Sponsors: University of Pennsylvania; University of Pennsylvania
Not yet recruiting - verified March 2012
Observational Evaluation of the Peristomal Skin Condition in Ostomates

Condition: Ostomy
Intervention:
Sponsors: ConvaTec Inc.; ConvaTec Inc.
Recruiting - verified February 2012
A Mindfulness Meditation-Based Intervention for Younger Breast Cancer Survivors

Condition: Younger Breast Cancer Survivors
Intervention: Behavioral: Mindful Awareness practices (MAPs)
Sponsors: Jonsson Comprehensive Cancer Center; Jonsson Comprehensive Cancer Center; Susan G. Komen Breast Cancer Foundation
Recruiting - verified March 2012
Use of the Epidermal Micrografts for Wound Healing After Mohs or Excisional Surgery for Skin Cancer

Condition: Neoplasm of Skin
Intervention: Device: Momelan Technologies Epidermal Graft Harvesting System
Sponsors: Momelan Technologies; Momelan Technologies
Recruiting - verified February 2012
Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide

Conditions: Breast Cancer; Obesity
Interventions: Drug: Doxorubicin; Drug: Cyclophosphamide
Sponsors: Texas Tech University Health Sciences Center; Texas Tech University Health Sciences Center; University of Texas
Recruiting - verified April 2012
Cognitive Rehabilitation Group Intervention for Breast Cancer Survivors

Condition: Breast Cancer
Intervention: Behavioral: Improving Cognition with group intervention
Sponsors: Jonsson Comprehensive Cancer Center; Jonsson Comprehensive Cancer Center; Breast Cancer Research Foundation
Recruiting - verified April 2012
Exploratory Study of Topical Norepinephrine in Breast Cancer Patients Receiving Radiotherapy

Condition: Radiodermatitis
Intervention: Drug: Norepinephrine
Sponsors: ProCertus BioPharm, Inc; ProCertus BioPharm, Inc; H. Lee Moffitt Cancer Center and Research Institute
Recruiting - verified March 2012
Combination Therapy With 5-FU and PDT for the Treatment of Post-transplant Premalignant Skin Disease

Conditions: Actinic Keratosis; Solid Organ Transplant With Actinic Keratosis
Intervention: Drug: 5-Fluorouracil
Sponsors: The Cleveland Clinic; The Cleveland Clinic; National Cancer Institute (NCI)
Recruiting - verified February 2012
Evaluation of Daptomycin for the Emergency Department Treatment of Complicated Skin and Skin Structure Infections

Conditions: Cellulitis; Skin Infections
Interventions: Drug: Daptomycin; Drug: Vancomycin
Sponsors: University of Cincinnati; University of Cincinnati
Not yet recruiting - verified March 2012
Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol

Conditions: Sturge Weber Syndrome; Port Wine Mark
Interventions: Drug: Timolol; Drug: Balanced salt ophthalmic solution
Sponsors: Wills Eye; Wills Eye; University of Medicine and Dentistry New Jersey
Not yet recruiting - verified February 2012
Tracking & Feedback Registry to Reduce Breast Cancer Treatment Disparities

Condition: Breast Cancer
Interventions: Other: Tracking & Feedback; Other: Control
Sponsors: Mount Sinai School of Medicine; Mount Sinai School of Medicine; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012
Evaluation of BIS for Quantification of Lymphedema

Condition: Breast Cancer
Intervention: Other: Bioimpedance Spectroscopy
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified February 2012
A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis

Condition: Sclerosis, Systemic
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: Placebo; Drug: tocilizumab [RoActemra/Actemra]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
Tobacco Dependence in Breast Cancer Patients Scheduled for Mastectomy/Reconstructive Surgery Trial of Varenicline (Chantix)

Conditions: Breast Cancer; Tobacco Dependence
Interventions: Drug: placebo; Drug: varenicline
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Pfizer
Recruiting - verified February 2012
Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer

Condition: Breast Cancer
Intervention: Biological: 9 Peptides from Her-2/neu, CEA, & CTA + poly-ICLC
Sponsors: University of Virginia; University of Virginia
Not yet recruiting - verified February 2012
Patient Satisfaction in Cutaneous Surgery

Condition: Skin Cancer
Intervention:
Sponsors: Northwestern University; Northwestern University
Recruiting - verified February 2012
Pulsed Dye Laser (PDL) vs. Microsecond 1064-nm Nd:YAG Laser for Treatment of Diffuse Facial Redness

Condition: Rosacea
Intervention: Procedure: Pulse Dye Laser/YAG laser
Sponsors: Northwestern University; Northwestern University
Recruiting - verified February 2012
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients

Conditions: Hot Flashes; Breast Cancer
Interventions: Drug: solifenacin; Drug: Clonidine
Sponsors: University of Arkansas; University of Arkansas
Recruiting - verified February 2012
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Aplastic Anemia; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Grade III Lymphomatoid Granulomatosis; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Congenital Amegakaryocytic Thrombocytopenia; Diamond-Blackfan Anemia; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Paroxysmal Nocturnal Hemoglobinuria; Peripheral T-cell Lymphoma; Polycythemia Vera; Post-transplant Lymphoproliferative Disorder; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Secondary Myelofibrosis; Severe Combined Immunodeficiency; Severe Congenital Neutropenia; Shwachman-Diamond Syndrome; Splenic Marginal Zone Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Waldenstrom Macroglobulinemia; Wiskott-Aldrich Syndrome
Interventions: Drug: fludarabine phosphate; Drug: melphalan; Radiation: total-body irradiation; Drug: tacrolimus; Drug: mycophenolate mofetil; Drug: methotrexate; Other: laboratory biomarker analysis; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified March 2012
Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE)

Condition: Pseudoxanthoma Elasticum
Interventions: Drug: Magnesium Oxide; Drug: Placebo
Sponsors: Mount Sinai School of Medicine; Mark Lebwohl
Not yet recruiting - verified February 2012
Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Allergic Subjects

Conditions: Allergic Asthma; Allergic Dermatitis; Allegic Rhinitis
Interventions: Drug: Omalizumab; Drug: Placebo; Drug: MEDI4212
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified May 2012
A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study

Conditions: Major Cutaneous Abscess; Cellulitis; Erysipelas
Intervention: Drug: TR701 FA
Sponsors: Trius Therapeutics, Inc.; Trius Therapeutics, Inc.; Bayer
Recruiting - verified January 2012
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Dovitinib; Drug: Fulvestrant
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer

Condition: Locally Advanced HER2-Negative Breast Cancer
Interventions: Drug: Eribulin Mesylate; Drug: Cyclophosphamide; Drug: Docetaxel
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Eisai Inc.
Not yet recruiting - verified March 2012
Donor Atorvastatin Calcium in Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Donor Peripheral Blood Stem Cell Transplant

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Disseminated Neuroblastoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; High Risk Metastatic Gestational Trophoblastic Tumor; Juvenile Myelomonocytic Leukemia; Low Risk Metastatic Gestational Trophoblastic Tumor; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Plasma Cell Neoplasm; Previously Treated Childhood Rhabdomyosarcoma; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Gestational Trophoblastic Tumor; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Neuroblastoma; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Small Lymphocytic Lymphoma; Recurrent Wilms Tumor and Other Childhood Kidney Tumors; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage II Ovarian Epithelial Cancer; Stage II Ovarian Germ Cell Tumor; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Childhood Small Noncleaved Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Malignant Testicular Germ Cell Tumor; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Ovarian Epithelial Cancer; Stage III Ovarian Germ Cell Tumor; Stage III Small Lymphocytic Lymphoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Breast Cancer; Stage IV Childhood Hodgkin Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Childhood Small Noncleaved Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: atorvastatin calcium; Procedure: peripheral blood stem cell transplantation; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012
A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer

Condition: Breast Cancer
Intervention: Drug: PM01183
Sponsors: PharmaMar; PharmaMar
Not yet recruiting - verified January 2012
Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer

Conditions: Melanoma; Merkel Cell Carcinoma; Squamous Cell Carcinoma; Penile Carcinoma; Urethral Carcinoma; Extramammary Paget's Disease; Scrotal Carcinoma; Anal Cancer; Vulvar Cancer; Skin Cancer; Lymphadenopathy
Interventions: Procedure: Videoscopic procedure; Procedure: Open, traditional approach
Sponsors: Emory University; Emory University
Recruiting - verified February 2012
Antimicrobial Stewardship Through MRSA Diagnosis in Emergency Department (ED) Patients With Abscesses

Condition: Cutaneous Abscess
Intervention: Device: Xpert MRSA/SA SSTI
Sponsors: George Washington University; George Washington University; Johns Hopkins University
Recruiting - verified January 2012
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer

Conditions: Inflammatory Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-negative Breast Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel albumin-stabilized nanoparticle formulation; Other: laboratory biomarker analysis
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
ActiV.A.C.+ Compression Therapy Versus Compression Therapy Alone for the Treatment of Chronic Venous Ulcerations

Condition: Chronic Venous Hypertension With Ulcer
Intervention: Device: ActiVAC System + Compression therapy
Sponsors: Georgetown University; Georgetown University
Not yet recruiting - verified April 2012
Split-face Tolerability Comparison Between Adapalene-BPO Gel Versus Tretinoin Gel

Condition: Acne Vulgaris
Interventions: Drug: Epiduo Gel; Drug: Retin-A Micro Microsphere 0.1%
Sponsors: Galderma Laboratories, L.P.; Galderma Laboratories, L.P.
Recruiting - verified March 2012
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

Conditions: Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Adult Primary Hepatocellular Carcinoma; Chondrosarcoma; Clear Cell Sarcoma of the Kidney; Conjunctival Kaposi Sarcoma; Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; Hormone-resistant Prostate Cancer; Limited Stage Small Cell Lung Cancer; Localized Resectable Adult Primary Liver Cancer; Male Breast Cancer; Mast Cell Sarcoma; Ovarian Sarcoma; Recurrent Adult Brain Tumor; Recurrent Adult Primary Liver Cancer; Recurrent Adult Soft Tissue Sarcoma; Recurrent Bladder Cancer; Recurrent Breast Cancer; Recurrent Colon Cancer; Recurrent Esophageal Cancer; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Gastric Cancer; Recurrent Kaposi Sarcoma; Recurrent Melanoma; Recurrent Non-small Cell Lung Cancer; Recurrent Osteosarcoma; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Prostate Cancer; Recurrent Rectal Cancer; Recurrent Renal Cell Cancer; Recurrent Small Cell Lung Cancer; Recurrent Uterine Sarcoma; Small Intestine Leiomyosarcoma; Stage I Colon Cancer; Stage I Rectal Cancer; Stage I Uterine Sarcoma; Stage IA Breast Cancer; Stage IA Gastric Cancer; Stage IA Ovarian Epithelial Cancer; Stage IA Ovarian Germ Cell Tumor; Stage IB Breast Cancer; Stage IB Gastric Cancer; Stage IB Ovarian Epithelial Cancer; Stage IB Ovarian Germ Cell Tumor; Stage IC Ovarian Epithelial Cancer; Stage IC Ovarian Germ Cell Tumor; Stage II Breast Cancer; Stage II Uterine Sarcoma; Stage IIA Colon Cancer; Stage IIA Gastric Cancer; Stage IIA Non-small Cell Lung Cancer; Stage IIA Ovarian Epithelial Cancer; Stage IIA Ovarian Germ Cell Tumor; Stage IIA Rectal Cancer; Stage IIB Colon Cancer; Stage IIB Esophageal Cancer; Stage IIB Gastric Cancer; Stage IIB Melanoma; Stage IIB Non-small Cell Lung Cancer; Stage IIB Ovarian Epithelial Cancer; Stage IIB Ovarian Germ Cell Tumor; Stage IIB Rectal Cancer; Stage IIC Colon Cancer; Stage IIC Melanoma; Stage IIC Ovarian Epithelial Cancer; Stage IIC Ovarian Germ Cell Tumor; Stage IIC Rectal Cancer; Stage III Uterine Sarcoma; Stage IIIA Breast Cancer; Stage IIIA Colon Cancer; Stage IIIA Esophageal Cancer; Stage IIIA Gastric Cancer; Stage IIIA Melanoma; Stage IIIA Non-small Cell Lung Cancer; Stage IIIA Ovarian Epithelial Cancer; Stage IIIA Ovarian Germ Cell Tumor; Stage IIIA Rectal Cancer; Stage IIIB Breast Cancer; Stage IIIB Colon Cancer; Stage IIIB Esophageal Cancer; Stage IIIB Gastric Cancer; Stage IIIB Melanoma; Stage IIIB Ovarian Epithelial Cancer; Stage IIIB Ovarian Germ Cell Tumor; Stage IIIB Rectal Cancer; Stage IIIC Breast Cancer; Stage IIIC Colon Cancer; Stage IIIC Esophageal Cancer; Stage IIIC Gastric Cancer; Stage IIIC Melanoma; Stage IIIC Ovarian Epithelial Cancer; Stage IIIC Ovarian Germ Cell Tumor; Stage IIIC Rectal Cancer; Stage IV Bladder Cancer; Stage IV Esophageal Cancer; Stage IV Gastric Cancer; Stage IV Melanoma; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Prostate Cancer; Stage IV Renal Cell Cancer; Stage IV Uterine Sarcoma; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sirolimus; Other: laboratory biomarker analysis; Biological: DEC-205-NY-ESO-1 fusion protein vaccine
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified March 2012
Vytorin in the Treatment of Alopecia Areata

Condition: Alopecia Areata
Interventions: Drug: vytorin; Drug: vytorin
Sponsors: University of Miami; University of Miami
Recruiting - verified January 2012
A Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections Due to Staphylococci

Conditions: Skin and Subcutaneous Tissue Bacterial Infections; Wound Infection; Cutaneous Abscess; Burn Infection; Cellulitis
Intervention: Drug: AFN-12520000
Sponsors: Affinium Pharmaceuticals, Ltd; Affinium Pharmaceuticals, Ltd
Recruiting - verified May 2012
A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pedis

Condition: Tinea Pedis
Interventions: Drug: Oxiconazole Nitrate Cream 1%; Drug: Oxiconazole Nitrate Cream 1% (Oxistat®); Drug: Placebo
Sponsors: Taro Pharmaceuticals USA; Taro Pharmaceuticals USA
Recruiting - verified January 2012
Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers

Condition: Pediculosis
Interventions: Drug: Ha44; Drug: Ha44 Placebo; Drug: Moxifloxacin Placebo; Drug: Moxifloxacin
Sponsors: Hatchtech Pty Ltd; Hatchtech Pty Ltd
Not yet recruiting - verified January 2012
Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab

Condition: Psoriasis
Intervention: Drug: etanercept
Sponsors: Amgen; Amgen
Recruiting - verified April 2012
Attention and Interpretation Modification (AIM) for Fear of Breast Cancer Recurrence: An Intervention Development Study

Condition: Breast Cancer
Intervention: Behavioral: AIM materials and assessments
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Brown University; Weill Medical College of Cornell University
Recruiting - verified March 2012
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects

Condition: Metastatic Breast Cancer
Interventions: Biological: OPT-822/OPT-821; Biological: Phosphate Buffer Saline (PBS)
Sponsors: Optimer Pharmaceuticals; Optimer Biotechnology, Inc.
Recruiting - verified January 2012
The Preoperative Health & Body Study

Condition: Breast Cancer
Interventions: Behavioral: Exercise; Behavioral: Surgical preparation program
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Yale University; Susan G. Komen Breast Cancer Foundation
Recruiting - verified January 2012
Tumor Suppressor Status as a Predictor of Chemotherapy Response in Triple Negative Breast Cancer

Condition: Breast Cancer
Intervention:
Sponsors: Thomas Jefferson University; Thomas Jefferson University
Recruiting - verified January 2012
A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function

Condition: Breast Cancer
Intervention: Drug: trastuzumab emtansine
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
A Therapeutic Equivalence Study of Two Metronidazole 1%Topical Gel Treatments for Patients With Rosacea

Condition: Rosacea
Interventions: Drug: Metronidazole Topical Gel 1%; Drug: Metronidazole Topical Gel 1% (Metrogel); Drug: Placebo
Sponsors: Taro Pharmaceuticals USA; Taro Pharmaceuticals USA
Recruiting - verified January 2012
Photoprovocation Testing in Subjects With Cutaneous Lupus

Conditions: Lupus Erythematosus; Photosensitivity
Intervention: Other: Phototesting
Sponsors: University of Pennsylvania; University of Pennsylvania
Recruiting - verified January 2012
Ustekinumab Quality of Life Study

Condition: Psoriasis
Intervention: Drug: Ustekinumab
Sponsors: University of California, San Francisco; University of California, San Francisco
Not yet recruiting - verified January 2012
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim

Conditions: Chemotherapy-induced Neutropenia; Breast Cancer
Interventions: Drug: LA-EP2006; Drug: Peg-Filgrastim
Sponsors: Sandoz; Sandoz
Recruiting - verified January 2012
Clinical Trial of Simvastatin to Treat Generalized Vitiligo

Condition: Vitiligo
Interventions: Drug: Simvastatin; Drug: Placebo
Sponsors: University of Massachusetts, Worcester; University of Massachusetts, Worcester
Recruiting - verified April 2012
External-Beam Partial-Breast Irradiation for Early Breast Cancer 40 Gy QD Over 2 Weeks

Condition: Breast Cancer
Intervention: Radiation: External Beam Partial-Breast Irradiation
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital
Recruiting - verified May 2012
Prevalence and Clinical Severity of Cutaneous Lupus Erythematosus

Condition: Cutaneous Lupus Erythematosus
Intervention:
Sponsors: University of Pennsylvania; University of Pennsylvania
Recruiting - verified January 2012
Lifestyle Intervention for High Risk Cancer Survivors

Condition: Breast Cancer
Interventions: Behavioral: Exercise Program; Behavioral: Telephone Counseling Calls; Behavioral: Standard Care; Behavioral: Health Behavior Survey
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2012
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer.

Condition: Metastatic Breast Cancer
Interventions: Drug: Veliparib; Drug: Temozolomide; Drug: Carboplatin; Drug: Paclitaxel; Drug: Placebo
Sponsors: Abbott; Abbott
Recruiting - verified March 2012
Real Time Optical Coherence Tomography (OCT) of Human Tissue

Condition: Breast Cancer
Intervention: Device: Optical Coherence Tomography
Sponsors: Diagnostic Photonics, Inc.; Diagnostic Photonics, Inc.; University of Illinois
Not yet recruiting - verified March 2012
Vitamin D Status, Disease Specific and Quality of Life Outcomes in Patients With Cutaneous Lupus

Condition: Cutaneous Lupus Erythematosus
Intervention: Dietary Supplement: vitamin D
Sponsors: Emory University; Emory University; Dermatology Foundation
Recruiting - verified January 2012
Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study

Condition: Psoriasis
Intervention:
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Immunex Corporation
Recruiting - verified February 2012
Effect of Samples on Acne Treatment With Epiduo® Gel

Condition: Acne Vulgaris
Interventions: Drug: Adapalene + benzoyl peroxide samples; Drug: Adapalene + benzoyl peroxide from standard tube
Sponsors: Wake Forest University; Wake Forest University; Galderma Laboratories, L.P.
Recruiting - verified January 2012
Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer

Conditions: Breast Cancer; Invasive Adenocarcinoma of the Breast
Interventions: Procedure: Cryoablation; Biological: Ipilimumab
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012
The Immune System's Response to Young Women's Breast Cancer

Conditions: Breast Cancer; Young Women Breast Cancer; Pregnancy Associated Breast Cancer
Intervention:
Sponsors: University of Colorado, Denver; University of Colorado, Denver
Recruiting - verified December 2011
Part II: Exercise in Hispanic Breast Cancer Survivors

Condition: Breast Cancer
Interventions: Behavioral: Baseline Fitness Test; Behavioral: Questionnaires; Behavioral: Individualized Exercise Program; Behavioral: Written Materials
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012
BKM120 in Cancers With PIK3CA Activating Mutations

Conditions: Lung Cancer; Breast Cancer; Colorectal Cancer; Cholangiocarcinoma; Solid Tumors
Intervention: Drug: BKM120
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Novartis Pharmaceuticals
Recruiting - verified April 2012
Epigenetic Testing for Breast Cancer Risk Stratification

Condition: Breast Cancer
Intervention:
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center; Department of Defense
Not yet recruiting - verified September 2011
Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris

Condition: Acne Vulgaris
Interventions: Drug: Placebo; Drug: gevokizumab; Drug: gevokizumab
Sponsors: XOMA (US) LLC; XOMA (US) LLC
Recruiting - verified December 2011
A Phase 2b Study of LY3009104 in Participants With Moderate to Severe Psoriasis

Conditions: Psoriasis; Skin Diseases; Skin Diseases, Papulosquamous
Interventions: Drug: Placebo; Drug: LY3009104
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Incyte Corporation
Recruiting - verified May 2012
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections

Condition: Complicated Skin and Soft Tissue Infection
Interventions: Drug: Ceftaroline fosamil; Drug: Vancomycin; Drug: Aztreonam
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Not yet recruiting - verified March 2012
MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I

Condition: Breast Cancer
Interventions: Drug: TAC chemotherapy; Drug: TC chemotherapy; Drug: Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy; Drug: TCH chemotherapy
Sponsors: Agendia; Agendia; University of South Florida; University of Miami
Recruiting - verified January 2012
Fluoride Varnish for Treatment of White Spot Lesions

Condition: White Spot Lesions
Interventions: Device: Vanish varnish; Device: Oral B Minute-Gel
Sponsors: 3M; 3M; University of Tennessee Health Science Center
Recruiting - verified February 2012
Therapy to Prevent Sexual Pain in Breast Cancer Survivors

Conditions: Vulvodynia; Dyspareunia; Breast Cancer; Menopause
Intervention: Drug: Topical liquid lidocaine
Sponsors: Oregon Health and Science University; Oregon Health and Science University
Recruiting - verified February 2012
Probiotics in Patients With Moderate-to-severe Distention/ Bloating From Systemic Sclerosis

Condition: Improvement in Distention/Bloating Scale ≥ 0.14 at the End of 4 Weeks.
Intervention: Drug: Lactobacillus
Sponsors: University of Michigan; University of Michigan
Not yet recruiting - verified December 2011
Effect of Diet and Exercise in Breast Cancer Survivors

Conditions: Breast Cancer; Obesity
Intervention: Behavioral: aerobic exercise
Sponsors: West Virginia University; West Virginia University
Recruiting - verified February 2012
ADRN Influenza Vaccine Pilot

Condition: Atopic Dermatitis
Intervention: Drug: Fluzone® Intradermal (Sanofi Pasteur Inc.)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified December 2011
Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema

Condition: Angiotensin-converting Enzyme (ACE) Inhibitor-associated Angioedema
Interventions: Drug: HOE-140; Other: Placebo
Sponsors: Vanderbilt University; Vanderbilt University; University of California, San Diego; Massachusetts General Hospital; University of California, Los Angeles
Recruiting - verified April 2012
Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors

Conditions: Cancer Survivor; Human Papilloma Virus Infection
Interventions: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine; Other: questionnaire administration; Other: laboratory biomarker analysis; Other: survey administration; Other: medical chart review
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Not yet recruiting - verified December 2011
Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells

Conditions: Mestatic Melanoma; Skin Cancer
Interventions: Drug: Fludarabine; Drug: Cycolphosphamide; Drug: Aldesleukin; Drug: MART-1 Reactive CD8+ PBL
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified April 2012
HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Condition: Breast Cancer
Interventions: Drug: HKI-272; Drug: HKI-272; Procedure: Surgical Resection
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Translational Breast Cancer Research Consortium
Recruiting - verified February 2012
Phase 3 Papulopustular Rosacea Study

Condition: Papulopustular Rosacea (PPR)
Interventions: Drug: CD5024; Drug: Azelaic acid 15% Gel
Sponsors: Galderma; Galderma
Recruiting - verified April 2012
Phase 3 Papulopustular Rosacea Study

Condition: Papulopustular Rosacea
Interventions: Drug: CD5024; Drug: Azelaic acid 15% Gel
Sponsors: Galderma; Galderma
Recruiting - verified April 2012
Study of How Well Letrozole Works in Combination With Lapatinib Followed by an Addition of Everolimus in Postmenopausal Women With Advanced Endocrine Resistant Breast Cancer

Conditions: Breast Neoplasms; Endocrine Breast Diseases; Neoplasm Metastasis
Interventions: Drug: letrozole; Drug: lapatinib; Drug: everolimus
Sponsors: University of Maryland; University of Maryland; Novartis Pharmaceuticals; GlaxoSmithKline
Not yet recruiting - verified December 2011
The BEACON Study (Breast Cancer Outcomes With NKTR-102)

Conditions: Locally Recurrent Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: NKTR-102; Drug: Treatment of Physician's Choice (TPC)
Sponsors: Nektar Therapeutics; Nektar Therapeutics
Recruiting - verified April 2012
Anakinra as a Treatment for Hydradenitis Suppurativa

Condition: Hidradenitis Suppurativa
Intervention: Drug: anakinra
Sponsors: University of California, San Francisco; University of California, San Francisco
Not yet recruiting - verified March 2012
Study of the 532 nm KTP Laser for the Treatment of Poikiloderma of Civatte

Conditions: Poikiloderma of Civatte; Dyschromia; Pigmentation Disorders; Telangiectasia; Photosensitivity Disorders
Intervention: Device: 532 nm KTP laser
Sponsors: Cutera Inc.; Cutera Inc.
Recruiting - verified December 2011
Quantitative Subharmonic Breast Imaging

Condition: Breast Cancer
Intervention: Other: 3D HI and SHI of ultrasound contrast agent
Sponsors: Thomas Jefferson University; Thomas Jefferson University; National Cancer Institute (NCI); Lantheus Medical Imaging; University of California, San Diego
Recruiting - verified December 2011
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: trastuzumab; Drug: Aromatase Inhibitor; Drug: Induction Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
Alkaline Water in Reducing Skin Toxicity in Women With Breast Cancer Undergoing Radiation Therapy

Conditions: Radiation Toxicity; Recurrent Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer
Interventions: Dietary Supplement: alkaline water; Dietary Supplement: distilled water; Radiation: external beam radiation therapy (EBRT)
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012
Integrative Approaches for Cancer Survivorship

Condition: Breast Cancer
Intervention: Behavioral: Individualized manualized Ayurvedic intervention
Sponsors: University of California, San Francisco; University of California, San Francisco; National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified March 2012
Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Condition: Plaque Psoriasis
Intervention: Drug: Apo805K1
Sponsors: ApoPharma; ApoPharma
Recruiting - verified January 2012
Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers

Condition: Leishmaniasis
Interventions: Biological: LEISH-F3 + GLA-SE; Biological: LEISH-F3 + GLA-SE; Biological: LEISH-F3 alone
Sponsors: Infectious Disease Research Institute; Infectious Disease Research Institute
Recruiting - verified January 2012
A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis

Condition: Psoriasis
Interventions: Drug: CNTO 1959 (5 mg); Drug: CNTO 1959 (15 mg); Drug: CNTO 1959 (50 mg); Drug: CNTO 1959 (100 mg); Drug: CNTO 1959 (200 mg); Drug: Adalimumab; Drug: Placebo to CNTO 1959 (100 mg)
Sponsors: Janssen Inc.; Janssen Inc.
Recruiting - verified February 2012
Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer

Conditions: Male Breast Cancer; Recurrent Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: mifepristone; Drug: placebo; Drug: nab-paclitaxel
Sponsors: University of Chicago; Rita Nanda
Recruiting - verified December 2011
Deposition of Terbinafine After Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail

Condition: Onychomycosis
Intervention: Drug: Terbinafine HCl
Sponsors: Nitric BioTherapeutics, Inc; Nitric BioTherapeutics, Inc
Recruiting - verified December 2011
Patient Factors Impacting Adherence to Oral Chemotherapy

Conditions: Breast Cancer; Gastrointestinal Cancer
Intervention: Behavioral: questionnaire and interview
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012
Understanding Patient Perspectives on the Risks of Ionizing Radiation Used for Medical Imaging

Conditions: Breast Cancer; Colon Cancer; Lung Cancer; Neuroblastoma; Testicular Cancer
Interventions: Behavioral: Focus Group Sessions; Behavioral: Focus Group Sessions; Behavioral: Focus Group Sessions; Behavioral: Focus Group Sessions; Behavioral: Focus Group Sessions; Behavioral: Focus Group Sessions
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012
A Study of Oral Rucaparib in Patients With gBRCA Mutation Breast or Ovarian Cancer, or Other Solid Tumor

Conditions: Metastatic Solid Tumor; Breast Cancer; Ovarian Cancer
Intervention: Drug: Rucaparib
Sponsors: Clovis Oncology, Inc.; Clovis Oncology, Inc.
Recruiting - verified May 2012
Imaging Study for FdCyd and THU Cancer Treatment

Conditions: Head and Neck Neoplasms; Lung Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms
Interventions: Drug: Tetrahydrouridine (THU); Drug: [F-18]-5-FLUORO-2'-DEOXYCYTIDINE
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified October 2011
Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab

Condition: Breast Cancer
Interventions: Drug: AMG 479; Drug: Trastuzumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Amgen
Not yet recruiting - verified November 2011
Efficacy and Safety Study of NeuVax(TM) Vaccine to Prevent Breast Cancer Recurrence

Condition: HER2 Negative Breast Cancer
Interventions: Biological: NeuVax vaccine; Biological: Leukine (sargramostim, GM-CSF) and water for injection
Sponsors: Galena Biopharma, Inc.; Galena Biopharma, Inc.
Recruiting - verified May 2012
Phase II Trial of RA-18C3 in Subjects With Moderate to Severe Acne Vulgaris

Condition: Acne Vulgaris
Intervention: Drug: RA-18C3
Sponsors: XBiotech, Inc.; XBiotech, Inc.
Recruiting - verified April 2012
NBRST: Prospective Neo-adjuvant REGISTRY Trial

Condition: Breast Cancer
Interventions: Device: MammaPrint; Device: BluePrint; Device: TargetPrint; Device: TheraPrint
Sponsors: Agendia; Agendia
Recruiting - verified April 2012
A Phase 3 Study in Participants With Moderate to Severe Psoriasis

Condition: Psoriasis
Interventions: Drug: 80mg LY2439821 Dosing Regimen; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy

Condition: Arthritis, Psoriatic
Interventions: Biological: Placebo matching BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified January 2012
A Multicenter "Ablate and Resect" Study of Novilase® Interstitial Laser Therapy for the Ablation of Small Breast Cancers

Condition: Malignant Tumor
Intervention: Device: Novilase Interstitial Laser Therapy
Sponsors: Novian Health Inc.; Novian Health Inc.
Recruiting - verified April 2012
GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

Conditions: Breast Cancer; Brain Metastases
Interventions: Drug: GRN1005; Drug: Trastuzumab
Sponsors: Geron Corporation; Geron Corporation
Recruiting - verified May 2012
Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK)

Condition: Actinic Keratosis
Interventions: Drug: Broad Area ALA 1-hour incubation; Drug: Broad Area ALA 2-hr incubation; Drug: broad area ALA 3-hour incubation; Drug: Spot application ALA 2 hour incubation; Drug: Vehicle PDT
Sponsors: DUSA Pharmaceuticals, Inc.; DUSA Pharmaceuticals, Inc.
Recruiting - verified February 2012
Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole

Conditions: Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
Interventions: Dietary Supplement: omega-3 fatty acid; Other: placebo; Procedure: quality-of-life assessment; Procedure: assessment of therapy complications; Procedure: magnetic resonance imaging; Other: laboratory biomarker analysis; Other: questionnaire administration
Sponsors: Ohio State University Comprehensive Cancer Center; Maryam Lustberg; Cancer and Leukemia Group B; Alliance
Recruiting - verified May 2012
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa

Condition: Hidradenitis Suppurativa (HS)
Interventions: Biological: adalimumab; Biological: placebo; Biological: adalimumab
Sponsors: Abbott; Abbott
Recruiting - verified March 2012
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa

Condition: Hidradenitis Suppurativa (HS)
Interventions: Biological: adalimumab; Biological: placebo; Biological: adalimumab
Sponsors: Abbott; Abbott
Recruiting - verified December 2011
Vitamin D and Breast Cancer in Obesity: Therapeutic Trials

Condition: Breast Cancer
Interventions: Drug: Vitamin D3; Drug: Vitamin D3
Sponsors: Stanford University; Robert Carlson
Recruiting - verified December 2011
Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis

Condition: Atopic Dermatitis
Intervention: Drug: Fluocinonide cream
Sponsors: Wake Forest University; Wake Forest University; Medicis Pharmaceutical Corporation
Recruiting - verified November 2011
Evaluation of Specific Biomarkers in Primary Invasive Breast Cancer

Condition: Primary Invasive Breast Cancer
Intervention:
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified May 2012
Neuropsychologic and Electrophysiological Features of Cancer-Related Cognitive Side Effects in Racial and Ethnic Minority Breast Cancer Patients

Condition: Breast Cancer
Interventions: Other: EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire; Other: EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire; Other: EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; The City College of New York; Ralph Lauren Center for Cancer Care and Prevention; Lincoln Hospital
Recruiting - verified November 2011
A Retrospective Study to Evaluate the Effectiveness of the Ulthera System

Conditions: Skin Laxity; Wrinkles
Intervention:
Sponsors: Ulthera, Inc; Ulthera, Inc
Recruiting - verified January 2012
Examining a Common Complaint of Women Who Receive Chemotherapy for Breast Cancer- Cognitive Difficulty

Conditions: Breast Cancer; Neurocognitive Impairment; Quality of Life
Intervention: Other: Neurocognitive impairment observation
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University; National Institute of Nursing Research (NINR)
Not yet recruiting - verified March 2012
A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus

Condition: Cutaneous Lupus Erythematosus
Interventions: Drug: PD-0360324; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Metformin; Other: Placebo
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Susan G. Komen Breast Cancer Foundation
Not yet recruiting - verified February 2012
The Young Women's Breast Cancer Study

Condition: Breast Cancer
Intervention:
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Recruiting - verified November 2011
Registry for the Atopic Dermatitis Research Network

Conditions: Atopic Dermatitis; Eczema Herpeticum
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012
A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus

Condition: Discoid Lupus
Interventions: Drug: CC-930; Drug: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified March 2012
Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris

Condition: Psoriasis Vulgaris
Interventions: Drug: CT327 0.05%; Drug: CT327 0.1%; Drug: CT327 0.5%; Drug: Placebo
Sponsors: Creabilis SA; Creabilis SA
Recruiting - verified May 2012
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients

Conditions: Systemic Sclerosis; Ulcers
Interventions: Drug: macitentan 3mg; Drug: macitentan 10mg; Drug: placebo
Sponsors: Actelion; Actelion
Recruiting - verified May 2012
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients

Conditions: Systemic Sclerosis; Ulcers
Interventions: Drug: macitentan 3mg; Drug: macitentan 10mg; Drug: placebo
Sponsors: Actelion; Actelion
Recruiting - verified May 2012
Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults

Condition: Breast Cancer
Intervention:
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Institutes of Health (NIH); National Institute on Aging (NIA)
Recruiting - verified November 2011
Development of a Nanosecond Pulsed Electric Field System to Treat Skin Cancer

Condition: Basal Cell Carcinomas
Intervention: Device: PulseCure pulse generator and Derm-pulse electrode
Sponsors: Children's Hospital & Research Center Oakland; Children's Hospital & Research Center Oakland
Recruiting - verified October 2011
Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib

Conditions: Breast Cancer; Breast Neoplasm
Intervention: Drug: Pazopanib
Sponsors: University of California, San Francisco; Hope Rugo, MD; GlaxoSmithKline
Recruiting - verified April 2012
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Older Patients With Metastatic Breast Cancer

Conditions: Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation; Other: questionnaire administration
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012
Grafting of Epidermolysis Bullosa Wounds Using Cultured Revertant Autologous Keratinocytes

Condition: Epidermolysis Bullosa
Intervention: Procedure: Grafting of Autologous Cultured Revertant Keratinocytes
Sponsors: Stanford University; Stanford University
Recruiting - verified October 2011
Web-based Support to Manage Arthritis Pain

Conditions: Osteoarthritis; Rheumatoid Arthritis; Ankylosing Spondylitis; Other Arthritic Conditions (e.g., Psoriatic Arthritis)
Intervention: Behavioral: painACTION: Arthritis
Sponsors: Inflexxion, Inc.; Inflexxion, Inc.
Recruiting - verified October 2011
Levulan PDT Versus Vehicle for Extremity Actinic Keratoses (AK)

Condition: Keratosis, Actinic
Interventions: Drug: Aminolevulinic Acid PDT (ALA); Drug: Vehicle PDT (VEH)
Sponsors: DUSA Pharmaceuticals, Inc.; DUSA Pharmaceuticals, Inc.
Recruiting - verified November 2011
Correlates of Oral Human Papillomavirus Infection in Adolescents and Young Adults With Behaviorally Acquired HIV

Condition: HIV Infection
Intervention:
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH)
Recruiting - verified November 2011
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia

Conditions: Adult Acute Lymphoblastic Leukemia; Adult Acute Myeloid Leukemia; Adult Burkitt Lymphoma; Adult Diffuse Large Cell Lymphoma; Adult Diffuse Mixed Cell Lymphoma; Adult Diffuse Small Cleaved Cell Lymphoma; Adult Hodgkin Lymphoma; Adult Immunoblastic Large Cell Lymphoma; Adult Lymphoblastic Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Breast Cancer; Chronic Eosinophilic Leukemia; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Cutaneous T-cell Non-Hodgkin Lymphoma; Disseminated Neuroblastoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3 Follicular Lymphoma; Malignant Testicular Germ Cell Tumor; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Multiple Myeloma; Mycosis Fungoides/Sezary Syndrome; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Neutropenia; Nodal Marginal Zone B-cell Lymphoma; Ovarian Epithelial Cancer; Ovarian Germ Cell Tumor; Plasma Cell Neoplasm; Poor Prognosis Metastatic Gestational Trophoblastic Tumor; Primary Myelofibrosis; Prolymphocytic Leukemia; Small Lymphocytic Lymphoma; Splenic Marginal Zone Lymphoma
Intervention: Drug: cefepime hydrochloride
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified November 2011
Vascular and Cognitive Assessments in Patients With Breast Cancer Undergoing Chemotherapy After Surgery

Conditions: Cognitive/Functional Effects; Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
Interventions: Procedure: ultrasound imaging; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment; Procedure: magnetic resonance imaging
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified February 2012
Forehead Scars Following Mohs Micrographic Surgery and Reconstruction for Skin Cancer

Condition: Scar
Interventions: Drug: Dysport (abobotulinumtoxinA); Drug: Bacteriostatic 0.9% Sodium Chloride (vehicle)
Sponsors: AboutSkin Dermatology and DermSurgery, PC; AboutSkin Dermatology and DermSurgery, PC; University Hospitals of Cleveland; Medicis Pharmaceutical Corporation
Recruiting - verified January 2012
Efficacy, Safety and Tolerability of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema

Condition: Hereditary Angioedema
Intervention: Drug: Icatibant
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Shire Human Genetic Therapies, Inc.
Recruiting - verified April 2012
Study of ABT-700 in Subjects With Advanced Solid Tumors

Condition: Subjects With Advanced Solid Tumors (Including, But Not Limited to Gastric, Head and Neck, NSCLC, Colon, Mesothelioma and Triple Negative Breast Cancer).
Interventions: Drug: ABT-700; Drug: ABT-700 plus erlotinib; Drug: ABT-700 plus Oxaliplatin and Capecitabine
Sponsors: Abbott; Abbott
Recruiting - verified March 2012
Diode Laser Treatment of Onychomycosis

Condition: Onychomycosis
Intervention: Device: Diode Laser Treatment
Sponsors: ConBio, a Cynosure Company; ConBio, a Cynosure Company
Recruiting - verified October 2011
Experience of Non-Melanoma Skin Cancer (NMSC) Mohs Surgery Project

Condition: Non-Melanoma Skin Cancer
Intervention:
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified May 2012
Neoadjuvant Trial of Eribulin Followed by Dose Dense Doxorubicin and Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer

Conditions: Breast Neoplasms; Breast Cancer; Breast Tumors; Cancer of the Breast; Neoplasms, Breast; Tumors, Breast
Interventions: Drug: Eribulin; Drug: Doxorubicin; Drug: Cyclophosphamide
Sponsors: Emory University; Emory University; Eisai Inc.
Recruiting - verified December 2011
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212

Condition: Breast Cancer
Intervention: Drug: GSK1120212
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; GlaxoSmithKline
Recruiting - verified February 2012
Patient Preferences for Breast Reconstruction After Mastectomy

Condition: Breast Cancer
Intervention:
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI); North Carolina TraCS Institute
Not yet recruiting - verified December 2011
A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab

Conditions: Locally Advance Breast Cancer (LABC); Metastatic Breast Cancer (MBC)
Interventions: Drug: BEZ235 + Trastuzumab Phase l/Phase ll); Drug: Lapatinib + Capecitabine (Phase II)
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

Conditions: Colorectal Cancer; Squamous Cell Head and Neck Cancer; Non-small Cell Lung Cancer; Triple Negative Breast Cancer; Other Tumors With EGFR Dependence
Interventions: Drug: MM-121 (SAR256212); Drug: Irinotecan; Drug: Cetuximab
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals; Sanofi-Aventis
Recruiting - verified January 2012
Clinical Evaluation of the APTIMA® HPV Assay Using the PANTHER™ System

Condition: Human Papilloma Virus Infection
Intervention:
Sponsors: Gen-Probe, Incorporated; Gen-Probe, Incorporated
Not yet recruiting - verified October 2011
VA MERIT: A Comparative Efficacy Study: Treatment of Non-Healing Diabetic Foot Ulcers

Condition: Diabetic Foot Ulcer
Interventions: Device: SECONDARY dressing gauze and tape; Procedure: debridement, irrigation; Device: Dermagraft™; Device: Oasis™
Sponsors: VA Northern California Health Care System; VA Northern California Health Care System
Recruiting - verified October 2011
A Pilot Study of the Administration of Young Tumor Infiltrating Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotrheraphy Regimen in Metastatic Melanoma

Conditions: Metastatic Melanoma; Skin Cancer
Interventions: Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Young TIL
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011
Peer Navigator Education in Improving Survivorship Care in African American Breast Cancer Survivors

Condition: Breast Cancer
Interventions: Other: educational intervention; Other: questionnaire administration; Other: counseling intervention; Other: survey administration; Procedure: quality-of-life assessment
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified May 2012
Intestine Bacteria and Breast Cancer Risk

Conditions: Breast Cancer; Microbiota; Estrogens
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2011
Anakinra for Behcet's Disease

Conditions: Autoimmune/Connective Tissue Diseases; Immune System Diseases; Behcet's Disease
Interventions: Drug: Anakinra; Other: Placebo
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified August 2011
Vitamin D Levels in the Skin of Healthy Subjects After Oral Supplementation

Conditions: Healthy, no Evidence of Disease; Non-melanomatous Skin Cancer
Interventions: Dietary Supplement: cholecalciferol; Genetic: gene expression analysis; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); University of Arizona; National Cancer Institute (NCI)
Recruiting - verified December 2011
The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)

Conditions: Bladder Cancer; Colorectal Cancer; Endometrial Cancer; Kidney Cancer; Skin Cancer; Uterus Cancer
Intervention: Behavioral: Health and Diet Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer

Conditions: Inoperable Locally Advanced Breast Cancer; Metastatic Breast Cancer (MBC)
Intervention: Drug: BEZ235 + Paclitaxel
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml®

Conditions: Breast Cancer; Ductal Carcinoma in Situ
Interventions: Device: Mammosite ML; Device: Mammosite ML
Sponsors: St. John's Mercy Research Institute, St. Louis; St. John's Mercy Research Institute, St. Louis
Recruiting - verified October 2011
AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer

Conditions: Breast Cancer; Ovarian Cancer
Interventions: Drug: AZ2281; Drug: Carboplatin
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2011
111 Indium CHX-A DTPA Trastuzumab (Indium-Herceptin) for Imaging Breast Cancer

Condition: Breast Cancer
Interventions: Radiation: 111 Indium CHX-A DTPA-Trastuzumab; Drug: 111Indium Trastuzumab
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified April 2012
Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial

Condition: Scleroderma
Interventions: Procedure: Rituximab sandwich regiment followed by SCT; Procedure: cyclophosphamide regiment followed by SCT
Sponsors: Northwestern University; Richard Burt, MD
Recruiting - verified April 2012
Efficacy and Safety of Chloroquine in Combination With Taxane or Taxane-like Chemotherapy in the Treatment of Advanced or Metastatic Breast Cancer Patients Who Have Failed an Anthracycline

Conditions: Breast Neoplasms; Breast Cancer
Interventions: Drug: Taxane; Drug: Taxotere; Drug: Abraxane; Drug: Ixabepilone
Sponsors: The Methodist Hospital System; The Methodist Hospital System
Recruiting - verified September 2011
Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors

Conditions: Advanced Solid Tumors; Metastatic Breast Cancer; Metastatic Renal Cell Carcinoma
Intervention: Drug: RAD001 + BEZ235
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Conditions: Breast Neoplasms; Neoplasm Metastasis
Interventions: Drug: afatinib; Drug: afatinib; Drug: Vinorelbine; Drug: Investigator's choice of treatment
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012
Collection of Blood From Cancer Patients for Genetic Analysis

Conditions: Prostate Cancer; Breast Cancer; Lung Cancer; Ovarian Cancer; Lymphoma
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Not yet recruiting - verified March 2012
Interleukin-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Treating Patients With Merkel Cell Cancer

Conditions: Recurrent Neuroendocrine Carcinoma of the Skin; Stage I Neuroendocrine Carcinoma of the Skin; Stage II Neuroendocrine Carcinoma of the Skin; Stage III Neuroendocrine Carcinoma of the Skin; Stage IV Neuroendocrine Carcinoma of the Skin
Interventions: Biological: interleukin-12 gene; Biological: electroporation-mediated plasmid DNA vaccine therapy; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Rural Women Connecting for Better Health

Conditions: Breast Cancer; Obesity
Interventions: Behavioral: Group phone counseling; Behavioral: Newsletter
Sponsors: University of Kansas; Christie Befort, PhD; National Cancer Institute (NCI)
Recruiting - verified April 2012
Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

Condition: Breast Cancer
Intervention: Drug: Cabozantinib
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Exelixis
Recruiting - verified January 2012
Decision Support for Women With Breast Cancer

Condition: Breast Neoplasms
Intervention: Behavioral: Decision control preference scale
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified October 2011
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer

Conditions: Estrogen Receptor Positive Tumor; Breast Cancer
Intervention: Drug: E7389 (eribulin mesylate) and capecitabine
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012
Treatment of Androgenetic Alopecia in Males and Females

Condition: Androgenetic Alopecia
Interventions: Device: TopHat 655 rejuvenation system; Device: Laser and/or Light Hair Rejuvenation System
Sponsors: Apira Science, Inc.; Apira Science, Inc.
Recruiting - verified September 2011
Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding

Condition: Herpes Simplex Type II
Interventions: Drug: Tenofovir; Drug: placebo gel; Drug: tenofovir disoproxil fumarate (TDF); Drug: placebo tablets
Sponsors: University of Washington; University of Washington; CONRAD; Gilead Sciences
Recruiting - verified March 2012
TKM 080301 for Primary or Secondary Liver Cancer

Conditions: Colorectal Cancer With Hepatic Metastases; Pancreas Cancer With Hepatic Metastase; Gastric Cancer With Hepatic Metastase; Breast Cancer With Hepatic Metastase; Ovarian Cancer With Hepatic Metastase
Intervention: Drug: TKM-080301
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified February 2012
Nurse Education in Subjects With Psoriasis Undergoing Treatment With Adalimumab

Condition: Psoriasis
Interventions: Behavioral: Standard nurse education; Behavioral: Additional nurse education
Sponsors: Wake Forest University; Wake Forest University
Recruiting - verified September 2011
Entinostat and Lapatinib Ditosylate in Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab

Condition: Breast Cancer
Interventions: Drug: entinostat; Drug: lapatinib ditosylate; Genetic: protein expression analysis; Other: circulating tumor cell analysis; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
A Comparison of the Treatment of Pressure Ulcers in Spinal Cord Injury Subjects With HP011—101 Ointment to That of Treatment With the Sites Usual Standard Care

Conditions: Pressure Ulcers; Spinal Cord Injury
Interventions: Drug: HP011-101 (Xenaderm Ointment); Drug: Standard Care
Sponsors: Healthpoint; Healthpoint
Recruiting - verified October 2011
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer

Condition: Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
Interventions: Drug: MEDI-573; Drug: Aromatase Inhibitor
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified May 2012
Measuring Adherence to Medication for Depression and Attention-deficit Hyperactivity Disorder

Conditions: Major Depressive Disorder; Attention-deficit Hyperactivity Disorder (ADHD)
Intervention:
Sponsors: Wake Forest University Baptist Medical Center; Wake Forest University Baptist Medical Center
Recruiting - verified September 2011
Safety and Efficacy of Luliconazole Solution, 10% in Subjects With Mild to Moderate Onychomycosis

Condition: Distal and Lateral Subungual Onychomycosis
Interventions: Drug: Luliconazole Solution, 10%; Drug: Vehicle Solution
Sponsors: Topica Pharmaceuticals; Topica Pharmaceuticals
Not yet recruiting - verified February 2012
Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities

Condition: Kawasaki Disease
Intervention: Drug: Atorvastatin
Sponsors: University of California, San Diego; University of California, San Diego
Not yet recruiting - verified September 2011
Dual-energy Contrast-enhanced (2D and 3D Mammography Versus Contrast-enhanced MRI)- A Pilot Study

Condition: Breast Cancer
Intervention:
Sponsors: Hologic, Inc.; Hologic, Inc.
Recruiting - verified September 2011
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Condition: Breast Cancer
Interventions: Drug: fulvestrant; Drug: GDC-0941; Drug: GDC-0980; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified April 2012
Systemic Dickkopf-related Protein 1 (DKK1)During Estrogen Level Changes in Post-menopausal Breast Cancer Patients Treated With Aromatase Inhibitors

Condition: Breast Cancer
Intervention:
Sponsors: University of Arkansas; University of Arkansas
Recruiting - verified March 2012
Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass

Conditions: Breast Cancer; Genitourinary Cancer; Malignant Female Reproductive System Neoplasm; Melanoma; Sarcoma
Intervention: Procedure: Punch Biopsy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Department of Defense
Recruiting - verified March 2012
Prospective Analysis of Symptoms and Lymphedema in Patients Following Treatment for Breast Cancer

Condition: Lymphedema
Intervention:
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Cancer Institute (NCI)
Recruiting - verified January 2012
Innovative Approaches to Gauge Progression of Sturge-Weber Syndrome

Condition: Sturge-Weber Syndrome
Intervention:
Sponsors: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; National Institutes of Health (NIH); University of California, San Francisco; National Institute of Neurological Disorders and Stroke (NINDS); Duke University; Children's Hospital of Michigan; Baylor College of Medicine; Texas Children's Hospital; Wills Eye; Nationwide Children's Hospital
Recruiting - verified February 2012
A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome

Conditions: Healthy Volunteers; Atopic Dermatitis; Netherton Syndrome
Interventions: Drug: BPR277 ointment (controlled application); Drug: Placebo (Vehicle); Drug: BPR277 ointment; Drug: Placebo (Vehicle); Drug: BPR277; Drug: Placebo (Vehicle)
Sponsors: Novartis; Novartis
Recruiting - verified November 2011
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer

Condition: Breast Cancer
Interventions: Biological: Ramucirumab (IMC-1121B); Drug: Eribulin
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified May 2012
Natural History and Development of Spondyloarthritis

Conditions: Arthritis; Spondylitis, Ankylosing
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified April 2012
Pharmacokinetics Study of Dapsone-Adapalene Fixed Combination Gel in Acne

Condition: Acne Vulgaris
Interventions: Drug: Fixed Combination dapsone/adapalene Formulation A Gel; Drug: Fixed Combination dapsone/adapalene Formulation B Gel; Drug: dapsone 5% gel; Drug: adapalene 0.3% gel
Sponsors: Allergan; Allergan
Not yet recruiting - verified May 2012
Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo After 12 Weeks of Oracea® and MetroGel® 1%

Condition: Rosacea
Interventions: Drug: oral doxycycline and topical metronidazole; Drug: oral doxycycline; Drug: placebo
Sponsors: Galderma Laboratories, L.P.; Galderma Laboratories, L.P.
Recruiting - verified January 2012
Patient Controlled Tissue Expansion for Breast Reconstruction

Condition: Breast Cancer
Interventions: Device: AeroForm Patient Controlled Tissue Expander; Procedure: Implantation of Saline Tissue Expander
Sponsors: AirXpanders, Inc.; AirXpanders, Inc.
Recruiting - verified April 2012
Non-Invasive Imaging for Cording in Breast Cancer Patients

Condition: Breast Cancer
Intervention: Other: Non invasive venous ultrasound
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Cancer Institute (NCI)
Recruiting - verified April 2012
Daptomycin Versus Vancomycin in Patients With Skin Infections Due to MRSA

Condition: Staphylococcal Skin Infections
Interventions: Drug: Daptomycin; Drug: Vancomycin
Sponsors: Cubist Pharmaceuticals; Cubist Pharmaceuticals
Recruiting - verified March 2012
Fluocinonide Cream in Treating Symptoms of Vaginal Dryness and Painful Sexual Intercourse In Patients With Breast Cancer Undergoing Hormone Therapy

Condition: Breast Cancer
Interventions: Other: questionnaire administration; Drug: fluocinonide cream; Procedure: management of therapy complications
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified April 2012
AMG 827 in Subjects With Psoriatic Arthritis

Condition: Psoriatic Arthritis
Interventions: Drug: AMG 827; Drug: Placebo; Drug: AMG 827
Sponsors: Amgen; Amgen
Recruiting - verified January 2012
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis

Condition: Psoriasis
Intervention: Drug: AMG 557 or PLACEBO
Sponsors: Amgen; Amgen
Recruiting - verified April 2012
Cooling Lower Leg Skin to Prevent Venous Leg Ulcers in Patients With Poor Vein Circulation

Conditions: Venous Disease; Venous Vascular Diseases and Syndromes; Venous Insufficiency; Venous Ulcers
Interventions: Procedure: Cryotherapy: Cooling gel wrap; Procedure: Usual care
Sponsors: Medical University of South Carolina; Medical University of South Carolina; National Institute of Nursing Research (NINR)
Recruiting - verified January 2012
Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Biological: trastuzumab; Drug: Neratinib
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); Pfizer
Recruiting - verified March 2012
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer

Conditions: ER Positive, Her2 Negative Breast Cancer Patients; Triple Negative Breast Cancer Patients
Interventions: Drug: MM-121 (SAR256212) plus paclitaxel; Drug: Paclitaxel
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals; Sanofi-Aventis
Recruiting - verified April 2012
Toll-like Receptor (TLR) 7 Agonist and Radiotherapy for Breast Cancer With Skin Metastases

Conditions: Breast Cancer; Metastatic Breast Cancer; Recurrent Breast Cancer
Interventions: Radiation: Radiation; Drug: Imiquimod
Sponsors: New York University School of Medicine; New York University School of Medicine; National Cancer Institute (NCI)
Recruiting - verified April 2012
Promoting a Healthier Lifestyle Among Breast Cancer Survivors

Condition: Breast Cancer
Interventions: Behavioral: Motivational Interviewing; Behavioral: Counseling
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Department of Defense
Recruiting - verified January 2012
Clinical and Basic Investigations Into Erdheim Chester Disease

Conditions: Myelofibrosis; Gaucher Disease; Pulmonary Fibrosis; Hermansky-Pudlak Syndrome (HPS); Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified June 2011
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA)

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: anti-cancer therapy
Sponsors: Genentech; Genentech
Recruiting - verified March 2012
Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis

Condition: Plaque-type Psoriasis
Interventions: Drug: secukinumab 150mg; Drug: secukinumab 10mg/kg i.v. regimen
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified December 2011
Systemic Therapies for Pediatric Atopic Dermatitis

Condition: Dermatitis, Atopic
Intervention:
Sponsors: Northwestern University; Northwestern University; University of California, San Diego
Recruiting - verified December 2011
A Study Comparing Combination Clindamycin Phosphate/Tretinoin Gel Alone Versus With Benzoyl Peroxide Foaming Cloths for Facial Acne

Condition: Acne Vulgaris
Interventions: Drug: clindamycin phosphate 1.2%/tretinoin 0.025% gel alone; Drug: clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths
Sponsors: Zeichner, Joshua, M.D.; Zeichner, Joshua, M.D.
Recruiting - verified August 2011
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors

Conditions: Advanced Solid Tumors; Excluding Breast Cancer
Intervention: Drug: TKI258
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
A Study of LY2523355 in Patients With Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: LY2523355; Drug: Ixabepilone; Drug: pegfilgrastim; Drug: filgrastim
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis

Condition: Actinic Keratosis
Interventions: Drug: Imiquimod cream 3.75%; Drug: Placebo cream
Sponsors: Medicis Global Service Corporation; Medicis Global Service Corporation
Recruiting - verified April 2012
OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas

Condition: Pancreatic Cancer, Metastatic
Interventions: Drug: Gemcitabine, Erlotinib, OSI-906; Drug: Gemcitabine, Erlotinib
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Not yet recruiting - verified May 2012
High-Dose Cyclophosphamide and Anti-Thymocyte Globulin Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Systemic Scleroderma

Condition: Systemic Scleroderma
Interventions: Procedure: peripheral blood stem cell transplantation; Drug: cyclophosphamide; Biological: anti-thymocyte globulin; Other: questionnaire administration; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment; Biological: filgrastim; Procedure: autologous hematopoietic stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012
Therapeutic Study of Bevacizumab Injection Directly Inside the Keloid Tissue

Condition: Keloid
Intervention: Biological: bevacizumab
Sponsors: Tirgan, Michael H., M.D.; Tirgan, Michael H., M.D.
Recruiting - verified February 2012
Epigenetics and Psychoneurologic Symptoms in Women With Breast Cancer

Condition: Breast Cancer
Intervention:
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University
Recruiting - verified August 2011
Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid

Conditions: Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; Invasive Ductal Breast Carcinoma; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer
Interventions: Drug: zoledronic acid; Other: laboratory biomarker analysis; Procedure: therapeutic conventional surgery
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012
Cook for Your Life

Condition: Breast Cancer
Interventions: Other: Arm A; Behavioral: Arm B
Sponsors: Columbia University; Columbia University; National Cancer Institute (NCI)
Recruiting - verified October 2011
Using Santyl on Diabetic Foot Ulcers

Conditions: Diabetic Foot Ulcers; Diabetic Foot Wounds
Interventions: Biological: Santyl; Procedure: Standard Care
Sponsors: Healthpoint; Healthpoint
Recruiting - verified May 2012
Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer

Conditions: Inflammatory Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Mucinous Ductal Breast Carcinoma; Papillary Ductal Breast Carcinoma; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Tubular Ductal Breast Carcinoma
Intervention: Radiation: External beam radiation therapy
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI)
Recruiting - verified August 2011
Genetic Susceptibility to Radiation-Induced Skin Reactions in Racial/Ethnic Groups of Patients With Breast Cancer

Conditions: Breast Cancer; Cognitive/Functional Effects; Depression; Fatigue; Pain; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Skin Reactions Secondary to Radiation Therapy
Interventions: Genetic: DNA analysis; Genetic: gene expression analysis; Other: enzyme-linked immunosorbent assay; Other: flow cytometry; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: adjuvant therapy; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment; Radiation: 3-dimensional conformal radiation therapy; Radiation: breast irradiation; Radiation: external beam radiation therapy; Radiation: hypofractionated radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: whole breast irradiation
Sponsors: National Cancer Institute (NCI); Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified May 2012
Interferon Responses in Eczema Herpeticum (ADEH)

Conditions: Atopic Dermatitis; Eczema Herpeticum; Herpes Simplex Infections; Eczema Vaccinatum
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Jewish Health; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2011
Effects of Aminocaproic Acid (ACA) on Rosacea-specific Inflammation

Condition: Rosacea
Interventions: Drug: Topical aminocaproic acid (ACA) mixed with Vanicream; Drug: Vehicle cream
Sponsors: University of California, San Diego; University of California, San Diego
Recruiting - verified April 2011
Study to Assess the Safety and Immunological Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI

Condition: Melanoma
Intervention: Other: recMAGE-A3 + AS15 ASCI
Sponsors: University of Virginia; Craig L Slingluff, Jr; GlaxoSmithKline
Recruiting - verified August 2011
Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens

Condition: Moderate to Severe Plaque-type Psoriasis
Interventions: Biological: secukinumab 150 mg; Drug: If disease relapses patient is treated with secukinumab 150 mg. If disease does not relapse patient is treated with placebo; Biological: secukinumab 300 mg; Biological: If disease relapses patient is treated with secukinumab 300 mg. If disease does not relapse patient is treated with placebo.
Sponsors: Novartis; Novartis
Recruiting - verified April 2012
UAB HRFD Core Center: Core A: The Hepato/Renal Fibrocystic Diseases Translational Resource

Conditions: Hepato/Renal Fibrocystic Disease; Autosomal Recessive Polycystic Kidney Disease; Joubert Syndrome; Bardet Biedl Syndrome; Meckel-Gruber Syndrome; Congenital Hepatic Fibrosis; Caroli Syndrome; Oro-Facial-Digital Syndrome Type I; Nephronophithisis; Glomerulocystic Kidney Disease
Intervention:
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified September 2011
X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) Carrier Outlook Toward Reproduction Survey

Conditions: Hypohidrotic Ectodermal Dysplasia; X-Linked Hypohidrotic Ectodermal Dysplasia
Intervention:
Sponsors: Edimer Pharmaceuticals; Edimer Pharmaceuticals
Recruiting - verified August 2011
Partial Breast Irradiation Using Non Invasive Machine for Early Stage Breast Cancer

Condition: Breast Cancer
Intervention: Radiation: Accelerated partial breast irradiation
Sponsors: Brown University; Jaroslaw Hepel; The Miriam Hospital; Rhode Island Hospital
Recruiting - verified May 2012
Online Health Survey of Patients With Vitiligo Vulgaris/ Online Survey of Pediatric Patients With Vitiligo

Condition: Vitiligo Vulgaris
Intervention:
Sponsors: St. Luke's-Roosevelt Hospital Center; St. Luke's-Roosevelt Hospital Center
Recruiting - verified March 2011
Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy

Condition: Metastatic Breast Cancer
Interventions: Drug: eribulin mesylate; Drug: eribulin mesylate; Drug: eribulin mesylate, trastuzumab
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Eisai Inc.
Recruiting - verified March 2012
Cosmetic Evaluation of Lumpectomy Versus Oncolytic Mammoplasty With Bilateral Breast Reduction for Early Stage Breast Cancer

Condition: Breast Carcinoma
Intervention:
Sponsors: New Hanover Regional Medical Center; New Hanover Regional Medical Center; National Cancer Institute (NCI); Coastal Carolina Radiation Oncology (CCRO)
Recruiting - verified August 2011
Fresolimumab and Radiotherapy in Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: fresolimumab (GC1008); Drug: fresolimumab (GC1008); Radiation: Radiation Therapy
Sponsors: New York University School of Medicine; New York University School of Medicine; University of California, Los Angeles
Recruiting - verified May 2012
Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors

Conditions: Unspecified Adult Solid Tumor - Protocol Specific; Breast Cancer - Female
Interventions: Drug: Pazopanib; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI); GlaxoSmithKline
Recruiting - verified September 2011
Radiofrequency Ablation After Breast Lumpectomy (ABLATE)

Condition: Breast Cancer
Intervention: Procedure: Radiofrequency Ablation
Sponsors: University of Kansas; University of Kansas; Angiodynamics, Inc.
Recruiting - verified October 2011
Study of Tocilizumab to Treat Polymyalgia Rheumatica

Condition: Polymyalgia Rheumatica (PMR)
Intervention: Drug: Tocilizumab
Sponsors: Hospital for Special Surgery, New York; Hospital for Special Surgery, New York; Genentech
Recruiting - verified January 2012
Restore Calcium Alginate Dressing, Silver vs Aquacel Ag in the Treatment of Critically Colonized Venous Leg Ulcers

Conditions: Venous Ulcer; Infection
Interventions: Device: Restore Calcium Alginate Dressing; Device: AquaCel Ag Wound Dressing
Sponsors: Hollister Wound Care LLC; Hollister Wound Care LLC
Recruiting - verified November 2011
Effects of Controlled Ovarian Hyperstimulation (COH) With Letrozole and Gonadotropin

Conditions: Infertility; Breast Cancer
Intervention: Procedure: Random Peri-Areolar Fine Needle Aspiration (RPFNA)
Sponsors: University of Kansas; University of Kansas
Recruiting - verified July 2011
A Novel Prosocial Online Support Group for Distressed Breast Cancer Survivors

Condition: Breast Neoplasms
Interventions: Behavioral: prosocial online support group; Behavioral: Standard Online Support Group
Sponsors: Temple University; Temple University; Cancer Support Community
Not yet recruiting - verified July 2011
Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)

Condition: Psoriatic Arthritis
Interventions: Biological: Secukinumab (75 mg); Biological: Secukinumab (150 mg); Biological: Placebo Comparator
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Diindolylmethane in Treating Patients With Breast Cancer

Conditions: Ductal Breast Carcinoma in Situ; Lobular Breast Carcinoma in Situ; Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer
Interventions: Drug: diindolylmethane; Other: placebo; Other: questionnaire administration; Procedure: digital mammography; Procedure: magnetic resonance imaging; Other: biomarker analysis of blood and urine
Sponsors: University of Arizona; University of Arizona; National Cancer Institute (NCI)
Recruiting - verified May 2011
Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer

Condition: HER-2 Positive Breast Cancer
Interventions: Drug: eribulin; Drug: carboplatin; Drug: trastuzumab
Sponsors: ACORN Research, LLC; ACORN Research, LLC; Eisai Inc.
Recruiting - verified January 2012
Cryoablation for Invasive Breast Carcinoma Following Neoadjuvant Therapy

Condition: Breast Cancer
Interventions: Device: Visica 2™ Treatment System; Procedure: Cryoablation; Procedure: Surgical Resection
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified January 2012
Natural History of Individuals With Immune System Problems That Lead to Fungal Infections

Conditions: Fungal Infections; APECED; Chronic Mucocutaneous Candidiasis; Fungal Immunopathogenesis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2012
Male Subjects Affected By Hypohidrotic Ectodermal Dysplasia: Intrafamilial Variation

Condition: Hypohidrotic Ectodermal Dysplasia
Intervention:
Sponsors: Edimer Pharmaceuticals; Edimer Pharmaceuticals
Recruiting - verified June 2011
Pediatric Atopic Dermatitis (AD) Internet Survey

Condition: Atopic Dermatitis
Interventions: Behavioral: Weekly Internet survey; Drug: Topical Triamcinolone
Sponsors: Wake Forest University; Wake Forest University
Recruiting - verified June 2011
A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema

Condition: Hereditary Angioedema
Intervention: Drug: icatibant
Sponsors: Shire Human Genetic Therapies, Inc.; Shire Human Genetic Therapies, Inc.
Recruiting - verified May 2012
Real-Time Near-infrared (NIR) Mapping of Sentinel Lymph Nodes in Breast Cancer

Condition: Breast Cancer
Intervention: Device: NIR Imaging with FLARE and Mini-FLARE Imaging System
Sponsors: Beth Israel Deaconess Medical Center; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; Dana-Farber Cancer Institute
Recruiting - verified February 2012
Understanding Decision Making Processes for Undergoing Genetic Testing Among Women With Newly Diagnosed Breast Cancer

Condition: Breast Cancer
Intervention: Genetic: BRCA testing and questionnaire assessments
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012
Vaccination of High Risk Breast Cancer Patients

Condition: Stage IV Breast Cancer
Intervention: Biological: Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG
Sponsors: University of Arkansas; University of Arkansas; Department of Defense
Recruiting - verified January 2012
Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Patients With Stage I, Stage II, or Stage III Breast Cancer Receiving Hormone Therapy

Conditions: Arthralgia; Breast Cancer; Pain
Interventions: Dietary Supplement: omega-3 fatty acid; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Efficacy of Hair Transplantation Compared With Hypodermic Needle Irritation in Alopecia Areata

Conditions: Alopecia Areata; Alopecia; Balding
Interventions: Procedure: Hair transplantation; Procedure: Hypodermic needle irritation
Sponsors: Emer, Jason, M.D.; Emer, Jason, M.D.
Recruiting - verified June 2011
Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy

Conditions: Breast Neoplasms; Peritoneal Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms
Interventions: Other: ²¹²Pb-TCMC-Trastuzumab; Biological: trastuzumab
Sponsors: Areva Med LLC; Areva Med LLC
Recruiting - verified January 2012
Investigating the Impact of Tamoxifen Therapy on Ovarian Aging

Conditions: Breast Cancer; Fertility
Intervention:
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified February 2012
Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus

Conditions: Cutaneous Lupus; Lupus
Interventions: Drug: AMG 557; Drug: AMG 557 Placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

Conditions: Metastatic ER+ Her2- Breast Cancer; Postmenopausal
Interventions: Drug: Exemestane; Drug: Abiraterone acetate + Prednisone/ Prednisolone + Exemestane; Drug: Abiraterone acetate + Prednisone or Prednisolone
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012
Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy

Conditions: Breast Cancer; Lymphoma
Intervention:
Sponsors: University of Rochester; University of Rochester
Recruiting - verified July 2011
Test Uniformity of Transdermal Drug Delivery to Breast Using Diclofenac Epolamine

Condition: Breast Cancer
Intervention: Other: Diclofenac epolamine patch
Sponsors: Northwestern University; Northwestern University
Recruiting - verified May 2012
Therapeutic Estradiol and Exemestane in Treating Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer

Conditions: Estrogen Receptor-positive Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer
Interventions: Biological: therapeutic estradiol; Drug: exemestane; Other: laboratory biomarker analysis; Other: enzyme-linked immunosorbent assay
Sponsors: University of Arizona; University of Arizona; National Cancer Institute (NCI)
Recruiting - verified May 2012
The Jewels in Our Genes Study - an African American Family Study of Breast Cancer

Condition: Breast Cancer
Intervention:
Sponsors: University at Buffalo; University at Buffalo; Susan G. Komen Breast Cancer Foundation
Recruiting - verified June 2011
Determination of the Pathophysicologic Collagen Changes in the Diabetic Achilles Tendon

Conditions: Diabetic Foot Ulcers; Equinus Deformity
Intervention:
Sponsors: Georgetown University; Georgetown University
Recruiting - verified January 2012
Comparing Cetaphil Restoraderm System Versus Standard Skin Care in Infants

Condition: Atopic Dermatitis
Interventions: Other: Cetaphil Restoraderm; Other: Standard of Care
Sponsors: Oregon Health and Science University; Oregon Health and Science University; Galderma
Recruiting - verified June 2011
Efficacy Study of the Application of Low Level Laser Light to Treat Venous Stasis Ulcers

Condition: Venous Stasis Ulcer
Interventions: Device: Erchonia ML Scanner (MLS); Device: Inactive Erchonia ML Scanner (MLS)
Sponsors: Erchonia Corporation; Erchonia Corporation
Recruiting - verified June 2011
Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers

Conditions: Breast Cancer; Gastrointestinal Cancer; Genitourinary Cancer; Sarcoma; Gynecologic Cancer
Interventions: Drug: Doxorubicin; Drug: Sildenafil
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University
Recruiting - verified April 2012
Evaluating AlloMax in Immediate Expander-Based Breast Reconstruction Study

Conditions: Malignant Neoplasm of the Breast; Acquired Absence of the Breast
Intervention:
Sponsors: National Center for Plastic Surgery, Virginia; National Center for Plastic Surgery, Virginia; Inova Health Care Services; Ohio State University Comprehensive Cancer Center; Walter Reed Army Medical Center; C. R. Bard
Recruiting - verified August 2011
A Novel Optical Spectral Imaging System for Imaging Breast Tumor Margins

Condition: Breast Cancer
Intervention:
Sponsors: Duke University; Duke University; National Institutes of Health (NIH)
Recruiting - verified February 2012
Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis

Condition: Psoriasis
Intervention: Drug: RA-18C3
Sponsors: XBiotech, Inc.; XBiotech, Inc.
Recruiting - verified April 2012
Multi-Compression Spot Mammography

Condition: Breast Diseases
Intervention:
Sponsors: State University of New York - Upstate Medical University; State University of New York - Upstate Medical University
Recruiting - verified December 2010
Online Wound Electronic Medical Record (OWEMR) to Decrease Amputations in Diabetics

Conditions: Wounds; Diabetes Complications; Diabetic Foot; Foot Ulcer
Intervention: Other: Online Wound Electronic Medical Record
Sponsors: New York University School of Medicine; New York University School of Medicine; Agency for Healthcare Research and Quality (AHRQ)
Recruiting - verified March 2012
Vaccine Therapy in Treating Patients With Metastatic Solid Tumors

Conditions: Malignant Solid Tumour; Breast Cancer; Malignant Tumor of Colon; GIST; Ovarian Cancer
Intervention: Biological: HER-2 vaccine
Sponsors: Ohio State University Comprehensive Cancer Center; Ohio State University Comprehensive Cancer Center
Recruiting - verified February 2012
Axillary Reverse Mapping

Condition: Breast Cancer
Interventions: Procedure: Injection of isotope; Procedure: Axillary lymph node dissection
Sponsors: University of Kansas; University of Kansas
Recruiting - verified October 2011
Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor

Condition: Ductal Carcinoma in Situ
Intervention: Drug: SOM 230 / Pasireotide
Sponsors: New York University School of Medicine; New York University School of Medicine
Recruiting - verified April 2012
Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma

Conditions: Metastatic Melanoma; Skin Cancer
Interventions: Drug: Cyclophosphamide; Drug: Fludarabine; Biological: Tumor Infiltrating Lymphocytes; Drug: IL-15
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified February 2012
Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma

Conditions: Metastatic Melanoma; Skin Cancer
Interventions: Drug: Cyclophosphamide; Drug: Fludarabine; Biological: Aldesleukin; Biological: Tumor Infiltrating Lymphocytes
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012
Head Circumference Growth in Children With Ehlers-Danlos Syndrome Who Develop Dysautonomia Later in Life

Conditions: Ehlers Danlos Syndrome; External Hydrocephalus; Dysautonomia; Postural Orthostatic Tachycardia Syndrome; Venous Insufficiency
Intervention:
Sponsors: Genetic Disease Investigators; Genetic Disease Investigators
Recruiting - verified June 2011
Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years

Conditions: Staphylococcal Infections; Staphylococcal Vaccines; Bacterial Infections; Staphylococcal Skin Infections
Interventions: Biological: SA4Ag vaccine low dose; Procedure: Blood draw; Procedure: Colonization swab sample; Biological: SA4Ag vaccine mid dose; Procedure: Blood sample; Procedure: Colonization swab sample; Biological: SA4Ag vaccine high dose; Procedure: Blood draw; Procedure: Colonization swab sample; Biological: Placebo; Procedure: Blood draw; Procedure: Colonization swab sample
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment

Conditions: Urticaria; Angioedema; Hives; Swelling
Interventions: Drug: Vitamin D; Drug: Vitamin D
Sponsors: University of Nebraska; University of Nebraska
Not yet recruiting - verified June 2011
Nuevo Amanecer: Promoting the Psychosocial Health of Latinas

Conditions: Breast Neoplasms; Psychology, Social
Intervention: Behavioral: Peer Support Program
Sponsors: University of California, San Francisco; University of California, San Francisco; California Breast Cancer Research Program; Circulo de Vida Cancer Support and Resource Center
Recruiting - verified January 2012
Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer

Conditions: Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
Interventions: Drug: goserelin acetate; Drug: letrozole; Drug: anastrozole; Procedure: therapeutic conventional surgery; Genetic: DNA analysis; Other: immunohistochemistry staining method; Procedure: positron emission tomography; Genetic: comparative genomic hybridization; Procedure: biopsy; Other: laboratory biomarker analysis; Drug: chemotherapy
Sponsors: Washington University School of Medicine; Washington University School of Medicine; National Cancer Institute (NCI)
Recruiting - verified March 2012
An Evaluation of a Self-contained Direct Digital Radiography System for Breast Specimen Imaging

Condition: Breast Cancer
Interventions: Device: Trident Specimen Radiography System; Device: Bioptics, Faxitron, and Full Field Digital Mammography (FFDM) Selenia
Sponsors: Levine, Gary M. , M.D.; Levine, Gary M. , M.D.; Hologic, Inc.
Recruiting - verified March 2012
Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients

Conditions: Estrogen Receptor-negative Breast Cancer; HER2-negative Breast Cancer; Male Breast Cancer; Progesterone Receptor-negative Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-negative Breast Cancer
Interventions: Drug: eribulin mesylate; Drug: carboplatin; Procedure: biopsy
Sponsors: Northwestern University; Northwestern University; Eisai Inc.
Recruiting - verified May 2012
Integrative Oncology Outcomes Study in Breast Cancer

Condition: Breast Cancer
Intervention:
Sponsors: Bastyr University; Bastyr University; Fred Hutchinson Cancer Research Center; National Institutes of Health (NIH); National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified April 2012
Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2

Conditions: Breast Cancer; Non-Small-Cell Lung Cancer; Glioblastoma; Other Cancers
Intervention: Drug: FPPRGD2
Sponsors: Stanford University; Stanford University
Recruiting - verified February 2012
Bisphosphonate Users Radiographic Characteristics of the Hip (BURCH) Study

Conditions: Osteoporosis; Bone Diseases, Metabolic; Hip Fractures
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified January 2012
AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer

Conditions: Breast Cancer; Metastatic Breast Cancer; HER-2 Positive Breast Cancer; ER Positive Breast Cancer
Intervention: Drug: AUY922
Sponsors: Texas Tech University Health Sciences Center; Texas Tech University Health Sciences Center
Recruiting - verified May 2012
Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Tinea Pedis

Conditions: Tinea Pedis; Athlete's Foot
Interventions: Drug: Econazole Nitrate Foam 1%; Drug: Vehicle Foam; Drug: Econazole Nitrate Cream 1%; Other: Placebo Cream
Sponsors: Quinnova Pharmaceuticals, Inc.; Quinnova Pharmaceuticals, Inc.; AmDerma Pharmaceuticals, LLC
Recruiting - verified May 2011
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: placebo; Drug: trastuzumab [Herceptin]; Drug: Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Breast International Group; Genentech
Recruiting - verified February 2012
Proton Therapy for Lymph Nodes in Breast Cancer

Condition: Breast Cancer
Interventions: Radiation: Photon; Radiation: 3D-Proton/Conventional plan
Sponsors: University of Florida; University of Florida
Recruiting - verified May 2012
Vaccine Therapy in Combination With Ampligen® and/or Sargramostim in Patients With Stage II-IV HER2-Positive Breast Cancer

Conditions: HER2-positive Breast Cancer; Male Breast Cancer; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: Ampligen; Biological: synthetic HER-2/neu peptide vaccine; Biological: GM-CSF; Other: laboratory biomarker analysis; Other: immunoenzyme technique
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Multiple Myeloma

Conditions: Multiple Myeloma; Non-Hodgkin's Lymphoma; Glioblastoma Multiforme; Head and Neck Squamous Cell Cancer; Triple Negative Breast Cancer; Hormone Receptor-Positive Breast Cancer; Castration-Resistant Prostate Cancer; Ewing's Family of Sarcomas
Intervention: Drug: CC-115
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012
Endogenous Progenitors Cell Therapy for Diabetic Foot Ulcers

Condition: Diabetic Ulcer
Intervention: Drug: AMD3100 injection + rhPDGF-BB topical
Sponsors: New York University School of Medicine; New York University School of Medicine; National Institutes of Health (NIH); Genzyme
Not yet recruiting - verified May 2011
The CEASE Study: Computer Based Educational Module for the Reduction of Arthralgia Syndrome Associated With Endocrine Therapy for Breast Cancer

Conditions: Breast Cancer; Arthralgia
Interventions: Behavioral: Education and exercise intervention; Behavioral: Education and General Exercise
Sponsors: Georgetown University; Georgetown University
Recruiting - verified May 2011
LLLT Combined With CDT in Breast Cancer-Related Lymphedema

Conditions: Breast Cancer; Lymphedema
Interventions: Device: Low Level Laser Therapy; Device: Low Level Laser
Sponsors: New York University School of Medicine; New York University School of Medicine; Hunter College
Recruiting - verified January 2012
Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis

Conditions: Tinea Pedis; Tinea Cruris; Tinea Corporis
Intervention: Drug: Product 33525
Sponsors: Tinea Pharmaceuticals; Tinea Pharmaceuticals
Recruiting - verified October 2011
Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Drug: azacitidine; Drug: entinostat; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2012
Higher-Dose Radiation Therapy or Standard Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

Condition: Breast Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: accelerated radiation therapy; Radiation: hypofractionated radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: whole breast irradiation
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
SNaP Wound Care System Over Skin Cancer Excision Sites and Split Thickness Skin Grafts (STSGs)

Conditions: Split Thickness Skin Graft; Skin Cancer Excision Site; Skin Graft
Intervention: Device: SNaP® Wound Care System
Sponsors: Spiracur, Inc.; Spiracur, Inc.
Recruiting - verified February 2012
A Study of Oral LGK974 in Patients With Melanoma and Lobular Breast Cancer

Conditions: Melanoma; Breast Neoplasms; Lobular Carcinoma
Intervention: Drug: LGK974
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer

Conditions: Breast Cancer; Metastatic Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: Ixabepilone; Drug: Capecitabine; Drug: Motesanib
Sponsors: Thomas Jefferson University; Thomas Jefferson University; Susan G. Komen Breast Cancer Foundation; Amgen
Not yet recruiting - verified January 2012
Biomarker Development in Sturge-Weber Syndrome

Condition: Sturge-Weber Syndrome
Intervention:
Sponsors: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; National Institutes of Health (NIH); University of California, San Francisco; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified February 2012
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema

Condition: ACE Inhibitor Induced Angioedema
Interventions: Drug: ecallantide; Drug: ecallantide; Drug: ecallantide; Drug: placebo
Sponsors: Dyax Corp.; Dyax Corp.
Recruiting - verified April 2012
Risk Education and Assessment for Cancer Heredity

Conditions: Breast Cancer; Ovarian Cancer; Genetic Predisposition
Intervention: Behavioral: BRCA1/BRCA2 Genetic Counseling
Sponsors: University of Utah; University of Utah; National Cancer Institute (NCI); Huntsman Cancer Institute
Recruiting - verified November 2011
Bioelectrical Impedance for Self-monitoring of Lymphedema

Condition: Lymphedema
Intervention: Behavioral: self-monitoring of arm volume
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified June 2011
MK2206 and Anastrozole, Letrozole, Exemestane, or Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Akt inhibitor MK2206; Drug: anastrozole; Drug: exemestane; Drug: fulvestrant; Drug: letrozole
Sponsors: National Cancer Institute (NCI); Washington University Siteman Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Pilot Study of Tumor-Derived Exosomes as Diagnostic and Prognostic Markers in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

Condition: Breast Neoplasms
Intervention:
Sponsors: Leo W. Jenkins Cancer Center; Leo W. Jenkins Cancer Center
Recruiting - verified January 2012
Changes in Breast Cancer Biomarkers Using Synergistic Prostaglandin Inhibitors

Condition: Breast Cancer
Interventions: Drug: Celecoxib; Drug: Placebo; Drug: Cholecalciferol
Sponsors: University of North Dakota; University of North Dakota; Department of Defense
Recruiting - verified August 2011
Proton Radiation Therapy for Invasive Breast Cancer Following Mastectomy

Condition: Invasive Breast Cancer
Intervention: Radiation: Proton Radiation
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified April 2011
Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy

Conditions: Breast Cancer; Colon Cancer; Bladder Cancer
Interventions: Drug: Glycosylated Recombinant Human Interleukin-7; Biological: Diphtheria-Tetanus Vaccine; Biological: Polio Vaccine; Biological: Pneumaococcal Vaccine; Biological: Hepatitis A Vaccine; Biological: Hepatitis B Vaccine; Biological: Influenza Vaccine; Biological: PhiX 174
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors

Conditions: Locally Advanced Solid Tumor; Metastatic Solid Tumor; Breast Cancer; Non Small Cell Lung Cancer; Melanoma; Colorectal Cancer
Intervention: Drug: MSC1936369B and SAR245409
Sponsors: EMD Serono; EMD Serono; Sanofi
Recruiting - verified April 2012
Radioactive Iodide (131I) Treatment of 124I PET/CT Detected Breast Cancers

Conditions: Breast Cancer; Metastatic Breast Cancer
Interventions: Procedure: 124 PET/CT imaging; Drug: Na134I; Drug: Tri-iodothyronine; Drug: Tri-iodothyronine
Sponsors: Stanford University; Stanford University
Recruiting - verified May 2011
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer

Conditions: Castration-resistant Prostate Cancer,; Metastatic Breast Cancer
Intervention: Drug: LFA102
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer

Conditions: Estrogen Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: PI3K inhibitor BKM120; Drug: fulvestrant; Procedure: biopsy
Sponsors: Washington University School of Medicine; Washington University School of Medicine; National Cancer Institute (NCI)
Not yet recruiting - verified October 2011
Study of Laser Treatment of Melasma

Condition: Refractory Mixed Type Melasma
Interventions: Device: Q-Switched Nd:YAG Laser (RevLite); Other: Microdermabrasion
Sponsors: ConBio, a Cynosure Company; ConBio, a Cynosure Company
Recruiting - verified August 2011
A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin

Condition: Breast Cancer
Interventions: Drug: Gemcitabine and Carboplatin; Drug: P276-00 along with Gemcitabine and carboplatin
Sponsors: Piramal Healthcare Limited; Piramal Healthcare Limited
Recruiting - verified January 2012
Genomic Testing for Primary Breast Cancer

Condition: Breast Cancer
Interventions: Procedure: Tumor Biopsy; Other: Breast Cancer Registry
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Susan G. Komen Breast Cancer Foundation; Kellogg Company
Recruiting - verified March 2012
Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Condition: Breast Cancer
Interventions: Drug: Liposomal Doxorubicin; Drug: Seliciclib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Institutes of Health (NIH)
Not yet recruiting - verified March 2012
Effects of IGF-I in HIV Metabolic Disease

Condition: HIV Lipodystrophy
Interventions: Drug: mecasermin; Drug: Placebo control
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center
Recruiting - verified March 2012
Promoting Breast Cancer Screening in Non-adherent Women

Condition: Breast Cancer
Interventions: Behavioral: reminder letter; Behavioral: reminder call; Behavioral: Counselor Call; Behavioral: Booster reminder; Behavioral: Booster reminder; Behavioral: Booster reminder
Sponsors: University of Massachusetts, Worcester; University of Massachusetts, Worcester; Reliant Medical Group; Fallon Community Health Plan; National Cancer Institute (NCI)
Recruiting - verified April 2012
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions

Conditions: Marfan Syndrome; Turner Syndrome; Ehlers-Danlos Syndrome; Loeys-Dietz Syndrome; FBN1, TGFBR1, TGFBR2, ACTA2 or MYH11 Genetic Mutation; Bicuspid Aortic Valve Without Known Family History; Bicuspid Aortic Valve With Family History; Bicuspid Aortic Valve With Coarctation; Familial Thoracic Aortic Aneurysm and Dissections; Shprintzen-Goldberg Syndrome; Other Aneurysms and Dissections of the Thoracic Aorta Not Due to Trauma, <50yo; Other Congenital Heart Disease
Intervention:
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified May 2012
A Post Marketing Study of Apligraf in Non-healing Wounds of Subjects With Venous Leg Ulcers

Condition: Venous Ulcer
Interventions: Device: Apligraf; Other: Standard of care dressings
Sponsors: Organogenesis; Organogenesis
Recruiting - verified April 2012
Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer

Conditions: Breast Cancer; Hot Flashes
Interventions: Drug: Z-endoxifen hydrochloride; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Other: pharmacological study; Other: questionnaire administration
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified August 2011
Afatinib (BIBW2992) in HER2-overexpressing Inflammatory Breast Cancer

Condition: Breast Neoplasms
Interventions: Drug: Vinorelbine Weekly; Drug: Afatinib once daily (OD)
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012
Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer

Condition: Anal Cancer
Interventions: Drug: Tempol; Drug: 5-Fluorouracil; Drug: Mitomycin-C; Procedure: Radiation Therapy
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011
Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Intervention: Drug: TRC105
Sponsors: Tracon Pharmaceuticals Inc.; Tracon Pharmaceuticals Inc.; Roswell Park Cancer Institute; Department of Defense
Recruiting - verified March 2012
Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer

Condition: Her2normal
Intervention: Drug: eribulin mesylate
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified February 2012
18-F-Fluoroacetate as PET Imaging Agent

Conditions: Brain Cancer; Breast Cancer; Prostate Cancer
Intervention: Drug: 18F-fluoroacetate
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified December 2011
Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab.

Condition: Psoriasis
Intervention: Drug: Adalimumab
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; Abbott
Recruiting - verified September 2011
Clinical Evaluation of T.R.U.E. TEST Panel 3.2 in Children and Adolescents

Condition: Contact Dermatitis
Intervention: Biological: Patch Test
Sponsors: Allerderm; Allerderm
Not yet recruiting - verified March 2011
Prospective Randomized Study of Cell Therapy for Metastatic Melanoma Using Short-Term Cultured Tumor Infiltrating Lymphocytes Plus IL-2 Following Either a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Alone or in Conjunction w/1200 TBI

Conditions: Metastatic Melanoma; Skin Cancer
Interventions: Drug: Aldesleukin; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Young Tumor Infiltrating Lymphocytes; Procedure: 1200 Gy Irradiation
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011
PD0332991/Paclitaxel in Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Drug: PD0332991; Drug: Paclitaxel
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified February 2012
Topical Sodium Nitrite for Chronic Leg Ulcers in Adult Patients With Blood Disorders

Conditions: Sickle Cell Anemia; Sickle Cell Disease; Chronic Hemolytic Disorders
Intervention: Drug: Sodium Nitrite Cream
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2012
Diet Composition, Weight Control, and Breast Carcinogenesis

Condition: Breast Cancer
Intervention: Other: Weight Loss Dietary Pattern
Sponsors: Colorado State University; Colorado State University
Recruiting - verified February 2012
A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica

Conditions: Polymyalgia Rheumatica; Inflammatory Diseases
Interventions: Drug: AIN457; Drug: ACZ885 (canakinumab); Drug: Prednisone
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
SPY Intra-Operative Angiography & Skin Perfusion in Immediate Breast Reconstruction w/ Implants

Condition: Breast Cancer
Intervention: Procedure: SPY Intra-Operative Angiography
Sponsors: Stanford University; Stanford University
Recruiting - verified July 2011
Abatacept Costimulatory Blockade in the Treatment of Alopecia Totalis/Universalis

Condition: Alopecia Totalis/Universalis
Interventions: Drug: Abatacept; Drug: Inactive infusion
Sponsors: Columbia University; Columbia University
Not yet recruiting - verified September 2011
Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer

Condition: Breast Cancer
Intervention: Drug: AZ6244
Sponsors: University of Miami Sylvester Comprehensive Cancer Center; University of Miami Sylvester Comprehensive Cancer Center
Recruiting - verified March 2012
Effectiveness of Using Biomarkers to Detect and Identify Cardiotoxicity and Describe Treatment (PREDICT)

Conditions: Breast Cancer; Gastrointestinal Cancer; Genitourinary Cancer; Leukemia; Lung Cancer
Intervention: Other: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Biosite
Recruiting - verified December 2011
A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Placebo/CP-690,550; Drug: Placebo/CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer

Condition: Breast Cancer
Intervention: Radiation: Trastuzumab
Sponsors: Northwestern University; Northwestern University
Recruiting - verified May 2012
Safety and Efficacy Study of a New Treatment for Recurrent Symptoms of Oral Herpes Virus Infection

Condition: Oral Herpes Simplex
Interventions: Drug: BTL TML HSV; Drug: Matching placebo
Sponsors: Beech Tree Labs, Inc.; Beech Tree Labs, Inc.; Norwich Clinical Research Associates LTD
Recruiting - verified January 2012
Telephone Counseling-Mailed Materials Versus Internet Interventions in Overweight Cancer Survivors

Conditions: Breast Cancer; Colorectal Cancer; Prostate Cancer
Interventions: Behavioral: Standard Arm (mail/telephone); Behavioral: Internet Arm; Behavioral: Surveys and Questionnaires; Behavioral: Exercise and Diet
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Bioprosthetic Mesh to Expand the Lower Pole in Tissue Expander Reconstruction

Condition: Breast Cancer
Interventions: Device: Alloderm; Device: Surgimend
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo

Condition: Rosacea
Interventions: Drug: Doxycycline; Other: Placebo
Sponsors: Galderma Laboratories, L.P.; Galderma Laboratories, L.P.
Recruiting - verified February 2012
ABT-888 With Cyclophosphamide in Refractory BRCA-Positive Ovarian, Primary Peritoneal or Ovarian High-Grade Serous Carcinoma, Fallopian Tube Cancer, Triple-Negative Breast Cancer, and Low-Grade Non-Hodgkin's Lymphoma

Conditions: Ovarian; Primary Peritoneal; Serous Carcinoma; Triple-Negative Breast; Fallopian Tube
Interventions: Drug: ABT-888 with Cyclophospharmide; Drug: Cyclophosphamide
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011
A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases

Condition: HER-2 Positive Breast Cancer
Interventions: Drug: Everolimus; Drug: Vinorelbine; Drug: Trastuzumab
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; Novartis Pharmaceuticals
Recruiting - verified April 2012
Fear of Recurrence Pilot Intervention for Women With Breast Cancer

Condition: Cancer Recurrence
Intervention: Behavioral: Acceptance and Commitment Therapy
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified February 2012
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer

Condition: Breast Cancer
Intervention: Drug: MM-302
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals
Recruiting - verified November 2011
Reach for Health Study: Obesity-related Mechanisms and Mortality in Breast Cancer Survivors

Condition: Breast Neoplasms
Interventions: Drug: Metformin; Drug: Placebo; Behavioral: Lifestyle intervention; Behavioral: Standard printed dietary guidelines
Sponsors: University of California, San Diego; University of California, San Diego
Recruiting - verified February 2012
Contrast-Enhanced Digital Mammography (CEDM) for Identifying a Change in Management of Women With Newly Diagnosed Breast Cancer

Condition: Breast Cancer
Intervention: Other: DE-CEDM and CE-BMRI
Sponsors: GE Healthcare; GE Healthcare
Recruiting - verified January 2012
Study of BKM120 or BEZ235 and Capecitabine in Patients With Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: BMK120; Drug: Capecitabine; Drug: BEZ235
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; Novartis Pharmaceuticals
Recruiting - verified April 2012
MRI Evaluation of the Breast Areolar Margin and Paryenchyma

Condition: Breast Cancer
Intervention: Other: MRI
Sponsors: Piedmont Healthcare; Piedmont Healthcare
Recruiting - verified June 2011
Study of the P16 Gene as a Predictor of Myelosuppression in Breast Cancer Patients

Condition: Breast Cancer
Intervention:
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center
Recruiting - verified April 2012
Rosuvastatin to Lower Circulating Tissue Factor Bearing Microparticles in Metastatic Breast Cancer

Condition: Breast Cancer
Intervention: Drug: rosuvastatin
Sponsors: Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute; Massachusetts General Hospital; National Institutes of Health (NIH)
Recruiting - verified February 2012
Prospective Analysis of Changes in Background Parenchymal Enhancement (BPE) and Amount of Fibroglandular Tissue on Breast MRI

Condition: Breast Cancer
Intervention: Other: MRI
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012
Clinical Trial To Evaluate ANT-1207 In Subjects With Acne

Condition: Acne Vulgaris
Intervention: Biological: ANT-1207
Sponsors: Anterios Inc.; Anterios Inc.
Recruiting - verified January 2012
Intraoperative Boost Radiotherapy With Electrons (IOERT) Followed By Hypofractionated Whole-Breast Irradiation (WBRT)

Condition: Invasive Lobular and Ductal Carcinoma
Interventions: Radiation: Hypofractionated Whole Breast Radiation Therapy; Radiation: Intraoperative Electron Radiation Therapy
Sponsors: St. Joseph Hospital of Orange; St. Joseph Hospital of Orange
Recruiting - verified March 2012
Androgenetic Alopecia in Fabry Disease

Condition: Fabry Disease
Intervention:
Sponsors: Baylor Research Institute; Baylor Research Institute
Recruiting - verified February 2012
The Use of Bioimpedance to Determine Pre-Clinical Lymphedema in the Post-Operative Breast Cancer Patient

Condition: Breast Cancer
Intervention: Device: Garment Sleeve
Sponsors: Main Line Health; Main Line Health; Sharpe Strumia Foundation
Recruiting - verified January 2012
Effects of High Dose Calcitriol in Breast Cancer Patients

Condition: Breast Cancer
Intervention: Drug: Calcitriol
Sponsors: University of Rochester; University of Rochester
Recruiting - verified August 2011
Photodynamic Therapy Using Methyl-5-Aminolevulinate Hydrochloride Cream in Determining Pain Threshold in Patients With Skin Cancer

Conditions: Basal Cell Carcinoma of the Skin; Pain; Recurrent Skin Cancer
Interventions: Drug: methyl-5-aminolevulinate hydrochloride cream; Drug: photodynamic therapy; Procedure: laser therapy
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified May 2012
Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer

Conditions: Ductal Breast Carcinoma in Situ; Lobular Breast Carcinoma in Situ; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer
Interventions: Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery; Other: laboratory biomarker analysis; Other: enzyme-linked immunosorbent assay; Genetic: gene expression analysis; Drug: systemic chemotherapy; Drug: tamoxifen citrate; Drug: aromatase inhibition therapy
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University; National Cancer Institute (NCI)
Recruiting - verified April 2012
Transdermal Continuous Oxygen Therapy for Diabetic Foot Ulcers

Condition: Diabetic Foot Ulcers
Interventions: Device: Epiflo; Other: Moist Wound Therapy
Sponsors: Ogenix Corporation; Ogenix Corporation
Recruiting - verified December 2011
Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery

Conditions: Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Triple-negative Breast Cancer
Interventions: Drug: azacitidine; Other: laboratory biomarker analysis; Other: immunohistochemistry staining method; Genetic: polymerase chain reaction; Genetic: western blotting; Genetic: nucleic acid sequencing; Procedure: therapeutic conventional surgery
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012
The Effects of Radiation in Reconstructed Breasts

Condition: Breast Cancer
Interventions: Procedure: contract-enhanced MRI; Radiation: Unilateral Adjuvant Radiation Therapy
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified May 2012
Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Carboplatin; Radiation: 3D-RT or IMRT
Sponsors: New York University School of Medicine; New York University School of Medicine
Recruiting - verified March 2012
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32

Conditions: Breast Cancer; Depression; Fatigue; Sleep Disorders
Interventions: Drug: metformin hydrochloride; Genetic: DNA analysis; Genetic: RNA analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012
Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer

Conditions: HER2-negative Breast Cancer; Male Breast Cancer; Recurrent Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: paclitaxel; Biological: bavituximab; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: University of Arizona; University of Arizona; National Cancer Institute (NCI)
Recruiting - verified May 2012
Trial of Drain Antisepsis After Tissue Expander Breast Reconstruction

Conditions: Nonmalignant Breast Conditions; Breast Cancer
Interventions: Device: sodium hypochlorite (Dakins Soln); Drug: Chlorhexidine gluconate disk
Sponsors: Mayo Clinic; Mayo Clinic; University of California, San Francisco
Recruiting - verified April 2012
Dietary Fish and Omega 3 Fatty Acids for Breast Cancer Prevention

Condition: Breast Cancer
Intervention: Other: Dietary fish versus omega 3 fatty acid supplement capsules
Sponsors: Ohio State University Comprehensive Cancer Center; Ohio State University Comprehensive Cancer Center
Recruiting - verified May 2012
Lapatinib Ditosylate and MK2206 in Treating Women With Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Akt inhibitor MK2206; Drug: lapatinib ditosylate; Genetic: cytogenetic analysis; Genetic: gene expression analysis; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified July 2011
A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis.

Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Placebo/CP-690,550; Drug: Placebo/CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Pilot Study of Secondary Causes of Osteopenia/Osteoporosis in Adults With Breast and Prostate Cancer

Conditions: Breast Cancer; Prostate Cancer; Osteopenia; Osteoporosis
Intervention:
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified February 2012
Akt Inhibitor MK-2206 in Patients With Advanced Breast Cancer Who Have Tumors With a PIK3CA Mutation and/or PTEN Loss

Condition: Breast Cancer
Intervention: Drug: MK2206
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Institutes of Health (NIH)
Recruiting - verified April 2012
Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors

Conditions: Breast Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: cilengitide; Drug: paclitaxel; Other: enzyme-linked immunosorbent assay; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2012
Accelerated Hypofractionated Radiotherapy (AHF-RT) for the Treatment of Breast Cancer

Condition: Breast Cancer
Intervention: Radiation: accelerated hypofractionated radiotherapy (AHF-RT)
Sponsors: James Graham Brown Cancer Center; James Graham Brown Cancer Center; University of Louisville
Recruiting - verified December 2011
Predicting Pathological Response Within the 1st Week of Chemotherapy Using Diffuse Optical Spectroscopic Imaging

Condition: Breast Cancer
Intervention: Device: Diffuse Optical Spectroscopy Imaging
Sponsors: University of California, Irvine; Montana Compton
Recruiting - verified December 2011
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012
Trial on Wheeled Mobility for Preventing Pressure Ulcers

Condition: Mobility Limitation
Interventions: Device: Lightweight wheelchair; Device: Skin Protection Cushion
Sponsors: University of Pittsburgh; University of Pittsburgh; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified June 2011
Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Intervention: Drug: Lapatinib and RAD-001
Sponsors: University of Kansas; University of Kansas
Recruiting - verified October 2011
Endoxifen in Adults With Hormone Receptor-Positive Solid Tumors

Conditions: Hormone Receptor-Positive Breast; Gynecologic; Desmoid; Hormone Receptor-Positive Neoplasms
Interventions: Drug: z-Endoxifen; Drug: [(18)F] Fluoroestradiol
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: exemestane; Drug: letrozole; Drug: systemic chemotherapy; Drug: tamoxifen citrate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer

Condition: Breast Cancer
Intervention: Drug: pertuzumab in combination with trastuzumab and paclitaxel
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Genentech; University of Pennsylvania
Recruiting - verified April 2012
A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer

Conditions: Breast Neoplasms; Breast Cancer; Cancer of the Breast
Intervention: Drug: Lapatinib and Everolimus
Sponsors: Emory University; Emory University
Recruiting - verified January 2012
Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Metastatic Breast Cancer

Conditions: Breast Neoplasms; HER2 Protein, Human; Geriatric Health Services
Interventions: Drug: Lapatinib; Drug: Trastuzumab
Sponsors: City of Hope Medical Center; City of Hope Medical Center; GlaxoSmithKline; Genentech
Recruiting - verified January 2012
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Placebo; Drug: secoisolariciresinol
Sponsors: University of Kansas; Carol Fabian, MD; Lignan Research, Inc.
Recruiting - verified February 2012
Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer

Condition: Breast Cancer
Intervention: Drug: Eribulin Mesylate
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified March 2012
Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa

Conditions: Epidermolysis Bullosa Dystrophica; Epidermolysis Bullosa
Intervention: Genetic: LZRSE-Col7A1 Engineered Autologous Epidermal Sheets (LEAES)
Sponsors: Stanford University; Stanford University; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified January 2012
Prevalence of Human Papillomavirus in Men Living in the Northern Plains

Condition: Human Papillomavirus Infection
Intervention:
Sponsors: Sanford Health; Sanford Health
Recruiting - verified September 2011
Engaging Diverse Underserved Communities to Bridge the Mammography Divide

Condition: Breast Cancer Screening
Interventions: Other: MI2 intervention arm; Other: Control
Sponsors: University of Kansas; University of Kansas
Recruiting - verified May 2012
Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma

Condition: Melanoma
Interventions: Biological: MELITAC 12.1; Drug: Imiquimod
Sponsors: University of Virginia; University of Virginia
Recruiting - verified January 2012
Hypofractionation Trial

Condition: Breast Cancer
Interventions: Radiation: Hypofractionated Whole Breast Irradiation; Radiation: Conventionally Fractionated Whole Breast Irradiation
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified December 2011
Effects of Growth Hormone Releasing Hormone in HIV

Conditions: HIV; HIV Lipodystrophy
Interventions: Drug: tesamorelin; Drug: placebo
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified April 2012
A New Micrografting Technique for Vitiligo

Condition: Vitiligo
Interventions: Device: Dermabrasion-Micrografting; Procedure: Dermabrasion
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Momelan Technologies
Recruiting - verified May 2012
Exploratory Study of Norepinephrine to Prevent Radiodermatitis in Breast Cancer Patients

Condition: Radiodermatitis
Intervention: Drug: Norepinephrine
Sponsors: ProCertus BioPharm, Inc; ProCertus BioPharm, Inc; University of Wisconsin, Madison
Recruiting - verified January 2012
Feasibility Study of Biomarkers of Response to Neoadjuvant Paclitaxel in Locally Advanced Breast Cancer

Condition: Breast Cancer
Intervention: Procedure: tumor biopsy and blood draw
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison
Recruiting - verified February 2012
TKI258 for Metastatic Inflammatory Breast Cancer Patients

Condition: Breast Cancer
Intervention: Drug: Dovitinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis
Recruiting - verified January 2012
Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis

Condition: Dermatitis
Interventions: Biological: REGN668; Biological: REGN668; Biological: REGN668
Sponsors: Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Sanofi-Aventis
Recruiting - verified February 2012
Efficacy and Safety of a Sunscreen Against Porfimer Sodium-induced Phototoxicity to Visible Light

Conditions: High-grade Dysplasia in Barrett Esophagus; Non Small Cell Lung Cancer; Esophageal Cancer
Interventions: Drug: Solar Protection Formula SPF® 60; Procedure: Photobiological testing; Procedure: Blood collection
Sponsors: Pinnacle Biologics Inc.; Pinnacle Biologics Inc.
Not yet recruiting - verified May 2012
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis [PSA, PALACE 4]

Condition: Psoriatic Arthritis
Interventions: Drug: Apremilast; Drug: • Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified June 2011
GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases

Conditions: Lupus Erythematosus, Systemic; Systemic Vasculitis; Isolated Angiitis of Central Nervous System; Lung Disease With Systemic Sclerosis; Lung Disease Interstitial Diffuse
Interventions: Drug: depot leuprolide acetate 3.75 mg; Drug: Placebo
Sponsors: University of Michigan; Joseph Mccune; National Institutes of Health (NIH)
Recruiting - verified February 2012
Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging

Condition: Breast Cancer
Intervention: Device: Diffuse Optical Spectroscopy Imaging
Sponsors: University of California, Irvine; Montana Compton; American College of Radiology Imaging Network; Massachusetts General Hospital; University of Pennsylvania; Dartmouth-Hitchcock Medical Center; Brown University; University of San Francisco
Recruiting - verified October 2011
Delayed-Delayed Breast Reconstruction

Condition: Breast
Intervention: Procedure: Delayed Breast Reconstruction
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer

Conditions: Breast Neoplasms; Breast Cancer; Breast Tumors; Cancer of Breast; Cancer of the Breast; Human Mammary Carcinoma; Neoplasms, Breast
Interventions: Procedure: Remove tumor only; Procedure: Removal of tumor and tissue
Sponsors: Emory University; Emory University
Recruiting - verified March 2012
A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer

Condition: Breast Neoplasms
Intervention: Drug: GRN163L in combination with trastuzumab
Sponsors: Indiana University; Indiana University; Breast Cancer Research Foundation; Geron Corporation
Recruiting - verified May 2012
Veliparib and Carboplatin in Treating Women With HER2-Negative Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: carboplatin; Drug: veliparib; Other: 3'-deoxy-3'-[18F]fluorothymidine; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Arthur G. James Cancer Hospital & Richard J. Solove Research Institute; National Cancer Institute (NCI)
Recruiting - verified April 2012
Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: bevacizumab; Drug: GDC-0980; Drug: paclitaxel
Sponsors: Genentech; Genentech
Recruiting - verified May 2012
BRCA Mutations in Latinas

Condition: Breast Neoplasms
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified August 2011
Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection

Conditions: Anal Cancer; Breast Cancer; Esophageal Cancer; Gastric Cancer; Head and Neck Cancer; Lung Cancer; Nonneoplastic Condition; Ovarian Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: vorinostat; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012
Histologic Assessment of the Difference Between 18F-2-fluoro-2-deoxy_D-glucose Positron Emission Mammography(PEM) and Magnetic Resonance Imaging (MRI) of the Breast

Condition: Breast Cancer
Intervention: Device: Positron Emission Mammography (PEM) and Magnetic Resonance Imaging (MRI)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012
Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)

Conditions: Stevens-Johnson Syndrome; Corneal Blindness
Intervention: Drug: Infliximab
Sponsors: Massachusetts Eye and Ear Infirmary; Massachusetts Eye and Ear Infirmary; Massachusetts Eye Research and Surgery Institution
Recruiting - verified May 2012
PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: BKM120; Drug: BEZ235; Drug: Letrozole; Drug: BKM120
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center
Recruiting - verified July 2011
Breast Cancer Risk Biomarkers in Premenopausal Women

Condition: Breast Cancer
Intervention: Drug: Lovaza™
Sponsors: University of Kansas; Carol Fabian, MD
Recruiting - verified February 2012
Breast Cancer Risk Biomarkers in Postmenopausal Women

Condition: Breast Cancer
Intervention: Drug: Lovaza™
Sponsors: University of Kansas; Carol Fabian, MD; GlaxoSmithKline
Recruiting - verified February 2012
Oral Curcumin for Radiation Dermatitis

Condition: Radiation-induced Dermatitis
Intervention: Drug: Curcumin
Sponsors: University of Rochester; University of Rochester; National Cancer Institute (NCI)
Recruiting - verified March 2012
Partial Breast Proton Beam Irradiation

Condition: Breast Cancer
Intervention: Radiation: Accelerated Partial Breast Irradiation (APBI)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer

Condition: Breast Cancer
Interventions: Procedure: palliative surgery; Procedure: therapeutic conventional surgery; Radiation: palliative radiation therapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Asthma, Missed Immunizations, and Vitamin D Deficiency in Atopic Dermatitis

Conditions: Atopic Dermatitis; Vitamin D Deficiency; Asthma
Intervention:
Sponsors: Medical College of Wisconsin; Medical College of Wisconsin; Children's Hospital and Health System Foundation, Wisconsin
Recruiting - verified July 2011
RO4929097, Paclitaxel, And Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: carboplatin; Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097; Drug: paclitaxel; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Arthur G. James Cancer Hospital & Richard J. Solove Research Institute; National Cancer Institute (NCI)
Recruiting - verified July 2011
Olaparib in Combination With Carboplatin for Refractory or Recurrent Women's Cancers

Conditions: Mixed Muellerian Cancer; Cervical Cancer; Ovarian Cancer; Breast Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer; Endometrial Cancer; Carcinosarcoma
Interventions: Drug: Carboplatin; Drug: Olaparib; Drug: Treatment Effect
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified August 2011
Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes

Conditions: Skin Cancer; Metastatic Melanoma
Interventions: Drug: Fludarabine; Drug: Cyclophosphamide; Other: Gene Transfer
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified August 2011
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients

Condition: Breast Cancer
Interventions: Biological: Ramucirumab DP; Biological: IMC-18F1; Drug: Capecitabine
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified May 2012
Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab

Condition: Advanced HER2-positive Breast Cancer
Intervention: Drug: AUY922 + Trastuzumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Entinostat and Anastrozole or Tamoxifen in Treating Women With Triple-Negative Breast Cancer That Can Be Removed by Surgery

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: entinostat; Drug: tamoxifen citrate; Genetic: reverse transcriptase-polymerase chain reaction; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); University of Chicago; National Cancer Institute (NCI)
Recruiting - verified January 2011
Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects?

Condition: Psoriasis
Intervention: Drug: Acitretin 17.5 mg/day
Sponsors: Frankel, Amylynne, M.D.; Frankel, Amylynne, M.D.; Stiefel, a GSK Company
Recruiting - verified June 2011
One-Time DNA Study for Vasculitis

Conditions: Churg-Strauss Syndrome; Giant Cell Arteritis; Granulomatosis With Polyangiitis (Wegener's); Microscopic Polyangiitis; Polyarteritis Nodosa; Takayasu's Arteritis
Intervention:
Sponsors: Boston University; Boston University; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Office of Rare Diseases (ORD); Rare Diseases Clinical Research Network
Recruiting - verified February 2012
Cryotherapy in Preventing Peripheral Neuropathy and Nail Toxicity in Patients With Breast Cancer Who Are Receiving Paclitaxel

Conditions: Chemotherapeutic Agent Toxicity; Pain; Peripheral Neuropathy; Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Therapy-related Toxicity
Interventions: Procedure: cryotherapy; Other: questionnaire administration; Procedure: quality-of-life assessment; Procedure: management of therapy complications; Procedure: assessment of therapy complications
Sponsors: Northwestern University; Northwestern University; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Eniluracil; Drug: 5-Fluorouracil; Drug: Leucovorin; Drug: Capecitabine
Sponsors: Adherex Technologies, Inc.; Adherex Technologies, Inc.
Recruiting - verified August 2011
MIRNA Profiling of Breast Cancer in Patients Undergoing Neoadjuvant or Adjuvant Treatment for Locally Advanced & Inflammatory Breast Cancer

Condition: Breast Cancer
Intervention:
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified January 2012
Prevention of Post-Mastectomy Breast Pain Using Ambulatory Continuous Paravertebral Blocks

Conditions: Paravertebral Catheter Insertion; Mastectomy; Breast Cancer
Interventions: Procedure: Placebo (normal saline) Continuous Infusion; Procedure: Ropivicaine 0.4% Continuous Infusion
Sponsors: University of California, San Diego; University of California, San Diego
Recruiting - verified March 2012
Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses

Condition: Actinic Keratosis
Interventions: Drug: Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm; Drug: Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
Sponsors: Frankel, Amylynne, M.D.; Frankel, Amylynne, M.D.; Graceway Pharmaceuticals, LLC
Recruiting - verified June 2011
A Multicenter, Prospective, Observational Study With PriMatrix for the Treatment of Neuropathic Diabetic Foot Ulcers

Condition: Foot Ulcers, Diabetic
Intervention: Device: PriMatrix
Sponsors: TEI Biosciences Inc.; TEI Biosciences Inc.; Mayo Clinic; California School of Podiatric Medicine; New York College of Podiatric Medicine; Temple University
Recruiting - verified June 2011
The Use of Bioscaffolds in Conjunction With Negative Pressure Therapy: A Prospective Randomized Double-Blinded Trial

Condition: Foot Ulcer, Diabetic
Intervention: Device: PriMatrix
Sponsors: TEI Biosciences Inc.; TEI Biosciences Inc.; Beth Israel Deaconess Medical Center
Recruiting - verified June 2011
Botulinum Toxin A for Herpes Labialis

Condition: Herpes Labialis
Interventions: Drug: onabotulinumtoxinA; Other: Bacteriostatic normal saline
Sponsors: DeNova Research; DeNova Research; Allergan
Recruiting - verified June 2011
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors

Condition: Breast Cancer
Interventions: Drug: BMS-754807; Drug: letrozole
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Mayo Clinic
Recruiting - verified December 2011
Vitamin D and Breast Cancer Biomarkers in Female Patients

Condition: Breast Cancer
Interventions: Dietary Supplement: vitamin D; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Participation Restrictions in Breast Cancer Survivors

Condition: Breast Cancer
Intervention: Behavioral: Behavioral activation/problem-solving (BA/PS)
Sponsors: Dartmouth-Hitchcock Medical Center; Dartmouth-Hitchcock Medical Center; National Cancer Institute (NCI)
Recruiting - verified June 2011
Studies of Disorders With Increased Susceptibility to Fungal Infections

Conditions: Primary Immune Deficiency; Candida; Autoimmune Polyendocrinopathy Candidiasis Ectodermal; Chronic Mucocutaneous Candidiasis (CMC); Fungal Infection
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2011
To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus

Condition: Cutaneous Lupus Erythematosus
Intervention: Drug: CC-11050
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified February 2012
Tesetaxel as First-line Therapy for Metastatic Breast Cancer

Condition: Breast Neoplasm
Intervention: Drug: Tesetaxel
Sponsors: Genta Incorporated; Genta Incorporated
Recruiting - verified November 2011
Tissue Expander Breast Reconstruction Study on Breast Volume and Shape Change

Condition: Post-Mastectomy Breast Cancer Reconstruction
Interventions: Device: Contour Profile Tissue Expander; Device: Standard Round Tissue Expander
Sponsors: Northwestern University; Northwestern University; Mentor Worldwide, LLC
Recruiting - verified July 2011
The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)

Condition: Breast Cancer
Interventions: Drug: Ridaforolimus + Dalotuzumab; Drug: Ridaforolimus; Drug: Dalotuzumab
Sponsors: Merck; Merck
Recruiting - verified May 2012
Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

Conditions: Neoplasms, Breast; WT1-positive Primary Invasive Breast Cancer
Interventions: Biological: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A; Biological: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Diffuse Optical Spectroscopy Imaging in Monitoring and Predicting Response in Patients With Locally Advanced Breast Cancer Undergoing Chemotherapy Before Surgery

Condition: Breast Cancer
Interventions: Drug: systemic chemotherapy; Other: laser spectroscopy; Procedure: breast imaging study; Procedure: magnetic resonance imaging; Procedure: mammography; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery; Procedure: ultrasound imaging
Sponsors: National Cancer Institute (NCI); American College of Radiology Imaging Network; National Cancer Institute (NCI)
Recruiting - verified January 2012
Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer

Conditions: BRCA1 Mutation Carrier; BRCA2 Mutation Carrier; Ductal Breast Carcinoma in Situ; Lobular Breast Carcinoma in Situ; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer
Interventions: Dietary Supplement: soy isoflavones; Other: placebo; Other: questionnaire administration; Procedure: magnetic resonance imaging; Procedure: biopsy; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: mammography
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; National Cancer Institute (NCI); California Breast Cancer Research Program
Recruiting - verified May 2012
Ultrasound vs. Predetermined Distance Techniques for Paravertebral Nerve Block in Patients Having Breast Surgery

Conditions: Mastectomy; Breast Neoplasms
Interventions: Procedure: ultrasound; Procedure: predetermined distance
Sponsors: Ochsner Health System; Ochsner Health System
Recruiting - verified October 2011
Pre-Surgery Positron Emission Mammography in Patients With Newly Diagnosed Breast Cancer

Conditions: Breast Cancer; Breast Cancer Surgery
Intervention: Device: Positron Emission Mammography (PEM)
Sponsors: Swedish Medical Center; Swedish Medical Center
Recruiting - verified May 2012
Evaluation of the Cook Biodesign Plastic Surgery Matrix

Conditions: Breast Cancer; Breast Reconstruction; Nipple Reconstruction
Intervention: Device: Nipple reconstruction
Sponsors: Cook; Cook
Recruiting - verified March 2012
A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZDO530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Anastrozole; Drug: ADZ0530; Drug: Placebo; Procedure: Pharmacokinetic studies; Procedure: Definitive Surgery; Procedure: Core Biopsy; Genetic: Tumor Tissue Collection for Genetic and Molecular Studies
Sponsors: University of Miami Sylvester Comprehensive Cancer Center; University of Miami Sylvester Comprehensive Cancer Center; Doris Duke Charitable Foundation
Recruiting - verified October 2011
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Sorafenib(Nexavar, BAY43-9006) / Capecitabine; Drug: Placebo / Capecitabine
Sponsors: Bayer; Bayer; Onyx Therapeutics, Inc.
Recruiting - verified April 2012
Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients

Conditions: Cryopyrin-associated Periodic Syndromes (CAPS); Familial Cold Autoinflam Syn (FCAS); Muckle-wells Syn (MWS); Neonatal Onset Multisystem Inflam Disease (NOMID)
Intervention:
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

Conditions: Melanoma; NY-ESO-1-positive; Progressive Metastatic Cutaneous Melanoma; Unresectable
Intervention: Biological: GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic (ASCI)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Positron Emission Tomography (PET)-Computed Tomography (CT) PET/CT Evaluation of Treatment Response in Breast Cancer

Condition: Breast Cancer
Interventions: Radiation: Radiopharmaceutical Administration [18F]-FDG; Radiation: Radiopharmaceutical: [18F]-FLT
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center
Recruiting - verified November 2011
Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males

Conditions: Anal Cancer; Nonneoplastic Condition; Penile Cancer; Precancerous Condition
Interventions: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012
Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction

Conditions: Breast Cancer; Ductal Carcinoma
Interventions: Procedure: Nipple Area Complex-Sparing Mastectomy; Radiation: Nipple Area Complex Irradiation; Procedure: Breast Reconstruction; Procedure: Axillary Dissection or Sentinel Node Biopsy (SNB); Drug: Chemotherapy
Sponsors: University of Miami Sylvester Comprehensive Cancer Center; University of Miami Sylvester Comprehensive Cancer Center
Recruiting - verified October 2011
Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer

Conditions: HER2-positive Breast Cancer; Male Breast Cancer; Stage IV Breast Cancer
Interventions: Biological: HER-2/neu peptide vaccine; Drug: cyclophosphamide; Biological: ex vivo-expanded HER2-specific T cells; Other: laboratory biomarker analysis; Other: flow cytometry; Other: immunoenzyme technique
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Not yet recruiting - verified May 2012
Questionnaire and Laboratory Data on Vitiligo Vulgaris

Condition: Vitiligo Vulgaris
Intervention:
Sponsors: St. Luke's-Roosevelt Hospital Center; St. Luke's-Roosevelt Hospital Center; Beth Israel Medical Center
Recruiting - verified July 2011
Partial Breast Irradiation (PBI) Using 40 Gy for Select Patients With Early Invasive or Noninvasive Breast Cancer

Condition: Breast Cancer
Intervention: Radiation: multiple beams utilizing either intensity-modulated or 3D-conformal techniques
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012
Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy

Condition: Actinic Keratosis
Interventions: Drug: Imiquimod/photodynamic therapy; Drug: Imiquimod only
Sponsors: Tennessee Clinical Research Center; Tennessee Clinical Research Center; Graceway Pharmaceuticals, LLC
Recruiting - verified July 2011
Yoga for Women With Breast Cancer Undergoing Radiotherapy

Condition: Breast Cancer
Interventions: Other: Yoga Program; Other: Stretching + Relaxation Program; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified December 2011
Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Abraxane; Drug: Carboplatin
Sponsors: Duke University; Duke University; Celgene Corporation
Recruiting - verified September 2011
A Study to Investigate the Efficacy, Safety and Tolerability of Nexagon® as a Topical Treatment for Subjects With Venous Leg Ulcers

Condition: Venous Leg Ulcers
Interventions: Drug: Nexagon® 1.0 mg/mL; Drug: Nexagon® 3.0 mg/mL; Drug: Nexagon® Vehicle; Device: Compression dressings
Sponsors: CoDa Therapeutics Inc.; CoDa Therapeutics Inc.
Recruiting - verified November 2011
Predictors of Ovarian Insufficiency in Young Breast Cancer Patients

Conditions: Breast Cancer; Ovarian Insufficiency; Ovarian Failure
Intervention:
Sponsors: University of California, San Diego; University of California, San Diego; University of Pennsylvania; American Cancer Society; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified August 2011
Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer

Condition: Advanced or Metastatic Breast Cancer
Intervention: Drug: KW-2450 in combination with lapatinib and letrozole
Sponsors: Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin Pharma, Inc.
Recruiting - verified February 2012
Study of Erlotinib in the Treatment of Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC) of the Skin

Condition: Skin Cancer
Intervention: Drug: Erlotinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; OSI Pharmaceuticals
Recruiting - verified February 2012
Low Dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction

Condition: Breast Cancer
Interventions: Drug: Tamoxifen Citrate; Drug: Placebo
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI); St. Jude Children's Research Hospital; University Health Network, Toronto; Emory University; University of Michigan
Recruiting - verified February 2012
A Phase I Study of MGAH22 in Patients With Refractory HER2 Positive Cancers

Conditions: Non-Small Cell Lung Neoplasms; Prostate Neoplasms; Bladder Neoplasms; Ovarian Neoplasms; Breast Neoplasms
Intervention: Drug: MGAH22
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012
Preoperative Clinical Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Triple Negative (ER-, PR-, Her2-)Early Stage Breast Cancer

Condition: Breast Cancer
Intervention: Drug: Sorafenib
Sponsors: Emory University; Emory University; Onyx Pharmaceuticals; Bayer
Recruiting - verified April 2012
Re-expression of ER in Triple Negative Breast Cancers

Conditions: Breast Cancer; Breast Tumors; Breast Neoplasms
Intervention: Drug: Decitabine, LHB589, Tamoxifen
Sponsors: Emory University; Emory University; Novartis; Eisai Inc.
Recruiting - verified May 2012
Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms

Conditions: Ductal Carcinoma in Situ; Estrogen Receptor-positive Breast Cancer; Progesterone Receptor-positive Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
Interventions: Drug: letrozole; Drug: zoledronic acid; Other: laboratory biomarker analysis; Other: enzyme-linked immunosorbent assay; Other: mass spectrometry; Procedure: bone scan; Procedure: quality-of-life assessment; Other: questionnaire administration; Other: pharmacogenomic studies; Other: high performance liquid chromatography
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified January 2012
Symptom Burden in Patients With Cancer- and Treatment-Related Skin Problems

Condition: Skin Cancer
Interventions: Behavioral: Part 1: Interview + Questionnaires; Behavioral: Part 2: Multiple Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects

Conditions: Human Papillomavirus Infection; Cervical Neoplasia
Interventions: Procedure: Gynaecological follow-up; Biological: Cervarix™; Biological: Placebo control
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks

Condition: Hereditary Angioedema
Interventions: Drug: rhC1INH; Drug: Placebo (Saline)
Sponsors: Pharming Technologies B.V.; Pharming Technologies B.V.
Recruiting - verified April 2012
Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors

Condition: Breast Cancer
Interventions: Device: Focused Microwave Thermotherapy; Drug: Chemotherapy (control)
Sponsors: Medifocus, Inc.; Medifocus, Inc.
Recruiting - verified August 2011
A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Optimal Type of Aerobic Training in Breast Cancer

Condition: Breast Cancer
Interventions: Behavioral: High-Intensity Aerobic Training; Behavioral: Moderate-Intensity Aerobic Training; Behavioral: Progressive Stretching
Sponsors: Duke University; Duke University
Recruiting - verified July 2011
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy

Condition: Breast Cancer
Interventions: Radiation: accelerated partial breast irradiation - 3D-conformal planning; Radiation: accelerated partial breast irradiation - IMRT planning
Sponsors: Rocky Mountain Cancer Centers; Rocky Mountain Cancer Centers
Recruiting - verified March 2011
Rehabilitation of Cognitive Changes in Breast Cancer Survivors

Condition: Breast Cancer
Intervention: Behavioral: Cogmed Working Memory Training Program
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; MARTELL FOUNDATION
Recruiting - verified October 2011
Study Evaluating the Safety and Efficacy of Onartuzumab (Metmab) And/Or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: bevacizumab; Drug: MetMAb; Drug: paclitaxel; Drug: placebo
Sponsors: Genentech; Genentech; Hoffmann-La Roche
Recruiting - verified March 2012
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

Conditions: Multiple Myeloma; Diffuse Large B-Cell Lymphoma; Glioblastoma Multiforme; Hepatocellular Carcinoma; Non-Small Cell Lung Cancer; Gastrointestinal Neuroendocrine Tumors of Non-Pancreatic Origin; Hormone Receptor-Positive Breast Cancer
Intervention: Drug: CC-223
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012
Psoriasis Inflammation and Systemic Co Morbidities

Condition: Psoriasis
Intervention:
Sponsors: Rockefeller University; Rockefeller University; Weill Medical College of Cornell University
Recruiting - verified May 2012
Cardiotoxicity of Cancer Therapy (CCT)

Condition: Subjects With Breast Cancer
Interventions: Other: Blood, Echocardiography, and Questionnaire Timepoints for Anthracycline abd Trastuzumab; Other: Blood, Echocardiography and Questionnaire for Trastuzumab; Other: Blood, Echocardiography and Questionnaire for Anthracycline Regimen
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified May 2012
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

Conditions: Estrogen Receptor Negative (ER-Negative) Breast Cancer; Progesterone Receptor Negative (PR-Negative) Breast Cancer; Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast Cancer; Brain Metastases
Intervention: Drug: INIPARIB + irinotecan
Sponsors: Sanofi-Aventis; Sanofi-Aventis; UNC Lineberger Comprehensive Cancer Center
Recruiting - verified October 2011
Natural History of Diseases Associated With Allergic Inflammation: Atopic Dermatitis and Genetic and Congenital Diseases Associated With Atopic Pathways

Conditions: Atopic Dermatitis; Netheron's Syndrome; Piebaldism; Hyper IgE Syndrome; Ichthyosis; Anaphylaxis; Severe Allergy
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012
Impact of Breast Magnetic Resonance Imaging (MRI) on Mastectomy Rates

Condition: Early Stage Breast Cancer
Intervention:
Sponsors: Summa Health System; Summa Health System
Recruiting - verified April 2012
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus

Conditions: Cutaneous Lupus; Discoid Lupus; Lupus; Systemic Lupus Erythematosus
Interventions: Drug: AMG811; Drug: AMG811 Placebo
Sponsors: Amgen; Amgen
Recruiting - verified March 2012
Acupuncture Study for the Prevention of Taxane Induced Myalgias and Neuropathy

Conditions: Taxane Induced Neuropathy; Breast Cancer
Interventions: Other: Electro-acupuncture; Other: Sham acupuncture
Sponsors: Columbia University; Columbia University; Breast Cancer Research Foundation
Recruiting - verified October 2011
Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity

Conditions: Pleural Metastases; Breast Cancer; Colon Cancer; Ovarian Cancer; Uterine Cancer; Renal Cell Cancer; Thymic Cancer
Intervention: Procedure: Surgical debulking and Intrathoracic Hyperthermic Chemotherapy
Sponsors: St. Luke's-Roosevelt Hospital Center; St. Luke's-Roosevelt Hospital Center
Recruiting - verified September 2011
A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer

Condition: Breast Cancer
Intervention: Drug: paclitaxel
Sponsors: University of Kansas; University of Kansas; Novartis
Recruiting - verified October 2011
Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer

Condition: Breast Neoplasms
Intervention: Drug: Platinum based chemotherapy, radiation, surgery
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011
Genetics of Mammographic Appearances and Patterns (The GenMap Study)

Conditions: High Mammographic Density; Breast Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified February 2012
Exercise Program of Breast Cancer Patients Undergoing Chemotherapy With or Without Radiation

Condition: Breast Cancer
Intervention: Other: standardized regimen of exercises, including a warm-up period, ROM arm exercises, and strength training exercises.
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified November 2011
Acupuncture for Sleep Disruption in Cancer Survivors

Conditions: Sleep Initiation and Maintenance Disorders; Breast Cancer
Intervention: Procedure: acupuncture
Sponsors: Stanford University; Stanford University; National Institutes of Health (NIH); National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified January 2012
Improved Breast DCE MRI With SWIFT

Condition: Breast Cancer
Intervention: Device: Magnetic resonance imaging
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

Condition: Neoplasms, Breast
Interventions: Drug: lapatinib; Drug: trastuzumab; Drug: Aromatase inhibitor; Drug: lapatinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Breast Cancer Patients: A Breast Cancer Rehabilitation and Exercise Laboratory

Condition: Early Stage Breast Cancer (Stage 0-III)
Intervention: Other: Exercise Regimen
Sponsors: Nevada Cancer Institute; Nevada Cancer Institute; Vons
Recruiting - verified July 2011
Moderating the Negative Impact of Abnormal Screening Mammograms

Condition: Breast Cancer
Intervention: Behavioral: Comprehensive Health Enhancement Support System (CHESS.)
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison; National Cancer Institute (NCI)
Recruiting - verified November 2011
Evaluate Reversal of Pathological Epidermal Phenotype in Severe Atopic Dermatitis (AD) With Suppression of Immune Activation During Cyclosporine A Therapy

Conditions: Atopic Dermatitis; Eczema
Intervention: Drug: Cyclosporine A
Sponsors: Rockefeller University; Rockefeller University
Recruiting - verified February 2012
Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer

Condition: Her2 Negative Breast Cancer Patients
Interventions: Drug: MM-121 (SAR256212) and Exemestane; Drug: Placebo and Exemestane
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals
Recruiting - verified May 2012
Improving Psoriasis Through Health and Well-Being

Condition: Psoriasis
Interventions: Behavioral: Mindfulness-Based Stress Reduction; Behavioral: Living Well
Sponsors: University of Rochester; University of Rochester; National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified December 2011
Interpersonal Therapy for Depression in Breast Cancer

Condition: Major Depression
Interventions: Behavioral: Interpersonal Psychotherapy; Behavioral: Problem-Solving Therapy; Behavioral: Brief Supportive Psychotherapy
Sponsors: New York State Psychiatric Institute; New York State Psychiatric Institute
Recruiting - verified February 2012
Excision Followed by Radiofrequency Ablation for Breast Cancer

Condition: Breast Cancer
Intervention: Device: Radiofrequency Ablation
Sponsors: University of Arkansas; University of Arkansas; Angiodynamics, Inc.
Recruiting - verified February 2012
RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: exemestane; Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097; Drug: goserelin acetate
Sponsors: National Cancer Institute (NCI); H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI)
Recruiting - verified June 2011
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy

Conditions: Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: vorinostat; Other: laboratory biomarker analysis; Procedure: biopsy; Radiation: F-18 16 alpha-fluoroestradiol; Procedure: positron emission tomography; Drug: anastrozole; Drug: letrozole; Drug: exemestane; Genetic: gene expression analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012
Intraoperative Radiotherapy for Early Stage Breast Cancer

Condition: Breast Cancer
Intervention: Device: Intraoperative Radiotherapy
Sponsors: Hoag Memorial Hospital Presbyterian; Hoag Memorial Hospital Presbyterian
Recruiting - verified April 2012
Group Eczema Education Visits:Impact on Patient and Family Quality of Life

Condition: Eczema
Interventions: Other: Group eczema education session; Other: Control group
Sponsors: Oregon Health and Science University; Oregon Health and Science University
Recruiting - verified May 2010
Safety Study of MGAH22 in HER2-positive Carcinomas

Conditions: Breast Cancer; Gastric Cancer; Bladder Cancer; Ovarian Cancer; Non-small Cell Lung Cancer
Intervention: Biological: MGAH22
Sponsors: MacroGenics; MacroGenics; Green Cross Corporation; National Cancer Institute (NCI)
Recruiting - verified April 2012
Laboratory-Treated T Cells After Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer Undergoing Surgery

Condition: Breast Cancer
Interventions: Biological: HER2Bi-armed activated T cells; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel; Other: laboratory biomarker analysis; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified January 2012
A Study to Look at the Effects of Four Weeks of Treatment on the Healing of Diabetic Foot Ulcers

Condition: Diabetic Foot Ulcers
Interventions: Drug: Santyl; Other: White Petrolatum
Sponsors: Healthpoint; Healthpoint
Recruiting - verified December 2011
Safety, Efficacy, and PK of Topical Paromomycin/Gentamicin Cream for Treatment of Cutaneous Leishmaniasis

Condition: Leishmaniasis, Cutaneous
Intervention: Drug: WR 279,396
Sponsors: U.S. Army Medical Research and Materiel Command; U.S. Army Medical Research and Materiel Command; Walter Reed National Military Medical Center; Walter Reed Army Institute of Research (WRAIR)
Recruiting - verified February 2012
Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer

Conditions: Breast Cancer; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Other: questionnaire administration; Procedure: evaluation of cancer risk factors; Procedure: quality-of-life assessment; Procedure: study of high risk factors
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
The Effect of Weight Loss on Psoriasis Area Severity Index in Adult Psoriasis Patients

Conditions: Psoriasis; Obesity
Intervention: Behavioral: Weight Loss
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston; National Institutes of Health (NIH)
Recruiting - verified February 2012
Biomarkers in Blood Samples From Older Breast Cancer Survivors

Condition: Breast Cancer
Interventions: Genetic: gene expression analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: laboratory biomarker analysis; Other: medical chart review; Other: questionnaire administration
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012
Ethnic Differences in the Impact of Breast Cancer on Employment Status, Financial Situation, and Quality of Life

Condition: Breast Cancer
Interventions: Behavioral: survey web-based or telephone interview; Behavioral: survey web-based or telephone interview
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; The City College of New York; New York City Health and Hospitals Corporation; Lincoln Medical and Mental Health Center; New York Hospital Queens; Ralph Lauren Center for Cancer Care and Prevention
Recruiting - verified May 2012
Effectiveness of a Cancer Center Based Physical Activity Intervention

Conditions: Breast Cancer; Quality of Life; Physical Activity
Intervention: Behavioral: Physical activity counseling
Sponsors: East Carolina University; East Carolina University
Recruiting - verified June 2011
A Pilot Study Using Anakinra/Kineret for the Treatment of Patients With Severe Atopic Dermatitis

Conditions: Anakinra; Kineret; Atopic Dermatitis; Eczema; Allergic Disease
Intervention: Drug: Anakinra
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified August 2011
Patient Registry: Partial Breast Irradiation

Condition: Breast Cancer
Intervention:
Sponsors: Aurora Health Care; David Rohde
Recruiting - verified January 2012
Multi-Beam Intensity-Modulated Radiation Therapy for Node-Positive Breast Cancer

Condition: Breast Cancer
Intervention: Radiation: Multi-Beam Intensity-Modulated Radiation Therapy
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012
RAD001 Plus Carboplatin in Breast Cancer Patients

Condition: Breast Cancer
Intervention: Drug: RAD001
Sponsors: New York University School of Medicine; New York University School of Medicine; Novartis Pharmaceuticals
Recruiting - verified December 2011
A Pilot Study of Docosahexaenoic Acid (DHA) in Obese Menopausal Women

Conditions: Breast Cancer; Rectal Cancer; Colon Cancer; Obesity
Intervention: Dietary Supplement: dietary intervention
Sponsors: Rockefeller University; Rockefeller University
Recruiting - verified April 2012
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer

Condition: Breast Cancer
Interventions: Drug: tamoxifen citrate; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
National Psoriasis Foundation - Dendritic Cell-Specific Transmembrane Protein (DC-Stamp) Biomarker Study

Condition: Psoriatic Arthritis
Interventions: Drug: Methotrexate; Drug: Anti-TNF
Sponsors: University of Rochester; University of Rochester; National Psoriasis Foundation
Recruiting - verified October 2011
Atralin Gel for the Treatment of Rosacea

Condition: Rosacea
Interventions: Drug: vehicle gel; Drug: Atralin gel
Sponsors: University of Michigan; University of Michigan; Valeant Pharmaceuticals International, Inc.
Recruiting - verified October 2011
LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment

Condition: Breast Neoplasms
Interventions: Drug: BIBW 2992; Drug: trastuzumab; Drug: vinorelbine; Drug: vinorelbine
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012
Safety and Efficacy of BKM120 in Combination With Trastuzumab in Patients With Relapsing HER2 Overexpressing Breast Cancer Who Have Previously Failed Trastuzumab

Conditions: Metastatic Breast Cancer; Trastuzumab; BKM120; HER2+
Intervention: Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Study to Evaluate the Effect of a Nu Skin Product and Device for Brown Spots

Condition: Hyperpigmentation
Interventions: Other: Nu Skin Product; Other: Cosmetic instrument; Drug: Tretinoin cream 0.05; Other: CeraVe moisturizer
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified July 2011
Cediranib and Olaparib in Combination for Recurrent Ovarian or Triple-Negative Breast Cancer

Conditions: Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer
Interventions: Drug: cediranib; Drug: olaparib
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Massachusetts General Hospital; Beth Israel Deaconess Medical Center; University of Chicago; National Cancer Institute (NCI)
Recruiting - verified April 2012
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: pertuzumab; Drug: pertuzumab-placebo; Drug: trastuzumab [Herceptin]; Drug: docetaxel; Drug: paclitaxel
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Genentech
Recruiting - verified March 2012
Role of Beta-Endorphin in Cancer Therapy Fatigue

Conditions: Breast Cancer; Fatigue
Intervention:
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified April 2012
Breast Cancer Rehabilitation Program in Improving Quality of Life in Breast Cancer Survivors

Conditions: Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer
Interventions: Other: questionnaire administration; Behavioral: exercise intervention; Procedure: quality-of-life assessment; Other: survey administration; Procedure: management of therapy complications; Procedure: psychosocial assessment and care
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University
Recruiting - verified April 2012
Reducing Breast Cancer Recurrence With Weight Loss

Conditions: Breast Cancer; Overweight; Obesity
Interventions: Behavioral: Intensive Group; Behavioral: Less Intensive Group
Sponsors: University of California, San Diego; University of California, San Diego; Washington University School of Medicine; University of Colorado, Denver; University of Alabama at Birmingham
Recruiting - verified March 2010
Immunogenetic Mechanisms in Behcet's Disease

Conditions: Behcet's Disease; Uveitis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Eye Institute (NEI)
Recruiting - verified February 2012
Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection

Conditions: Impetigo; Folliculitis; Secondarily Infected Eczema; Minor Soft Tissue Infections
Intervention: Drug: Retapamulin (Altabax)
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston; GlaxoSmithKline
Recruiting - verified February 2012
FNA Tumor Sampling for CD137 Modulation: A Pilot Study

Conditions: Head and Neck Cancer; Breast Cancer; Head and Neck Cancers
Intervention: Procedure: FNA Biopsy
Sponsors: Stanford University; Stanford University
Recruiting - verified May 2012
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer

Condition: Breast Cancer
Intervention: Drug: Temsirolimus plus Neratinib
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Comprehensive Cancer Network; Wyeth Pharmaceuticals, Inc., a Pfizer Company
Recruiting - verified May 2012
International Travel Patterns and Risk Behaviour of Breast Cancer, Lymphoma Patients and Bone Marrow Transplant Recipients

Conditions: Breast Cancer; Lymphoma
Intervention: Behavioral: questionnaires
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified November 2011
Evaluating Strategies to Prevent Methicillin-resistant Staphylococcus Aureus Skin and Soft Tissue Infections in Military Trainees

Conditions: Staphylococcus Aureus; Community-associated MRSA Infections; Staphylococcal Skin Infections
Interventions: Drug: Chlorhexidine gluconate; Other: Standardized training and education
Sponsors: Uniformed Services University of the Health Sciences; Uniformed Services University of the Health Sciences; Centers for Disease Control and Prevention
Recruiting - verified July 2011
Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas

Conditions: Skin Cancers; Carcinoma, Basal Cell; Skin Cancer; Basal Cell Carcinoma
Intervention: Drug: Itraconazole
Sponsors: Stanford University; Stanford University
Recruiting - verified December 2011
Fast Spectral Imaging Device for Tumor Margin Mapping

Condition: Breast Cancer
Intervention:
Sponsors: Duke University; Duke University; National Institutes of Health (NIH); National Cancer Institute (NCI)
Recruiting - verified June 2011
A Study to Evaluate the Safety and Efficacy of Apremilast in the Treatment of Skin Disease in Patients With Dermatomyositis

Condition: Dermatomyositis
Intervention: Drug: Apremilast
Sponsors: Stanford University; Stanford University
Recruiting - verified July 2011
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: letrozole; Drug: panobinostat; Genetic: RNA analysis; Genetic: microarray analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Patient Registry Study of Berinert® in Normal Clinical Practice

Condition: Includes: Hereditary Angioedema
Intervention: Biological: Berinert® (C1 Esterase Inhibitor)
Sponsors: CSL Behring; CSL Behring; Chiltern International Inc.
Recruiting - verified May 2012
Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Breast Cancer
Interventions: Drug: Fludarabine; Drug: Cyclophosphamide; Drug: Cyclosporine; Biological: Natural killer cells; Drug: IL-2; Drug: Methylprednisolone; Drug: Methylprednisolone; Drug: Interleukin-2
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2012
Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer

Conditions: Estrogen Receptor-negative Breast Cancer; Hereditary Breast/Ovarian Cancer - BRCA1; Hereditary Breast/Ovarian Cancer - BRCA2; Male Breast Cancer; Progesterone Receptor-negative Breast Cancer; Recurrent Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Triple-negative Breast Cancer
Interventions: Other: immunohistochemistry staining method; Genetic: gene expression analysis; Drug: veliparib; Drug: cisplatin; Drug: vinorelbine tartrate; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer

Condition: Breast Cancer
Interventions: Drug: metformin hydrochloride; Other: placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Intervention: Drug: Indibulin
Sponsors: ZIOPHARM; ZIOPHARM; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012
High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer

Conditions: brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer
Interventions: Dietary Supplement: cholecalciferol; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer

Conditions: HER2 Amplified Breast Cancer; Metastatic or Advanced Breast Cancer
Intervention: Drug: MM-111 and Herceptin
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals
Recruiting - verified March 2012
Neo-Adjuvant Study in Triple Negative Breast Cancer Patients

Condition: Breast Cancer
Interventions: Drug: Cetuximab; Drug: Ixabepilone
Sponsors: The Methodist Hospital System; The Methodist Hospital System; Bristol-Myers Squibb
Recruiting - verified June 2011
Cinryze for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12

Condition: Hereditary Angioedema
Intervention: Biological: Cinryze
Sponsors: ViroPharma; ViroPharma
Recruiting - verified April 2011
Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer

Conditions: Breast Cancer; Stage IV Breast Cancer
Interventions: Procedure: positron emission tomography; Radiation: copper Cu 64-DOTA-trastuzumab; Procedure: Biopsy; Other: Immunohistochemistry staining method; Other: laboratory biomarker analysis; Genetic: mutation analysis
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified May 2012
Efficacy and Safety of Ustekinumab in Patients With Moderate to Severe Palmar Plantar Psoriasis

Condition: Moderate to Severe Palmar Plantar Psoriasis
Intervention: Drug: Ustekinumab
Sponsors: Tufts Medical Center; Tufts Medical Center; Centocor, Inc.
Recruiting - verified July 2011
MLN8237 in Patients With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

Conditions: Ovarian Carcinoma; Fallopian Tube Cancer; Peritoneal Cancer; Breast Carcinoma
Interventions: Drug: MLN8237 + Paclitaxel; Drug: MLN8237+Paclitaxel vs. Paclitaxel alone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified December 2011
Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer

Condition: Stages II-III Breast Cancer
Interventions: Drug: Nanoparticle Albumin Bound Paclitaxel; Drug: doxorubicin; Drug: cyclophosphamide
Sponsors: University of South Alabama; University of South Alabama; Celgene Corporation
Recruiting - verified August 2011
A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal Cancers

Conditions: Breast Cancer; Lung Cancer; Renal Cancer; Adrenal Cancer
Intervention: Drug: F-18 Paclitaxel (FPAC)
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Not yet recruiting - verified September 2011
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

Condition: Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
Interventions: Biological: Rituximab; Other: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified December 2011
Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis

Condition: Scalp Psoriasis
Intervention: Drug: LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel)
Sponsors: LEO Pharma; LEO Pharma
Recruiting - verified March 2011
Female Cancer Patients' Preference For Sexual Health Interventions

Conditions: Breast Cancer; Gynecologic Cancer
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified December 2011
Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer

Conditions: Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: vorinostat; Drug: ixabepilone; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified March 2012
Estrogen for Triple Negative Breast Cancer

Condition: Female Breast Cancer
Intervention: Drug: Estradiol
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison
Recruiting - verified February 2012
Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery

Condition: Breast Cancer
Interventions: Other: circulating tumor cell analysis; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal accelerated partial breast irradiation
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011
Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer

Condition: Breast Cancer
Interventions: Drug: XL147 (SAR245408); Drug: XL765 (SAR245409); Drug: letrozole (Femara)
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents

Condition: Arthritis, Psoriatic
Interventions: Drug: placebo; Drug: ustekinumab; Drug: ustekinumab; Drug: placebo; Drug: placebo; Drug: ustekinumab; Drug: ustekinumab; Drug: ustekinumab
Sponsors: Centocor, Inc.; Centocor, Inc.
Recruiting - verified April 2012
Letrozole in Treating Healthy Postmenopausal Women at High Risk for Breast Cancer

Condition: Breast Cancer
Intervention: Drug: letrozole
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI); University of Arizona
Recruiting - verified October 2011
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Condition: Breast Cancer
Interventions: Drug: Cisplatin; Drug: Rucaparib; Drug: Cisplatin
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Clovis Oncology, Inc.
Recruiting - verified March 2012
Pilot Study Using Molecular Profiling to Find Potential Targets and Select Treatments for Patients With Metastatic Breast Cancer.

Condition: Metastatic Breast Cancer
Intervention: Drug: (will be assigned based on molecular profile and RPMA)
Sponsors: TGen Drug Development Services; TGen Drug Development Services; SideOut Foundation
Recruiting - verified January 2012
Low Level Laser Therapy for Hair Preservation With Chemotherapy for Breast Cancer

Condition: Breast Cancer
Intervention: Procedure: Low-Level Laser Therapy
Sponsors: Northwestern University; Northwestern University; Robert H. Lurie Cancer Center
Not yet recruiting - verified October 2011
American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis

Conditions: Wegener's Granulomatosis; Microscopic Polyangiitis; Churg Strauss Syndrome; Polyarteritis Nodosa; Giant Cell Arteritis; Takayasu Arteritis
Intervention:
Sponsors: University of Oxford; University of Oxford; American College of Rheumatology; The European League Against Rheumatism (EULAR); The Vasculitis foundation
Recruiting - verified January 2012
Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia

Condition: Critical Limb Ischemia
Interventions: Genetic: VM202; Genetic: VM202; Other: Normal Saline
Sponsors: ViroMed Co., Ltd.; ViroMed Co., Ltd.; VM Biopharma
Recruiting - verified February 2012
Stanford Accelerated Recovery Trial (START)

Conditions: Pain; Breast Cancer; Lung Cancer
Interventions: Drug: Gabapentin; Drug: Placebo
Sponsors: Stanford University; Stanford University
Recruiting - verified September 2011
Use of Plasmapheresis for Nephrogenic Fibrosing Dermopathy (NFD)/Nephrogenic Systemic Fibrosis (NSF) and Understanding Its Etiology

Conditions: Nephrogenic Fibrosing Dermopathy; Nephrogenic Systemic Fibrosis
Intervention: Procedure: Plasmapheresis
Sponsors: Loma Linda University; Loma Linda University
Recruiting - verified June 2011
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

Condition: Breast Cancer
Interventions: Drug: Placebo; Drug: Denosumab
Sponsors: Amgen; Amgen; Daiichi Sankyo Inc.
Recruiting - verified May 2012
N-Acetyl Cysteine in Pathologic Skin Picking

Conditions: Pathologic Skin Picking; Neurotic Excoriation; Psychogenic Excoriation; Dermatillomania
Interventions: Drug: N-Acetyl Cysteine; Drug: Placebo
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute
Recruiting - verified March 2012
A Safety and Efficacy Study of INTEGRA® Dermal Regeneration Template for the Treatment of Diabetic Foot Ulcers

Condition: Foot Ulcer, Diabetic
Interventions: Device: Integra® Dermal Regeneration Template; Other: Conventional Wound Therapy
Sponsors: Integra LifeSciences Corporation; Integra LifeSciences Corporation
Recruiting - verified August 2011
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema

Condition: Hereditary Angioedema
Intervention: Drug: ecallantide
Sponsors: Dyax Corp.; Dyax Corp.
Recruiting - verified April 2012
Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer

Conditions: Metastatic Non Small Cell Lung Cancer; Metastatic Breast Cancer
Interventions: Drug: Pazopanib; Drug: Vinorelbine
Sponsors: Northwestern University; Northwestern University; Robert H. Lurie Cancer Center
Recruiting - verified October 2011
Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin

Condition: Skin Cancer
Intervention: Drug: Erlotinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; OSI Pharmaceuticals
Recruiting - verified January 2012
To Evaluate the Characteristics of a Breast Cancer

Condition: Breast Cancer
Interventions: Drug: EF5; Procedure: Partial or Total Mastectomy
Sponsors: Duke University; Duke University; National Institutes of Health (NIH); National Cancer Institute (NCI)
Not yet recruiting - verified June 2011
Open Label Pilot Study of Apremilast in Treatment of Rosacea

Conditions: Erythematotelangiectatic Rosacea; Papulopustular Rosacea
Intervention: Drug: Apremilast
Sponsors: Columbia University; Columbia University; Celgene Corporation
Recruiting - verified February 2012
Rosuvastatin in Treating Women With Cardiovascular Complications Who Are Undergoing Chemotherapy For Breast Cancer

Conditions: Cardiovascular Complications; Recurrent Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: rosuvastatin; Other: placebo; Other: survey administration; Procedure: management of therapy complications
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified April 2012
Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Non-Metastatic, Post Menopausal Breast Cancer Patients

Condition: Breast Cancer
Interventions: Other: History and Physical Exam; Other: Grip Strength Measurement; Behavioral: Surveys; Other: Blood Collection; Procedure: Ultrasound of Hand/Wrist
Sponsors: University of California, Los Angeles; University of California, Los Angeles
Recruiting - verified February 2012
Acupuncture in Treating Nerve Pain in Patients With Stage I, Stage II, or Stage III Breast Cancer Who Are Receiving Paclitaxel

Conditions: Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
Interventions: Procedure: acupuncture therapy; Drug: paclitaxel; Other: questionnaire administration; Procedure: management of therapy complications
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified March 2012
Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Procedure: PRO Onc Assay; Drug: Trastuzumab; Drug: Pertuzumab
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Prometheus Therapeutics and Diagnostics; Genentech
Recruiting - verified April 2012
Characterization of Circulating Tumor Cells (CTCs) to Direct Pre-Operative and Systemic Therapy in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer

Conditions: Locally Advanced Breast Cancer; Metastatic (Stage IV) Breast Cancer; Stage III-IV Breast Cancer or Inflammatory
Intervention:
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI); Palo Alto Research Center
Recruiting - verified March 2012
Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis

Condition: Systemic Scleroderma
Interventions: Drug: fludarabine phosphate; Radiation: total-body irradiation; Drug: tacrolimus; Drug: mycophenolate mofetil; Biological: rituximab; Drug: cyclophosphamide; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Not yet recruiting - verified May 2012
MLN8237 in Adults With Nonhematological Malignancies, Followed by MLN8237 in Lung, Breast, Head and Neck or Gastroesophageal Malignancies

Conditions: Advanced Nonhematological Malignancies; Non-Small Cell Lung Cancer; Small Cell Lung Cancer; Metastatic Breast Cancer; Head and Neck Squamous Cell Carcinoma; Gastroesophageal Adenocarcinoma
Intervention: Drug: MLN8237
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012
Cone Beam Computed Tomography for Breast Imaging

Condition: Breast Cancer
Interventions: Device: Computed Tomography; Device: Computed Tomography
Sponsors: Koning Corporation; Koning Corporation; Elizabeth Wende Breast Care; National Cancer Institute (NCI)
Recruiting - verified January 2012
Study of Ad.p53 DC Vaccine and 1-MTin Metastatic Invasive Breast Cancer

Condition: Breast Cancer
Interventions: Biological: Ad.p53 DC vaccine; Drug: 1-methyl-D-tryptophan (1-MT)
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI)
Recruiting - verified February 2012
I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Conditions: Breast Neoplasms; Breast Cancer; Breast Tumors
Interventions: Drug: Neratinib; Drug: ABT-888; Drug: Standard Therapy; Drug: AMG 386; Drug: AMG 479 (Ganitumab) plus Metformin
Sponsors: Foundation for the National Institutes of Health; Foundation for the National Institutes of Health
Recruiting - verified December 2011
Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema

Condition: Angioedema
Intervention: Drug: ecallantide - Kallikrein inhibitor that blocks the production of bradykinin
Sponsors: Bernstein, Jonathan A., M.D.; Bernstein, Jonathan A., M.D.; Dyax Corp.
Recruiting - verified March 2012
Stem Cell Transplant for Epidermolysis Bullosa

Condition: Epidermolysis Bullosa
Interventions: Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Anti-thymocyte globulin; Drug: Cyclosporine A; Drug: Mycophenolate mofetil; Procedure: Hematopoietic stem cell transplant; Procedure: Mesenchymal stem cell transplant; Radiation: Total body irradiation
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified May 2012
Magnetic Resonance Imaging of Breast Cancer

Conditions: Breast Cancer; Breast Cancer Non-invasive Breast Cancer
Intervention: Procedure: MRI
Sponsors: Stanford University; Stanford University; National Institutes of Health (NIH)
Recruiting - verified May 2012
Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Panitumumab; Drug: Nab-paclitaxel; Drug: Carboplatin; Drug: 5-Fluorouracil; Drug: Epirubicin; Drug: Cyclophosphamide
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation; Amgen
Recruiting - verified April 2012
Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Intervention: Drug: Amrubicin
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Celgene Corporation
Recruiting - verified July 2011
Effectiveness of the CHESS eHealth Cancer Support Intervention in Population-based Care

Condition: Primary Breast Cancer
Intervention: Behavioral: Enhanced ICCS with KPNW web resources and the Comprehensive Health Enhancement Support System (CHESS.)
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison; National Cancer Institute (NCI)
Recruiting - verified November 2011
PD 0332991 in Treating Patients With Refractory Solid Tumors

Conditions: Adult Solid Tumor; Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum; Adult Central Nervous System Germ Cell Tumor; Adult Teratoma; Benign Teratoma; Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; Familial Testicular Germ Cell Tumor; HER2-negative Breast Cancer; HER2-positive Breast Cancer; Male Breast Cancer; Ovarian Immature Teratoma; Ovarian Mature Teratoma; Ovarian Monodermal and Highly Specialized Teratoma; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Recurrent Colon Cancer; Recurrent Extragonadal Germ Cell Tumor; Recurrent Extragonadal Non-seminomatous Germ Cell Tumor; Recurrent Extragonadal Seminoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Melanoma; Recurrent Ovarian Germ Cell Tumor; Recurrent Rectal Cancer; Stage III Extragonadal Non-seminomatous Germ Cell Tumor; Stage III Extragonadal Seminoma; Stage III Malignant Testicular Germ Cell Tumor; Stage III Ovarian Germ Cell Tumor; Stage IV Breast Cancer; Stage IV Colon Cancer; Stage IV Extragonadal Non-seminomatous Germ Cell Tumor; Stage IV Extragonadal Seminoma; Stage IV Melanoma; Stage IV Ovarian Germ Cell Tumor; Stage IV Rectal Cancer; Testicular Immature Teratoma; Testicular Mature Teratoma
Interventions: Drug: PD-0332991; Other: pharmacological study
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified February 2012
Longitudinal Impact of Adjuvant Chemotherapy on Functional Status, Comorbidity and Quality of Life

Condition: Breast Cancer
Intervention:
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified March 2012
Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)

Conditions: Carcinoma, Intraductal, Noninfiltrating; DCIS; Ductal Carcinoma In Situ
Interventions: Drug: Chloroquine Standard Dose (500mg/week); Drug: Chloroquine Low Dose (250mg/week); Procedure: Breast Biopsy
Sponsors: Inova Health Care Services; Inova Health Care Services; George Mason University; Department of Defense; U.S. Army Medical Research and Materiel Command
Recruiting - verified March 2012
Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children

Conditions: Eyelash Hypotrichosis; Alopecia Areata
Interventions: Drug: bimatoprost ophthalmic solution 0.03%; Drug: Vehicle Sterile Solution
Sponsors: Allergan; Allergan
Recruiting - verified November 2011
Serum Lipid Levels and Other Biomarkers of Cardiovascular Disease in Patients With Psoriasis

Conditions: Psoriasis; Cardiovascular Diseases; Dyslipidemia
Intervention:
Sponsors: George Washington University; George Washington University
Recruiting - verified October 2011
Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Women With HER2/Neu-Negative Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Biological: HER2Bi-armed activated T cells; Drug: Cyclophosphamide; Other: Laboratory biomarker analysis
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified November 2011
Internal Radiation Therapy of the Breast in Treating Women With Early-Stage Breast Cancer

Condition: Breast Cancer
Interventions: Radiation: accelerated partial breast irradiation; Radiation: intracavitary balloon brachytherapy
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; SenoRx, Inc.
Recruiting - verified December 2011
Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

Condition: Refractory Head and Neck Cancer, Squamous Cell Carcinoma of the Skin, Carcinoma of the Breast, and Malignant Melanoma
Intervention: Drug: HF10
Sponsors: Takara Bio Inc.; Takara Bio Inc.
Recruiting - verified October 2011
Chemotherapy-Induced Peripheral Neuropathy Survey

Conditions: Breast Cancer; Colorectal Cancer; Myeloma; Chemotherapy-induced Peripheral Neuropathy
Interventions: Behavioral: Questionnaire; Behavioral: Sensory Tests; Behavioral: Interview
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Safety and Efficacy Study of Combination Treatment With Excimer Laser, Clobex Spray, and Vectical Ointment in the Treatment of Psoriasis

Condition: Chronic Stable Plaque Psoriasis
Interventions: Drug: Clobex Spray; Drug: Vectical Ointment; Procedure: Excimer Laser
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified January 2012
Acupuncture in Treating Women With Stage I, Stage II, or Stage III Breast Cancer With Aromatase Inhibitor-Related Joint Pain

Conditions: Breast Cancer; Recurrent Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
Interventions: Procedure: acupuncture therapy; Procedure: sham intervention
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified May 2012
Staging of Axillary Lymph Nodes Using the PEM Flex Solo II Pet Scanner in Patients With Breast Cancer

Condition: Breast Cancer
Intervention: Device: Positron Emission Mammography
Sponsors: University of Chicago; University of Chicago
Recruiting - verified June 2011
Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer

Conditions: Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
Interventions: Biological: panitumumab; Drug: paclitaxel; Drug: carboplatin; Procedure: laboratory biomarker analysis; Procedure: immunohistochemistry staining method
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University
Recruiting - verified April 2012
Lisinopril or Carvedilol Phosphate in Reducing Side Effects in Women With HER2-Positive Breast Cancer Receiving Trastuzumab

Conditions: Breast Cancer; Cardiac Toxicity
Interventions: Drug: carvedilol phosphate extended-release capsule; Drug: lisinopril; Other: placebo
Sponsors: National Cancer Institute (NCI); University of South Florida; National Cancer Institute (NCI)
Recruiting - verified February 2012
Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Breast Cancer

Condition: Breast Cancer
Intervention: Drug: VPA FEC100
Sponsors: University of California, San Francisco; University of California, San Francisco; H. Lee Moffitt Cancer Center and Research Institute
Recruiting - verified March 2012
Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer

Condition: Breast Cancer
Interventions: Drug: ritonavir; Procedure: therapeutic conventional surgery
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota; Susan G. Komen Breast Cancer Foundation
Recruiting - verified January 2012
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer

Condition: Breast Cancer
Intervention: Other: ChemoFX Assay
Sponsors: Precision Therapeutics; Precision Therapeutics; Department of Defense
Recruiting - verified December 2011
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Trastuzumab; Drug: Neratinib; Drug: Trastuzumab (post surgery); Drug: Doxorubicin; Drug: Cyclophosphamide
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); Wyeth Pharmaceuticals, Inc., a Pfizer Company
Recruiting - verified February 2012
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

Conditions: HER2/Neu Over-expressing Locally Advanced Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: everolimus, vinorelbine, trastuzumab; Drug: Placebo + vinorelbine + trastuzumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Molecular Signature of Valproic Acid in Breast Cancer With Functional Imaging Assessment - a Pilot

Condition: Cancer
Intervention: Drug: Valproic Acid
Sponsors: University of Utah; University of Utah
Recruiting - verified January 2012
Acupuncture and Gabapentin for Hot Flashes Among Breast Cancer Survivors

Condition: Hot Flashes
Intervention: Drug: Gabapentin
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified May 2012
Safety Study of PLX108-01 in Patients With Solid Tumors

Conditions: Solid Tumors; Mucoepidermal Carcinoma (MEC) of the Salivary Gland; Pigmented Villo-nodular Synovitis (PVNS); Gastrointestinal Stromal Tumors (GIST); Anaplastic Thyroid Carcinoma (ATC); Solid Tumors With Documented Malignant Pleural or Peritoneal Effusions; Malignant Peripheral Nerve Sheath Tumor (MPNST); Neurofibromatosis Type I (NF-1); Melanoma; Schwannomatosis
Intervention: Drug: PLX3397
Sponsors: Plexxikon; Plexxikon
Recruiting - verified May 2012
Nipple Sparing Mastectomy - Cosmetic Outcomes

Conditions: Breast Cancer; Breast Reconstruction; Cosmesis
Intervention: Procedure: Nipple Sparing Mastectomy
Sponsors: Carolinas Healthcare System; Carolinas Healthcare System
Recruiting - verified June 2011
Tissue Repository for Correlation of Molecular Markers With Response to Neoadjuvant and Metastatic Chemotherapy

Condition: Breast Cancer
Interventions: Other: biologic sample preservation procedure; Other: laboratory biomarker analysis; Procedure: biopsy
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012
Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants

Conditions: Alopecia; Breast Cancer
Interventions: Drug: bimatoprost ophthalmic solution; Drug: placebo
Sponsors: University of California, Los Angeles; University of California, Los Angeles; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy

Condition: Breast Cancer
Interventions: Drug: Herceptin / Lapatinib; Drug: Letrozole
Sponsors: Baylor Breast Care Center; Baylor Breast Care Center; Translational Breast Cancer Reserach Consortium; GlaxoSmithKline
Recruiting - verified January 2012
Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors

Condition: Triple Negative Breast Cancer
Intervention: Drug: Temsirolimus, cisplatin, erlotinib
Sponsors: Columbia University; Columbia University; Wyeth is now a wholly owned subsidiary of Pfizer; Genentech
Recruiting - verified October 2011
Ultraviolet Light Exposure and Immunosuppression in Cutaneous Melanoma

Condition: Melanoma
Intervention:
Sponsors: New Mexico Cancer Care Alliance; New Mexico Cancer Care Alliance
Recruiting - verified December 2011
Study Comparing Whole Breast Radiotherapy With a Daily Versus a Weekly Tumor

Condition: Breast Cancer
Intervention: Radiation: Radiation therapy
Sponsors: New York University School of Medicine; New York University School of Medicine; department of radiation oncology
Recruiting - verified November 2011
A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib

Conditions: ErbB2 Overexpressing; Solid Tumors; Metastatic Breast Cancer; Neoplasms, Breast
Intervention: Drug: lapatinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified December 2011
High-dose Methotrexate and Liposomal Cytarabine in Treating Patients With CNS Metastases From Breast Cancer

Conditions: Central Nervous System Metastases; Leptomeningeal Metastases; Recurrent Breast Cancer; Stage IV Breast Cancer; Tumors Metastatic to Brain
Interventions: Drug: methotrexate; Drug: liposomal cytarabine; Other: quality-of-life assessment; Other: questionnaire administration
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012
A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer

Condition: Breast Cancer
Intervention:
Sponsors: University of Chicago; University of Chicago
Recruiting - verified June 2011
MUC1 Vaccine for Triple-negative Breast Cancer

Conditions: Breast Cancer; Inflammatory Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-negative Breast Cancer
Interventions: Biological: MUC-1 peptide vaccine; Biological: poly ICLC; Biological: MUC1 peptide-poly-ICLC adjuvant vaccine; Other: laboratory biomarker analysis; Other: enzyme-linked immunosorbent assay; Other: flow cytometry
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center
Recruiting - verified March 2012
Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen

Conditions: Atrophic Vaginitis; Breast Cancer
Intervention: Drug: Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012
Geriatric Group Psychoeducational Intervention for Elderly Patients With Cancer

Conditions: Breast Cancer; Prostate Cancer; Lung Cancer; Lymphoma Cancer; Gynecological Cancers
Interventions: Behavioral: group intervention and questionnaires; Behavioral: individual phone intervention and questionnaires
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified December 2011
Cyclosporine A in Combination With Nab-Paclitaxel in Patients With Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Cyclosporins; Drug: nab-paclitaxel
Sponsors: Northwestern University; Northwestern University; Avon Foundation
Recruiting - verified May 2012
Study to Evaluate the Effect of Sulforaphane in Broccoli Sprout Extract on Breast Tissue

Condition: Breast Cancer
Interventions: Drug: Broccoli sprout extract (sulforaphane); Dietary Supplement: Mango juice without extract
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; Breast Cancer Research Foundation
Recruiting - verified January 2012
Positron Emission Mammography (PEM) Flex Solo II Positron Emission Tomography (PET) Scanner and Stereo Navigator Biopsy Accessory for the Diagnosis of Breast Cancer

Condition: Breast Cancer
Intervention: Procedure: PEM Breast Biopsy
Sponsors: University of Cincinnati; University of Cincinnati
Recruiting - verified March 2012
The Effects of Aldara as an Adjunct to Laser Treatment

Condition: Port Wine Stains
Interventions: Drug: Imiquimod (Aldara); Drug: non-medicated petroleum cream
Sponsors: University of Kentucky; University of Kentucky; Graceway Pharmaceuticals, LLC
Recruiting - verified October 2011
Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer

Condition: Breast Cancer
Interventions: Dietary Supplement: Coenzyme Q10; Dietary Supplement: Coenzyme Q10 Placebo
Sponsors: Columbia University; Columbia University; National Institutes of Health (NIH)
Recruiting - verified October 2011
Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies

Conditions: Kaposiform Hemangioendotheliomas; Tufted Angioma; Capillary Venous Lymphatic Malformation; Venous Lymphatic Malformation; Microcystic Lymphatic Malformation; Mucocutaneous Lymphangiomatosis and Thrombocytopenia; Capillary Lymphatic Arterial Venous Malformations; PTEN Overgrowth Syndrome With Vascular Anomaly; Lymphangiectasia Syndromes
Intervention: Drug: sirolimus
Sponsors: Children's Hospital Medical Center, Cincinnati; Children's Hospital Medical Center, Cincinnati
Recruiting - verified February 2012
Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Biological: allogeneic GM-CSF-secreting breast cancer vaccine; Biological: trastuzumab; Drug: cyclophosphamide
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Cone Beam Computed Tomography for Breast Imaging

Condition: Breast Cancer
Interventions: Radiation: Computed Tomography; Radiation: Computed Tomography; Radiation: Computed Tomography
Sponsors: Koning Corporation; Koning Corporation
Recruiting - verified January 2012
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Conditions: Adenocarcinoma; Her2+; Advanced Metastatic Breast Cancer; Metastatic ErbB2; Invasive Breast Cancer; Advanced Breast Cancer; Cancer; ErbB2+
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism

Condition: Breast Cancer
Intervention: Drug: Capecitabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified May 2012
Early Detection and Intervention for Mild and Moderate Lymphedema in Patients Treated for Breast Cancer

Conditions: Lymphedema; Breast Cancer
Interventions: Device: Compression Sleeve; Device: Short-Stretch Compression Bandage
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Cancer Institute (NCI)
Recruiting - verified January 2012
A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel and Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer

Condition: Metastatic Breast Cancer, Locally Recurrent Breast Cancer
Interventions: Drug: bevacizumab; Drug: GDC-0941; Drug: paclitaxel
Sponsors: Genentech; Genentech
Recruiting - verified October 2011
Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Biological: trastuzumab; Drug: carboplatin; Drug: docetaxel; Other: laboratory biomarker analysis
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Community Volunteers Promoting Physical Activity Among Cancer Survivors

Condition: Breast Cancer
Intervention: Behavioral: Moving Forward Together 2
Sponsors: The Miriam Hospital; The Miriam Hospital; American Cancer Society
Recruiting - verified July 2011
Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome

Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Intervention: Dietary Supplement: Lactobacillus rhamnosus GG
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI)
Recruiting - verified November 2011
A Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants (PTN_Acyclo)

Conditions: Herpes Simplex Virus; Neonatal Sepsis
Intervention: Drug: Acyclovir
Sponsors: Duke University; Duke University; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified January 2012
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer

Condition: Breast Cancer
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; University of Chicago; Dana-Farber Cancer Institute; Georgetown University; Johns Hopkins University; M.D. Anderson Cancer Center; University of Alabama at Birmingham; University of California, San Francisco; University of North Carolina; Duke University; Vanderbilt-Ingram Cancer Center; Indiana University Melvin and Bren Simon Cancer Center; Mayo Clinic; University of Pittsburgh; University of Michigan Health System
Recruiting - verified March 2012
Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression

Condition: Breast Cancer
Interventions: Drug: nab-paclitaxel; Drug: trastuzumab; Drug: Doxorubicin; Drug: cyclophosphamide
Sponsors: University of Kansas; University of Kansas; Celgene Corporation
Recruiting - verified October 2011
Exemestane or Docetaxel-cytoxan in Low Recurrence Score Cancers

Condition: Breast Cancer
Interventions: Drug: Exemestane; Drug: Docetaxel, cytoxan
Sponsors: Emory University; Emory University; Pfizer
Recruiting - verified February 2012
A Study of DER 45-EV Gel to Treat Rosacea

Condition: Rosacea
Interventions: Drug: DER 45 EV; Drug: Vehicle
Sponsors: Sol-Gel Technologies, Ltd.; Sol-Gel Technologies, Ltd.
Recruiting - verified April 2012
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca

Condition: Breast Cancer
Interventions: Drug: everolimus; Drug: abraxane
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI)
Recruiting - verified October 2011
A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Patients With Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: docetaxel; Drug: pertuzumab
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
Mechanism of Action Study for Psoriasis

Condition: Psoriasis
Interventions: Drug: Methotrexate; Drug: Adalimumab (Humira)
Sponsors: Tufts Medical Center; Tufts Medical Center; Abbott
Recruiting - verified July 2011
A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis

Conditions: Psoriasis; Nonalcoholic Fatty Liver Disease
Intervention:
Sponsors: George Washington University; George Washington University
Recruiting - verified October 2011
Peds Metabolic Syndrome in Psoriasis

Conditions: Psoriasis; Metabolic Syndrome
Intervention:
Sponsors: Tufts Medical Center; Tufts Medical Center; Amgen
Recruiting - verified July 2011
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer

Condition: Breast Cancer
Interventions: Drug: cisplatin; Drug: everolimus; Drug: paclitaxel; Other: placebo
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified December 2011
Metformin Pre-Surgical Pilot Study

Condition: Breast Cancer
Intervention: Drug: Metformin
Sponsors: Columbia University; Columbia University; Breast Cancer Research Foundation
Recruiting - verified October 2011
Enhancing Physical Activity Adherence After Breast Cancer Diagnosis (BEAT Cancer II)

Condition: Breast Cancer
Interventions: Behavioral: Experimental 1: exercise with 2 counseling types; Other: Usual Care - written materials
Sponsors: Southern Illinois University; Southern Illinois University; National Cancer Institute (NCI); University of Illinois at Urbana-Champaign
Recruiting - verified March 2012
Aggressive Local Therapy for Limited Bone-only Metastasis

Condition: Breast Cancer
Interventions: Drug: Standard Therapy; Procedure: Local Therapy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012
Role of Positron Emission Mammography (PEM) Flex Solo II Positron Emission Tomography (PET) Scanner in Evaluating Neoadjuvant Chemotherapy Response in Patients With Breast Cancer

Condition: Breast Cancer
Intervention: Device: PEM Flex Solo II PET Scanner
Sponsors: University of Chicago; University of Chicago
Recruiting - verified June 2011
Survivor Stories: Impact on Cancer Patients' Quality of Life and Follow-up

Condition: Breast Cancer
Intervention: Other: The Survivor Stories Tablet
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified March 2012
Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy

Condition: Metastatic Breast Cancer
Interventions: Drug: GDC-0941; Drug: trastuzumab-MCC-DM1; Drug: Trastuzumab
Sponsors: Genentech; Genentech
Recruiting - verified August 2011
Safety and Efficacy of HO/03/03 10μg in the Treatment of Plantar Neuropathic Diabetic Foot Ulcers

Condition: Diabetic Foot Ulcer
Interventions: Drug: HO/03/03 10µg; Drug: Placebo
Sponsors: HealOr; HealOr; Clinigene International Ltd; Cato Research
Recruiting - verified December 2011
An Exploratory Evaluation of Biomarkers in Blister Fluid in Healthy Volunteers and Irradiated Skin

Conditions: Breast Cancer; Healthy Volunteer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011
A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced Malignancies

Conditions: Renal Cell Carcinoma; Breast Cancer; Colon Cancer; Lung Cancer; Non-Hodgkin Lymphoma
Intervention: Drug: dimethane sulfonate (DMS612, NSC 281612)
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011
The Natural History of Solid Organ Cancer Stem Cells (SOCSC)

Conditions: Hepatic Cancer; Pancreatic Ductal Cancer; Colorectal Cancer; Breast Cancer; Gastric Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Dasatinib; Drug: Ixabepilone
Sponsors: Accelerated Community Oncology Research Network; Accelerated Community Oncology Research Network; Bristol-Myers Squibb
Recruiting - verified February 2012
Laser Spectroscopy in Diagnosing Breast Cancer in Women With Breast Lesions

Condition: Breast Cancer
Interventions: Genetic: fluorescence in situ hybridization; Other: immunohistochemistry staining method; Other: medical chart review; Procedure: fluorescence spectroscopy; Procedure: histopathologic examination; Procedure: light-scattering spectroscopy
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Study of Breast Tissue From Women Who Have Undergone Breast Biopsy or Surgery

Condition: Breast Cancer
Interventions: Other: biologic sample preservation procedure; Other: immunohistochemistry staining method; Other: light microscopy; Other: medical chart review; Procedure: histopathologic examination; Procedure: needle biopsy; Procedure: spectroscopy
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Breast Cancer

Condition: Breast Cancer
Interventions: Genetic: gene expression analysis; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Green Tea and Reduction of Breast Cancer Risk

Condition: Breast Cancer
Interventions: Drug: Green tea extract supplement; Other: Placebo
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute
Recruiting - verified January 2012
Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.

Condition: Invasive Breast Cancer
Interventions: Drug: Fulvestrant; Drug: Anastrazole
Sponsors: University of Kansas; University of Kansas; AstraZeneca
Recruiting - verified October 2011
Safety Study of Topical Human FGF-1 for Wound Healing

Condition: Diabetic Foot Ulcers
Interventions: Drug: FGF-1 141; Drug: FGF-1 141
Sponsors: Phage Pharmaceuticals, Inc.; Phage Pharmaceuticals, Inc.
Not yet recruiting - verified March 2012
Xeloda (Capecitabine) and External Beam Radiation

Condition: Breast Cancer
Interventions: Radiation: Radiation Therapy; Drug: Capecitabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified January 2012
Randomized Phase II Trial of Trastuzumab or EVEROLIMUS in Hormone-refractory Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Trastuzumab (Herceptin); Drug: Trastuzumab (Herceptin) plus Everolimus
Sponsors: Emory University; Emory University; Genentech; Novartis Pharmaceuticals
Recruiting - verified November 2011
Radiation Therapy in Treating Women With Early Stage Breast Cancer

Condition: Breast Cancer
Interventions: Radiation: External beam boost; Radiation: whole breast irradiation
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI)
Recruiting - verified October 2011
Optical Tomography With Ultrasound Guidance

Condition: Breast Cancer
Intervention:
Sponsors: University of Connecticut Health Center; University of Connecticut Health Center; National Institute for Biomedical Imaging and Bioengineering (NIBIB); Donaghue Medical Research Foundation
Recruiting - verified June 2011
A Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Intervention: Drug: BZL101
Sponsors: Bionovo; Bionovo
Not yet recruiting - verified February 2012
A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer

Condition: Triple Negative Breast Cancer
Intervention: Drug: NK012
Sponsors: Nippon Kayaku Co.,Ltd.; Nippon Kayaku Co.,Ltd.
Recruiting - verified June 2011
Study of Radiation Exposure and Bilateral Breast Cancer

Condition: Breast Cancer
Intervention: Other: questionaire, blood or saliva sample
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Translational Genomics Research Institute, Phoenix, Arizona.; University of Southern California; University of Virginia; Lund University; Ontario Cancer Registry; Northern California Cancer Center; Fred Hutchinson Cancer Research Center; University of Iowa; Danish Cancer Society; Beckman Research Institute; City of Hope National Medical Center; M.D. Anderson Cancer Center; Vanderbilt University School of Medicine; New York University School of Medicine; University of Chicago; University of California, Irvine; Stanford University
Recruiting - verified January 2012
Gene Expression Profiling and Genetic Analysis of Tissues From Patients With Breast Cancer

Condition: Breast Cancer
Interventions: Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Genetic: molecular genetic technique; Other: immunohistochemistry staining method
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; North Central Cancer Treatment Group; Southwest Oncology Group
Recruiting - verified April 2012
Developing Mouse Models of Breast Cancer Using Tissue Samples From Women With Breast Cancer

Condition: Breast Cancer
Interventions: Other: laboratory biomarker analysis; Other: medical chart review
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012
Collecting and Storing Tissue Samples From Women With or Without Breast Cancer

Condition: Breast Cancer
Intervention: Other: biologic sample preservation procedure
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012
Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer

Conditions: Non-melanomatous Skin Cancer; Pancreatic Cancer; Small Intestine Cancer; Testicular Germ Cell Tumor
Interventions: Genetic: in situ hybridization; Genetic: protein expression analysis; Other: immunologic technique
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012
Study of Breast Tissue in Women Not Previously Diagnosed With Breast Cancer Who Are Undergoing Fine Needle Aspiration

Conditions: Breast Cancer; Healthy, no Evidence of Disease
Interventions: Procedure: Random fine need aspiration (rFNA); Other: Mammogram
Sponsors: Northwestern University; Northwestern University; National Cancer Institute (NCI)
Recruiting - verified May 2012
Biomarkers in Predicting Outcome in Postmenopausal Women With Hormone Receptor-Positive, Node-Positive Breast Cancer Treated With Tamoxifen With or Without Cyclophosphamide, Doxorubicin, and Fluorouracil

Condition: Breast Cancer
Interventions: Genetic: comparative genomic hybridization; Genetic: microarray analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: diagnostic laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2008
Biomarkers in Predicting Response to Tamoxifen and Letrozole in Postmenopausal Women With Primary Breast Cancer Treated on Clinical Trial CAN-NCIC-MA17

Condition: Breast Cancer
Interventions: Genetic: microarray analysis; Genetic: polymerase chain reaction; Genetic: protein expression analysis; Other: diagnostic laboratory biomarker analysis; Other: fluorescent antibody technique; Other: immunohistochemistry staining method; Other: immunologic technique
Sponsors: National Cancer Institute (NCI); Massachusetts General Hospital; National Cancer Institute (NCI)
Recruiting - verified April 2008
Positron Emission Mammography and Standard Mammography in Women With Dense Breast Tissue or Who Are at High Risk of Breast Cancer

Condition: Breast Cancer
Interventions: Other: questionnaire administration; Procedure: digital mammography; Procedure: positron emission mammography
Sponsors: Boston Medical Center; Boston Medical Center; Department of Defense
Recruiting - verified February 2012
Identifying Circulating Breast Cancer Cells in Women With Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Other: flow cytometry; Other: fluorescence activated cell sorting; Other: immunohistochemistry staining method; Other: immunologic technique; Other: biomarker analysis
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Gene Expression in Tumor Tissue From Women Undergoing Surgery for Breast Cancer or Core Biopsy of the Breast

Condition: Breast Cancer
Interventions: Genetic: microarray analysis; Procedure: breast biopsy
Sponsors: Georgetown University; Georgetown University; National Cancer Institute (NCI)
Recruiting - verified October 2011
Enalapril Maleate and Doxorubicin Hydrochloride in Treating Women With Breast Cancer

Condition: Breast Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: enalapril maleate
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified May 2012
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Conditions: Breast Cancer; Hypercalcemia of Malignancy; Colon Cancer; Endocrine Cancer; Head and Neck Cancer; Kidney Cancer; Lung Cancer; Lymphoma; Metastatic Cancer; Multiple Myeloma; Parathyroid Neoplasms; Renal Cancer; Thyroid Cancer; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Non-Small Cell Lung Cancer
Intervention: Drug: denosumab
Sponsors: Amgen; Amgen
Recruiting - verified May 2012
Intellectual Impairment in Women With Breast Cancer

Condition: Breast Cancer
Interventions: Behavioral: Cognitive Rehabilitation; Behavioral: Neurofeedback Training (randomized)
Sponsors: Stanford University; Stanford University
Recruiting - verified April 2012
Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Panitumumab; Drug: Carboplatin; Drug: Gemcitabine
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Amgen; Eli Lilly and Company
Recruiting - verified October 2011
Topical Application of Sulforaphane-containing Broccoli Sprout Extracts on Radiation Dermatitis

Conditions: Breast Cancer; Dermatitis
Interventions: Other: Sulforaphane-containing broccoli sprout extracts (active agent); Device: Vehicle (inactive control)
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified April 2012
Premature Coronary Artery Disease (CAD) in Severe Psoriasis

Conditions: Psoriasis; Coronary Artery Disease
Intervention: Procedure: CCTA Scan (Coronary CT Angiogram)
Sponsors: University of Michigan; University of Michigan
Recruiting - verified August 2011
Pathogenesis of Physical Induced Urticarial Syndromes

Conditions: Autoinflammatory Syndromes; Physical Urticaria
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2011
A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis

Conditions: Anaphylaxis; Hypotension; Bronchospasm; Angioedema
Interventions: Drug: Epinephrine; Procedure: Bone Marrow Apsiration; Drug: Omalizumab (Xolair)
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified December 2011
Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer

Condition: Breast Neoplasms
Intervention: Biological: 9 Peptides from Her-2/neu, CEA, & CTA
Sponsors: University of Virginia; University of Virginia; National Institutes of Health (NIH)
Recruiting - verified April 2012
Dose-escalation Study of Oral CX-4945

Conditions: Advanced Solid Tumors; Breast Cancer; Inflammatory Breast Cancer; Castleman's Disease; Multiple Myeloma
Intervention: Drug: CX-4945 oral formulation
Sponsors: Cylene Pharmaceuticals; Cylene Pharmaceuticals
Recruiting - verified June 2011
Study to Evaluate The Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy

Condition: Urticaria
Intervention: Drug: abatacept (Orencia ®)
Sponsors: Johns Hopkins University; Johns Hopkins University; Bristol-Myers Squibb
Recruiting - verified October 2011
Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Carboplatin; Drug: Sunitinib; Drug: Paclitaxel; Drug: Carboplatin; Drug: Sunitinib
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Pfizer
Recruiting - verified March 2012
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index

Conditions: Psoriasis; Atopic Dermatitis
Interventions: Other: Blood pressure; Other: Height; Other: Weight; Other: BMI; Other: Waist Circumference
Sponsors: Northwestern University; Northwestern University
Recruiting - verified September 2011
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Everolimus; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Conditions: Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: assessment of therapy complications
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Alternate Dosing Schedules Study for HPV Vaccine

Conditions: Cervical Cancer; Genital Warts
Intervention:
Sponsors: Duke University; Duke University; Centers for Disease Control and Prevention
Recruiting - verified June 2011
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed By Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Two Dimensional (2D) Silicon Transducer-Compression Plates for Breast Ultrasound

Conditions: Breast Masses; Breast Cysts
Intervention: Procedure: Breast Ultrasound imaging
Sponsors: University of Michigan; University of Michigan; National Institutes of Health (NIH)
Recruiting - verified May 2012
Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer: Concordance Study

Condition: Breast Cancer
Intervention:
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center
Recruiting - verified August 2011
Acyclovir in Preventing Herpes Simplex Virus Infection in Patients With Neutropenia

Condition: Herpes Simplex
Intervention: Drug: acyclovir sodium
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified April 2012
A Qualitative Exploration of the Impact of Positive BRCA1/2 Mutation Status on the Lives of Young Women

Condition: Breast Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2011
Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Biological: pegfilgrastim; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Screening Protocol for Genetic Diseases of Mast Cell Homeostasis and Activation

Conditions: Piebaldism; Idiopathic Anaphylaxis; Allergy; Chronic Urticara; Angioedema
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011
Exercise for Breast Cancer Patients (EXCAP)

Condition: Breast Cancer Related Fatigue
Interventions: Behavioral: Exercise; Behavioral: Progressive walking and resistance exercise treatment
Sponsors: University of Rochester; University of Rochester; National Cancer Institute (NCI)
Recruiting - verified November 2011
Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases

Conditions: Systemic Lupus Erythematosus; Systemic Sclerosis
Intervention: Procedure: Nonmyeloablative allogeneic stem cell transplant
Sponsors: Duke University; Duke University
Recruiting - verified February 2012
Protocol For The Quantitation Of Pain In The Diagnosis Of Polymyalgia Rheumatica

Conditions: Polymyalgia Rheumatica; Rheumatoid Arthritis; Rheumatic Disease
Intervention:
Sponsors: Lahey Clinic; Lahey Clinic
Recruiting - verified February 2012
Cancer Screening and Prevention Program for High Risk Women

Conditions: Ovarian Cancer; Breast Cancer
Intervention: Other: screening
Sponsors: New York University School of Medicine; New York University School of Medicine; Lynne Cohen Foundation for Ovarian Cancer Research
Recruiting - verified November 2011
Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Biological: allogeneic GM-CSF-secreting breast cancer vaccine; Biological: trastuzumab; Drug: cyclophosphamide; Other: flow cytometry; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: biopsy
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Etanercept in Kawasaki Disease

Conditions: Mucocutaneous Lymph Node Syndrome; Kawasaki Disease
Interventions: Drug: Etanercept; Drug: Placebo
Sponsors: Seattle Children's Hospital; Michael Portman; FDA Office of Orphan Products Development; Amgen
Recruiting - verified April 2012
Broccoli Sprout Extract in Treating Women Who Have Had a Mammogram and Breast Biopsy

Conditions: Breast Cancer; Precancerous Condition
Interventions: Dietary Supplement: broccoli sprout extract; Other: placebo
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified February 2012
Can We Miss Pigmented Lesions in Psoriasis Patients?

Conditions: Psoriasis; Melanoma; Non-melanoma Skin Cancer
Intervention: Drug: etanercept
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; Amgen
Recruiting - verified August 2011
Brief Interventions to Increase HPV Vaccine Acceptance in School-based Health Centers

Condition: Human Papillomavirus Infection
Interventions: Behavioral: Compliance; Behavioral: Message sidedness
Sponsors: Indiana University; Indiana University; Merck
Recruiting - verified March 2012
Breast Cancers: Risk Factors Among Mexican Women in Mexico, Mexican-American and African-American Women in the U.S.

Condition: Breast Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012
Cytokine Expression During Radiation for Breast Cancer

Condition: Breast Cancer
Intervention: Radiation: radiation therapy
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified April 2012
An Observational Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Herceptin During Pregnancy or Within 6 Months Prior to Conception

Conditions: Breast Cancer; Pregnancy
Intervention:
Sponsors: Genentech; Genentech
Recruiting - verified November 2011
Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores

Conditions: Breast Neoplasms; Breast Cancer; Cancer of the Breast
Intervention: Drug: Docetaxel and Cytoxan
Sponsors: Emory University; Emory University; Sanofi-Aventis
Recruiting - verified February 2012
An Open-Label Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine+Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer (EMILIA)

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: lapatinib; Drug: capecitabine [Xeloda]
Sponsors: Genentech; Genentech
Recruiting - verified April 2012
Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Sorafenib and Ixabepilone; Drug: Sorafenib and Ixabepilone
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Bayer; Bristol-Myers Squibb
Recruiting - verified October 2011
Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: trastuzumab; Drug: agatolimod sodium; Other: Correlative Studies
Sponsors: Ohio State University Comprehensive Cancer Center; Ohio State University Comprehensive Cancer Center; Pfizer
Recruiting - verified November 2011
Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer

Condition: Breast Cancer
Intervention: Other: Blood draw and questionaires
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; New York Medical College; New York Presbyterian Hospital; Weill Medical College of Cornell University
Recruiting - verified January 2012
Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer

Conditions: Male Breast Cancer; Recurrent Breast Cancer; Skin Metastases; Stage IV Breast Cancer
Interventions: Drug: imiquimod; Drug: Abraxane; Other: laboratory biomarker analysis; Genetic: RNA analysis; Other: immunoenzyme technique
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Conditions: Metastatic Breast Cancer; Metastases, Brain
Interventions: Drug: capecitabine; Drug: lapatinib; Drug: trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194

Condition: Breast Cancer
Intervention: Drug: Dasatinib and Paclitaxel
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb
Recruiting - verified February 2012
Use of Botulinum Toxin to Treat Psoriasis

Condition: Psoriasis Vulgaris
Interventions: Procedure: injection of botulinum toxin type A.; Procedure: normal saline
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute
Recruiting - verified July 2011
Efficacy and Safety of Masitinib (AB1010) in Comparison to Placebo in the Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap

Conditions: Smouldering Systemic Mastocytosis; Indolent Systemic Mastocytosis; Cutaneous Mastocytosis With Handicap; Mastocytosis
Interventions: Drug: masitinib (AB1010); Drug: placebo
Sponsors: AB Science; AB Science
Recruiting - verified January 2012
Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency

Conditions: Menkes Disease; Occipital Horn Syndrome; Unexplained Copper Deficiency
Intervention: Drug: Copper Histidine
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified September 2011
A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer

Condition: Triple Negative Breast Cancer
Intervention: Drug: gemcitabine plus carboplatin plus BSI-201
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Breast Cancer Research Foundation
Recruiting - verified December 2011
Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer

Condition: Breast Cancer
Interventions: Drug: exemestane; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified December 2011
Clinical, Cellular, and Molecular Investigation Into Oculocutaneous Albinism

Conditions: Albinism; Oculocutaneous Albinism; Foveal Hypoplasia; Hypopigmentation; Nystagmus
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified May 2012
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Conditions: Breast Cancer; Breast Neoplasms; Breast Tumors; Cancer; Locally Recurrent and Metastatic Breast Cancer; Metastases; Metastatic Cancer; Oncology; Solid Tumors; Tumors
Interventions: Drug: AMG 386 15 mg/kg, Capecitabine and Lapatinib; Drug: AMG 386 15mg/kg, Paclitaxel and Trastuzumab; Drug: AMG 386 30 mg/kg, Paclitaxel and Trastuzumab; Drug: AMG 386 30 mg/kg, Capecitabine and Lapatinib; Drug: AMG 386 10 mgkg, Paclitaxel and Trastuzumab; Drug: AMG 386 10 mg/kg, Capecitabine and Lapatinib
Sponsors: Amgen; Amgen
Recruiting - verified March 2012
Chronic Plaque Psoriasis (Ps) Registry

Condition: Chronic Plaque Psoriasis
Intervention: Biological: HUMIRA® (adalimumab)
Sponsors: Abbott; Abbott
Recruiting - verified January 2012
Photon/Proton Beam Radiation Therapy for Carcinoma of the Skin of the Head and Neck

Condition: Head and Neck Cancer
Intervention: Radiation: Photon/Proton Beam Radiation Therapy
Sponsors: University of Florida; University of Florida
Recruiting - verified March 2012
Effects of Short-term Growth Hormone in HIV-infected Patients

Condition: HIV Lipodystrophy
Interventions: Drug: Growth hormone; Drug: Growth Hormone Releasing Hormone
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified April 2012
Trastuzumab in Treating Older Women With Early-Stage Breast Cancer

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Other: laboratory biomarker analysis; Procedure: adjuvant therapy; Procedure: quality-of-life assessment
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified December 2011
Chemotherapeutic Agents in Brain/Breast

Conditions: Breast Cancer; Metastatic Cancer
Interventions: Drug: capecitabine; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: gemcitabine hydrochloride; Drug: lapatinib ditosylate; Drug: paclitaxel; Drug: vinorelbine ditartrate; Drug: Trastuzumab
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; Department of Defense; National Cancer Institute (NCI)
Recruiting - verified May 2012
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents

Conditions: Solid Tumors; Neoplasms, Breast; Cancer
Interventions: Drug: Lapatinib in combination with an anti-cancer agent; Drug: Lapatinib; Drug: Lapatinib in combination with an anti-cancer agent as specified by parent protocol
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012
Vaccine Therapy in Treating Patients With Stage IV Breast Cancer

Conditions: HER2-positive Breast Cancer; Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
Interventions: Biological: HER-2/neu peptide vaccine; Procedure: leukapheresis; Biological: ex vivo-expanded HER2-specific T cells; Drug: cyclophosphamide; Other: laboratory biomarker analysis; Biological: sargramostim; Other: flow cytometry; Other: immunoenzyme technique; Genetic: gene expression analysis; Genetic: polymerase chain reaction
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Vaccine Therapy and Aldesleukin in Treating Women With Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Biological: allogeneic large multivalent immunogen breast cancer vaccine; Biological: aldesleukin
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified May 2012
TOBI to Monitor Response to Neoadjuvant Therapy in Breast Cancer

Condition: Breast Cancer
Intervention: Device: Near-Infrared Tomographic Optical Breast Imaging
Sponsors: Massachusetts General Hospital; Steven Isakoff, MD, PhD
Recruiting - verified April 2012
Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia

Condition: Leukemia
Intervention: Drug: Midostaurin
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Personalized Treatment Selection for Dasatinib in Metastatic Breast Cancer

Condition: Breast Cancer
Intervention: Drug: Dasatinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb
Recruiting - verified May 2012
Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.

Condition: Breast Cancer
Intervention: Drug: Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim
Sponsors: University of Tennessee Cancer Institute; University of Tennessee Cancer Institute; National Comprehensive Cancer Network; Celgene Corporation; Genentech
Recruiting - verified February 2012
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified April 2012
Permission to Collect Blood Over Time for Research

Conditions: Pancreatic Cancer; Gastrointestinal Neoplasms; Colon Rectal Cancer Adenocarcinoma; Esophageal Cancer; Gall Bladder Cancer; Gastric (Stomach) Cancer; Gastrooesophageal Cancer; Gastrointestinal Stromal Tumor (GIST); Hepatobiliary Neoplasm; Liver Carcinoma; Gallbladder Carcinoma; Bile Duct Carcinoma; Carcinoma of the Large Intestine; Anal Cancer
Intervention: Procedure: Observation
Sponsors: Stanford University; Stanford University
Recruiting - verified June 2011
Using Alternative Implants for the Surgical Treatment of Hip Fractures (The FAITH Study)

Condition: Femoral Neck Fractures
Interventions: Device: Open reduction internal fixation (ORIF) with single sliding hip screw; Device: ORIF with multiple cancellous screws
Sponsors: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Canadian Institutes of Health Research (CIHR); Stichting Nuts Ohra (SNO); Physicians Services Incorporated (PSI) Foundation
Recruiting - verified April 2012
Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy

Condition: Metastatic Breast Cancer
Intervention: Drug: lapatinib
Sponsors: University of Kansas; University of Kansas
Recruiting - verified October 2011
Obtaining and Storing Standard of Care Wound Biopsies for Immediate or Future Wound-Related Scientific Study

Conditions: Diabetic Foot; Leg Ulcer; Decubitus Ulcer
Intervention:
Sponsors: Southwest Regional Wound Care Center; Southwest Regional Wound Care Center
Recruiting - verified March 2012
Use of MRI and PET for Assessing Disease Activity in Takayasu's Arteritis

Condition: Takayasu Arteritis
Intervention:
Sponsors: Boston University; Peter A. Merkel; Office of Rare Diseases (ORD); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Rare Diseases Clinical Research Network
Recruiting - verified February 2012
A Phase I/II Clinical Trial of Vidaza With Abraxane in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer

Conditions: Advanced or Metastatic Solid Tumors; Advanced or Metastatic Breast Cancer
Interventions: Drug: Azacitidine (Vidaza); Drug: Nab-paclitaxel (Abraxane)
Sponsors: University of South Alabama; University of South Alabama; Celgene Corporation
Recruiting - verified August 2011
IDO Inhibitor Study for Relapsed or Refractory Solid Tumors

Conditions: Breast Cancer; Lung Cancer; Melanoma; Pancreatic Cancer; Solid Tumors
Intervention: Drug: 1-methyl-D-tryptophan
Sponsors: NewLink Genetics Corporation; NewLink Genetics Corporation
Recruiting - verified December 2011
Impaired Wound Healing in Diabetic Foot Ulceration

Conditions: Diabetes Mellitus; Healthy Volunteers
Intervention:
Sponsors: Beth Israel Deaconess Medical Center; Beth Israel Deaconess Medical Center; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified June 2011
Optical Spectroscopy During Breast Cancer Surgery and Core Needle Biopsy

Condition: Breast Cancer
Intervention:
Sponsors: Duke University; Duke University
Recruiting - verified February 2012
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer

Conditions: Estrogen Receptor-negative Breast Cancer; HER2-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Stage IV Breast Cancer; Triple-negative Breast Cancer
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation; Biological: bevacizumab; Drug: erlotinib hydrochloride; Other: immunohistochemistry staining method; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Digital Mammography: Computer-Aided Breast Cancer Diagnosis

Conditions: Breast Cancer; Breast Abnormalities
Intervention: Procedure: digital mammography
Sponsors: University of Michigan; University of Michigan
Recruiting - verified August 2011
Cryoablation Therapy in Treating Patients With Invasive Ductal Breast Cancer

Condition: Breast Cancer
Interventions: Procedure: cryosurgery; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified May 2012
Breast Lesion Analysis for Tomosynthesis Mammography

Conditions: Breast Cancer; Breast Abnormalities
Intervention: Procedure: Computer aided analysis of breast lesions
Sponsors: University of Michigan; University of Michigan; National Institutes of Health (NIH)
Recruiting - verified August 2011
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Drug: PD 0332991; Drug: letrozole; Drug: letrozole
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Safety and Efficacy Study of Daptomycin in Pediatric Subjects (2-17 Years)With Skin and Skin Structure Infections

Condition: Skin Diseases, Infectious
Interventions: Drug: Daptomycin; Drug: Vancomycin, Clindamycin or semi-synthetic Penicillins
Sponsors: Cubist Pharmaceuticals; Cubist Pharmaceuticals
Recruiting - verified February 2012
Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: exemestane; Drug: letrozole; Procedure: assessment of therapy complications
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified April 2012
Potential Research Study Participant Registry

Conditions: Acne; Actinic Keratosis; Dysplastic Nevi; Eczema; Psoriasis; Skin Cancer; Rosacea; Leg Ulcers; Foot Ulcers; Atopic Dermatitis
Intervention:
Sponsors: University of California, Davis; University of California, Davis
Recruiting - verified June 2011
Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials

Conditions: Aids-related Malignancies; Lymphoma; Precancerous Condition; Sarcoma
Interventions: Genetic: polymerase chain reaction; Other: cytology specimen collection procedure; Other: histological technique; Procedure: colposcopic biopsy
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified November 2011
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

Condition: Metastatic Breast Cancer
Interventions: Drug: Dasatinib + Letrozole; Drug: Letrozole
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; US Oncology Research
Recruiting - verified February 2012
Study of Selected X-linked Disorders: Goltz Syndrome

Conditions: Focal Dermal Hypoplasia (FDH); Goltz Syndrome; X Linked Disorders
Intervention:
Sponsors: Baylor College of Medicine; Baylor College of Medicine; National Institutes of Health (NIH); National Foundation for Ectodermal Dysplasias; March of Dimes
Recruiting - verified June 2011
Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children

Conditions: Breast Cancer; Hereditary Breast/Ovarian Cancer (brca1, brca2)
Interventions: Other: counseling intervention; Other: educational intervention; Other: survey administration; Behavioral: psychosocial assessment and care; Behavioral: supportive care
Sponsors: Georgetown University; Georgetown University; National Cancer Institute (NCI); National Human Genome Research Institute (NHGRI)
Recruiting - verified October 2011
Ultrasound Based Localization of Lumpectomy Bed in Anatomical Coordinate System

Conditions: Resected Breast Cancer; Breast Cancer
Intervention: Other: ultrasound scan
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified April 2012
Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis

Condition: Psoriasis
Interventions: Procedure: Narrow band (310-312 nm) ultraviolet light B phototherapy; Drug: etanercept
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified February 2012
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy

Condition: Lipodystrophy
Intervention: Drug: metreleptin
Sponsors: Amylin Pharmaceuticals, Inc.; Amylin Pharmaceuticals, Inc.
Recruiting - verified March 2012
Phase II Study of KW2871 Combined With High Dose Interferon-alpha2b in Patients With Metastatic Melanoma

Conditions: Metastatic Melanoma; Cutaneous Melanoma
Interventions: Drug: Interferon alpha; Drug: KW2871; Drug: KW2871; Drug: interferon alpha; Drug: KW2871; Drug: Interferon alpha
Sponsors: Ludwig Institute for Cancer Research; Ludwig Institute for Cancer Research; Life Sciences Pharmaceuticals
Recruiting - verified April 2012
Quantitative Analysis of Outcomes in Breast Reconstruction

Condition: Breast Cancer
Interventions: Behavioral: Questionnaire; Procedure: Digital Imaging
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Biological: Gene Modified T Cells; Biological: Gene Modified T Cells and Interleukin 2
Sponsors: Roger Williams Medical Center; Roger Williams Medical Center; Department of Defense
Recruiting - verified January 2012
A Breast Cancer Information Registry for Participants With Breast Cancer or Characteristics of Hereditary Breast Cancer

Conditions: Breast Cancer; Precancerous Condition
Interventions: Other: medical chart review; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: Excess human biological tissue; Procedure: quality-of-life assessment
Sponsors: University of Nebraska; University of Nebraska; National Cancer Institute (NCI)
Recruiting - verified June 2011
Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

Conditions: Breast Cancer; Depression; Hot Flashes; Psychosocial Effects of Cancer and Its Treatment
Interventions: Drug: citalopram hydrobromide; Drug: escitalopram oxalate; Drug: gabapentin; Drug: sertraline hydrochloride; Drug: tamoxifen citrate; Drug: venlafaxine; Genetic: molecular genetic technique; Other: high performance liquid chromatography; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: adjuvant therapy
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified April 2012
Use of Sodium Stibogluconate as a Treatment for Leishmaniasis

Condition: Leishmaniasis
Intervention: Drug: Sodium Stibogluconate (SSG)
Sponsors: U.S. Army Medical Research and Materiel Command; U.S. Army Medical Research and Materiel Command; Walter Reed Army Medical Center
Recruiting - verified May 2012
Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: ABI-007l albumin-stabilized nanoparticle formulation
Sponsors: Loyola University; Loyola University; Genentech
Recruiting - verified September 2011
IRS Proteins and Trastuzumab Resistance

Condition: Breast Cancer
Intervention:
Sponsors: University of Massachusetts, Worcester; University of Massachusetts, Worcester
Recruiting - verified February 2012
Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery

Condition: Breast Cancer
Interventions: Drug: letrozole; Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: biopsy; Procedure: therapeutic conventional surgery
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012
Predictive Blood Tests for Severe Radiation Reactions in Breast Cancer Patients

Condition: Abnormalities, Radiation-Induced
Intervention:
Sponsors: State University of New York - Upstate Medical University; State University of New York - Upstate Medical University; Carol M. Baldwin Breast Cancer Research Fund, Inc.
Recruiting - verified July 2011
Use of Organic Germanium or Placebo for the Prevention of Radiation Induced Fatigue

Conditions: Localized Breast Cancer; Localized Prostate Cancer; Patients Receiving External Beam Radiotherapy
Interventions: Dietary Supplement: Organic Germanium; Dietary Supplement: Placebo
Sponsors: Arizona Oncology Services; Arizona Oncology Services
Recruiting - verified June 2011
Tissue Expander/Implant Reconstruction: A Single-Blinded, Randomized, Controlled Trial

Condition: Breast Cancer
Interventions: Procedure: Alloderm, Questionnaires; Procedure: Without ALLODERM, Questionnaires
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; University of Michigan; University of North Carolina, Chapel Hill
Recruiting - verified December 2011
Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Sorafenib; Drug: Letrozole
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; Cancer Institute of New Jersey
Recruiting - verified June 2011
Vibro-Acoustography Imaging in Finding Breast Microcalcifications and Lesions in Women

Condition: Breast Cancer
Intervention:
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified July 2011
Optical Spectroscopy in Evaluating Tumor Margins in Patients Who Have Undergone Surgery for Breast Tumors

Condition: Breast Cancer
Interventions: Procedure: breast biopsy; Procedure: histopathologic examination; Procedure: light-scattering spectroscopy; Procedure: therapeutic conventional surgery
Sponsors: Vanderbilt University; Vanderbilt University; National Cancer Institute (NCI)
Recruiting - verified January 2012
Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis

Conditions: Systemic Scleroderma; Severe Systemic Sclerosis
Interventions: Drug: fludarabine phosphate; Drug: Mycophenolic Acid; Drug: tacrolimus; Radiation: total-body irradiation; Procedure: bone marrow transplantation; Procedure: reduced intensity allogeneic hematopoietic stem cell transplantation; Procedure: quality-of-life assessment; Other: laboratory biomarker analysis; Other: flow cytometry; Procedure: biopsy; Drug: cyclophosphamide
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012
Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12

Condition: Breast Cancer
Interventions: Biological: Dendritic Cell/Tumor Fusion Vaccine; Drug: Interleukin-12; Drug: Interleukin-12
Sponsors: Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Harvard University; Department of Defense; National Cancer Institute (NCI)
Recruiting - verified October 2011
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer

Conditions: Breast Cancer,; Advanced Solid Tumors,; Cowden Syndrome
Intervention: Drug: BEZ235
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified November 2011
Studying the Effect of Freeze-Dried Table Grape Powder on Blood Estrogen Levels in Postmenopausal Women

Condition: Breast Cancer
Interventions: Dietary Supplement: standardized freeze-dried table grape powder; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2012
Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Carboplatin; Drug: nab-paclitaxel; Drug: trastuzumab
Sponsors: Brown University; Debora G. Isdale; Yale University
Recruiting - verified February 2012
Studies of Skin Microbes in Healthy People and in People With Skin Conditions

Conditions: Atopic Dermatitis; Eczema; Ichthyosis Vulgaris
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified July 2011
Confocal Reflectance Microscopy of Shave-Biopsy Sites on Skin in Vivo.

Conditions: Basal Cell Carcinoma; Melanoma; Squamous Cell Carcinoma; Non-Malignant Skin Disorders
Intervention: Procedure: confocal microscopy in vivo
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Institutes of Health (NIH)
Recruiting - verified March 2012
Magnetic Resonance Imaging in Patients With Breast Cancer

Condition: Breast Cancer
Intervention: Procedure: MRI
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Doxil; Drug: Carboplatin; Drug: Bevacizumab
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; Cancer Institute of New Jersey
Recruiting - verified October 2011
Combined MRI and Optical Imaging to Improved Breast Cancer Diagnosis

Condition: Breast Cancer
Intervention: Device: combined optical and MR imaging
Sponsors: University of California, Irvine; University of California, Irvine
Recruiting - verified August 2011
Measuring Patient Satisfaction and Quality of Life Following Body Image Altering Surgery

Conditions: Breast Cancer; Breast Surgery; Breast Reconstruction; Breast Reduction; Breast Augmentation
Interventions: Behavioral: questionnaires; Behavioral: questionnaires
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; McMaster University; University College, London; Dartmouth-Hitchcock Medical Center; University of British Columbia; Johns Hopkins University; University of Pittsburgh
Recruiting - verified January 2012
Intensity Modulated Radiotherapy for Breast Cancer

Condition: Breast Cancer
Intervention: Radiation: IMRT
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified September 2011
In Vivo Confocal Microscopy of Cutaneous Neoplasms and Normal Skin

Condition: Skin Cancer
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2012
Collection of Tissue, Blood, and Cells to Be Used For Studying the Causes, Prevention, Diagnosis, and Treatment of Breast Cancer

Condition: Breast Cancer
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Memorial University Medical Center
Recruiting - verified February 2012
Quantitative Dynamic Contrast Enhanced Breast MRI

Condition: Breast Cancer
Intervention: Other: perform dynamic contrast enhanced (DCE) MRI
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Oregon Health and Science University; DeltaPoint,Inc.
Recruiting - verified December 2011
Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ

Conditions: Breast Cancer; Lobular Carcinoma; Invasive Breast Cancer
Intervention: Other: Tissue specimen
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012
Spectroscopy With Surface Coils and Decoupling

Conditions: Adrenal Cortical Cancer; Brain Cancer; Breast Cancer; CNS Cancer; Colon Cancer; HEENT Cancer; Hodgkin's Disease; Kaposi's Sarcoma; Liver Cancer; Lung Cancer; Non-Hodgkin's Lymphoma; Ovarian Cancer; Pancreatic Cancer; Prostate Cancer; Rectal Cancer; Renal Cancer; Sarcoma; Squamous Cell Carcinoma; Thyroid Cancer
Interventions: Device: Proton-decoupled 31P MRS at 1.5T; Device: 1H Spectroscopy at 1.5T and 3T
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Columbia University; University of Pennsylvania; St.George's Hospital (England); Royal Marsden NHS Foundation Trust; University Medical Center Nijmegen; Weill Medical College of Cornell University
Recruiting - verified February 2012
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients

Conditions: Breast Cancer; Colon Cancer; Prostate Cancer
Intervention: Genetic: PCR/PCR/LDR Strategy
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Columbia University; Weill Medical College of Cornell University
Recruiting - verified November 2011
Clinical Outcomes in Hereditary Cancer

Conditions: Breast Cancer; Pancreatic Cancer
Intervention: Other: Genotyping
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified November 2011
Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers

Conditions: Breast Neoplasms; Ovarian Neoplasms; Colonic Neoplasms; Prostatic Neoplasms; Uterine Cervical Neoplasms; Leukemia; Lymphoma, Non-Hodgkin
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2012
Clinical Significance of Germline BRCA Mutations

Condition: Breast Cancer
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012
Study of Breast Cancer Prevention by Letrozole in High Risk Women

Condition: Breast Cancer
Interventions: Drug: Letrozole; Drug: Placebo
Sponsors: University of Kansas; Carol Fabian, MD; Novartis; National Cancer Institute (NCI)
Recruiting - verified February 2012
Sentinel Lymph Node Biopsy Using Peritumoral Injection With Blue Dye Confirmation

Condition: Breast Cancer
Intervention: Procedure: Sentinel Node Biopsy
Sponsors: University of Arkansas; University of Arkansas
Recruiting - verified January 2012
Percutaneous Removal and Margin Ablation for Breast Cancer

Condition: Breast Cancer
Intervention: Procedure: Percutaneous Removal and Margin Ablation
Sponsors: University of Arkansas; University of Arkansas; Department of Health and Human Services; Ethicon Endo-Surgery; RITA Medical Systems
Recruiting - verified January 2012
Analyzing the Composition of Tears to Identify Cancer

Conditions: Breast Cancer; Ovarian Cancer; Colon Cancer; Benign Disease
Intervention: Other: Tear collection
Sponsors: University of Arkansas; University of Arkansas; Tenenbaum Family Foundation
Recruiting - verified January 2012
Safety Study of Modified Vaccinia Virus to Cancer

Conditions: Melanoma; Breast Cancer; Head and Neck Squamous Cell Cancer; Liver Cancer; Colorectal Cancer; Pancreatic Adenocarcinoma
Interventions: Biological: Vaccinia virus (vvDD-CDSR); Biological: Vaccinia virus (vvDD-CDSR); Biological: Vaccinia virus (vvDD-CDSR)
Sponsors: University of Pittsburgh; University of Pittsburgh
Recruiting - verified April 2012
Safety and Efficacy Study of FLT Radiolabeled Imaging Agent With PET Scan in Invasive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: 3'-Deoxy-3'-18F Fluorothymidine; Drug: 3'-Deoxy-3'-18F Fluorothymidine
Sponsors: American College of Radiology Imaging Network; American College of Radiology Imaging Network; Virginia Commonwealth University
Recruiting - verified April 2012
Axillary Reverse Mapping

Condition: Cancer of the Breast
Intervention: Procedure: Axillary Reverse Mapping
Sponsors: University of Arkansas; University of Arkansas
Recruiting - verified January 2012
10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus

Condition: Atopic Dermatitis
Intervention: Drug: Pimecrolimus
Sponsors: Valeant Pharmaceuticals International, Inc.; Valeant Pharmaceuticals International, Inc.; Clinical Research Computing Unit (University of Pennsylvania)
Recruiting - verified May 2012
Brain Mets - Capecitabine and WBRT

Condition: Breast Cancer
Interventions: Drug: sunitinib; Drug: capecitabine; Radiation: WBRT
Sponsors: Baylor Breast Care Center; Baylor Breast Care Center
Recruiting - verified January 2012
Study of Combined Fulvestrant and RAD001 in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure

Condition: Breast Cancer
Interventions: Drug: RAD001; Drug: Fulvestrant
Sponsors: University of Kentucky; University of Kentucky; Novartis
Recruiting - verified December 2011
Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Arimidex with Faslodex; Drug: Arimidex without Faslodex
Sponsors: Baylor Breast Care Center; Baylor Breast Care Center; AstraZeneca
Recruiting - verified January 2012
Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival & Frozen Tissue Sample

Conditions: Breast Cancer; Stomach Neoplasms; Salivary Gland Neoplasms; Thyroid Cancer
Intervention:
Sponsors: Stanford University; Stanford University
Recruiting - verified April 2012
Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis

Conditions: Breast Cancer; Bone Metastases
Interventions: Drug: Dasatinib; Drug: Zoledronic Acid
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb
Recruiting - verified March 2012
Lapatinib in Treating Women With Ductal Carcinoma In Situ of the Breast

Condition: Breast Cancer
Interventions: Drug: lapatinib ditosylate; Other: placebo
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI); Breast Cancer Research Foundation
Recruiting - verified November 2011
Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Letrozole; Drug: Letrozole
Sponsors: International Breast Cancer Study Group; International Breast Cancer Study Group
Recruiting - verified March 2012
Cognitive Changes Associated With Breast Cancer Treatment

Conditions: Breast Cancer; Cognitive Side Effects of Cancer Treatments; Stage I, II and III A Breast Cancer
Interventions: Behavioral: Questionnaires, MRI, Comet assay and Cell senescence; Behavioral: Questionnaires, MRI, Comet assay and Cell senescence; Behavioral: Questionnaires, MRI, Comet assay and Cell senescence
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Weill Medical College of Cornell University; The City College of New York; Brigham and Women's Hospital
Recruiting - verified February 2012
Calibrating Imaging Techniques to Study Blood Flow

Condition: Healthy Volunteers Only
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified June 2011
Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2

Conditions: Breast Cancer; Metastatic Cancer
Interventions: Drug: lapatinib ditosylate; Genetic: gene expression analysis; Other: diagnostic laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); University of California, San Francisco; National Cancer Institute (NCI)
Recruiting - verified July 2009
Outcomes of a DIEP Flap Program

Condition: Breast Cancer
Intervention:
Sponsors: Beth Israel Deaconess Medical Center; Beth Israel Deaconess Medical Center
Recruiting - verified February 2012
Vaccine Therapy in Treating Patients With Breast Cancer

Condition: Breast Cancer
Interventions: Biological: GP2 peptide + GM-CSF vaccine; Biological: GM-CSF (sargramostim); Biological: AE37 + GM-CSF vaccine; Biological: GM-CSF (sargramostim)
Sponsors: San Antonio Military Medical Center; San Antonio Military Medical Center; Antigen Express, Inc.; Norwell, Inc.
Recruiting - verified March 2012
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer

Conditions: Inflammatory Breast Cancer; Male Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
Interventions: Drug: sunitinib malate; Drug: paclitaxel; Drug: doxorubicin hydrochloride; Drug: cyclophosphamide; Biological: filgrastim; Procedure: therapeutic conventional surgery; Other: laboratory biomarker analysis; Other: flow cytometry
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012
Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Conditions: Psoriasis; Arthritis, Psoriatic
Interventions: Biological: ustekinumab; Biological: Biological therapies other than infliximab and ustekinumab; Drug: conventional systemic agents; Biological: infliximab
Sponsors: Centocor Ortho Biotech Services, L.L.C.; Centocor Ortho Biotech Services, L.L.C.
Recruiting - verified May 2012
Primary Breast Cancer Occurring Concomitant With Pregnancy

Conditions: Breast Cancer; Pregnancy
Interventions: Drug: 5-Fluorouracil; Drug: Cyclophosphamide; Drug: Doxorubicin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis

Conditions: Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous
Intervention: Drug: sodium stibogluconate (Pentostam)
Sponsors: University of California, San Francisco; University of California, San Francisco
Available - verified July 2007
Effects of Tibetan Yoga on Fatigue and Sleep in Cancer

Condition: Breast Cancer
Interventions: Behavioral: Tibetan Yoga; Behavioral: Stretching Program; Other: No Intervention; Behavioral: Questionnaire; Behavioral: Booster Program
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified December 2011
Strength and Range of Motion in Women Undergoing Surgery for Breast Cancer

Condition: Breast Cancer
Intervention: Other: physiologic testing
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified November 2011
Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Abraxane; Drug: Bevacizumab; Drug: Carboplatin
Sponsors: Duke University; Duke University; Genentech
Recruiting - verified June 2011
A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis

Condition: Atopic Dermatitis
Intervention:
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified March 2012
Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis

Conditions: Psoriasis; Metabolic Syndrome; Hyperlipidemia; Obesity; Hypertension
Intervention: Drug: Etanercept
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Amgen
Recruiting - verified February 2012
Inflammatory Breast Cancer (IBC) Registry

Condition: Breast Cancer
Interventions: Other: Interview; Procedure: Blood and Tissue Collection
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012
Spectral Diagnosis of Cutaneous Malignancy

Condition: Skin Cancer
Intervention: Device: Spectral Diagnosis Probe
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; University of Texas
Recruiting - verified March 2012
Delayed-Immediate Breast Reconstruction

Condition: Breast Cancer
Intervention: Procedure: Delayed-Immediate Breast Reconstruction
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Susan G. Komen Breast Cancer Foundation
Recruiting - verified April 2012
Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis

Condition: Psoriasis
Interventions: Drug: Imiquimod; Drug: Clobetasol (glucosteroid); Device: Excimer laser (UVB light) treatment
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; University Hospital Case Medical Center
Recruiting - verified February 2012
Abraxane and Alimta in Advanced Solid Tumors

Conditions: Breast Cancer; Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation; Drug: pemetrexed disodium
Sponsors: University of California, Davis; University of California, Davis; National Cancer Institute (NCI)
Recruiting - verified May 2012
Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome

Conditions: Hermansky-Pudlak Syndrome (HPS); Pulmonary Fibrosis; Oculocutaneous Albinism; Platelet Storage Pool Deficiency; Metabolic Disease
Interventions: Drug: Losartan; Drug: Zileuton; Drug: N-Acetylcysteine; Drug: Prevastatin; Drug: Erythromycin
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified December 2010
Therapeutic Approaches to HAART-Induced Lipodystrophy

Conditions: HIV Infections; Lipodystrophy
Intervention: Drug: Metreleptin (Leptin)
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center; Amylin Pharmaceuticals, Inc.
Recruiting - verified August 2011
Novel Therapies for Metabolic Complications of Lipodystrophies

Conditions: Insulin Resistance; Hypertriglyceridemia; Diabetes; Hepatic Steatosis
Intervention: Other: low-fat diet ( Still recruiting )
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center; National Institutes of Health (NIH); Takeda Global Research & Development Center, Inc.; Amylin Pharmaceuticals, Inc.
Recruiting - verified August 2011
SCT for Dyskeratosis Congenita or SAA

Conditions: Dyskeratosis Congenita; Aplastic Anemia
Interventions: Drug: Campath 1H; Drug: Cyclophosphamide; Drug: Fludarabine; Procedure: Total Body Irradiation; Procedure: Stem Cell Transplantation; Drug: ATG
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2012
Changes in Breast Density and Breast Cancer Risk in Women With Breast Cancer and in Healthy Women

Condition: Breast Cancer
Interventions: Other: physiologic testing; Other: screening questionnaire administration; Procedure: breast imaging study; Procedure: radiomammography; Procedure: study of high risk factors
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012
Optical Imaging of Skin Cancers for Margin Delineation of Non-melanoma Skin Cancers

Condition: Skin Cancer
Intervention: Procedure: Optical Imaging
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting - verified March 2012
Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients

Condition: Breast Cancer
Interventions: Drug: Trastuzumab; Drug: Bevacizumab; Drug: Docetaxel
Sponsors: Ohio State University Comprehensive Cancer Center; Ohio State University Comprehensive Cancer Center; Genentech; Case Comprehensive Cancer Center; University of Pittsburgh
Recruiting - verified April 2012
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Conditions: Metastatic Breast Cancer; Advanced Breast Cancer; Gastrointestinal Stromal Tumor; Hepatocellular Carcinoma; Metastasizing Breast Cancer (F); Metastatic Castration-Resistant Prostrate Cancer; Metastatic Renal Cell Cancer; Non Small Cell Lung Cancer; Pancreatic Islet Cell Carcinoma
Intervention: Drug: sunitinib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Regional Anesthesia and Breast Cancer Recurrence

Condition: Breast Neoplasms
Interventions: Drug: Sevoflurane; Drug: Sevoflurane
Sponsors: Outcomes Research Consortium; Outcomes Research Consortium
Recruiting - verified May 2012
BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain

Conditions: Brain and Central Nervous System Tumors; Breast Cancer; Cognitive/Functional Effects; Drug/Agent Toxicity by Tissue/Organ; Psychosocial Effects of Cancer and Its Treatment
Interventions: Biological: trastuzumab; Drug: carboplatin; Drug: methotrexate; Drug: sodium thiosulfate
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012
Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and Immunogenicity

Condition: Breast Cancer
Intervention: Biological: MAB HER 2 (HERCEPTIN)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012
Spousal Relationships and Pain in Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Behavioral: Questionnaire; Behavioral: Interview
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Department of Defense
Recruiting - verified May 2012
Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status

Conditions: Lymphedema; Breast Cancer
Intervention: Device: Flexitouch
Sponsors: Stanford University; Stanford University
Recruiting - verified October 2011
Treatment Decision Making Based on Blood Levels of Tumor Cells in Women With Metastatic Breast Cancer Receiving Chemotherapy

Condition: Breast Cancer
Intervention: Drug: chemotherapy
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified September 2011
Naltrexone in Treating Women With Metastatic Breast Cancer That Did Not Respond to Hormone Therapy

Condition: Breast Cancer
Interventions: Drug: naltrexone hydrochloride; Procedure: Positron-emission tomography (PET) / computed tomography (CT)
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2012
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients

Conditions: Systemic Sclerosis; Scleroderma; Pulmonary Hypertension; Pulmonary Arterial Hypertension
Intervention:
Sponsors: Georgetown University; Georgetown University; Gilead Sciences
Recruiting - verified October 2011
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Conditions: Breast Cancer; Cognitive/Functional Effects; Lung Cancer; Metastatic Cancer; Prostate Cancer
Interventions: Radiation: radiation therapy; Radiation: stereotactic radiosurgery
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI); American College of Surgeons; Eastern Cooperative Oncology Group; Radiation Therapy Oncology Group
Recruiting - verified July 2011
Education With or Without Exercise and Counseling in Preventing Lymphedema in Women With Stage I, Stage II, or Stage III Breast Cancer Who Are Undergoing Axillary Lymph Node Dissection

Conditions: Breast Cancer; Lymphedema; Perioperative/Postoperative Complications
Interventions: Behavioral: exercise intervention; Other: educational intervention; Procedure: assessment of therapy complications; Procedure: complementary or alternative medicine procedure; Procedure: management of therapy complications; Procedure: quality-of-life assessment; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
T Cell Repertoire Analysis of Immune Mediated Skin Diseases

Conditions: Psoriasis; Mycosis Fungoides
Intervention:
Sponsors: University of California, Davis; University of California, Davis
Recruiting - verified June 2011
Investigation of Southern Tick-Associated Rash Illness (STARI)

Condition: Southern Tick-Associated Rash Illness
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012
A Study to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Blood of Stage IV Breast Cancer Patients

Condition: Breast Neoplasms
Interventions: Other: Blood draw; Other: Blood draw
Sponsors: Washington University School of Medicine; Washington University School of Medicine; National Institutes of Health (NIH)
Recruiting - verified September 2011
Effect of Chemotherapy Administered Before Surgery on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

Condition: Breast Neoplasms
Intervention: Procedure: Biopsies for tissue and blood collection
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified September 2011
Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer

Condition: Breast Cancer
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Drug: lyso-thermosensitive liposomal doxorubicin; Procedure: hyperthermia treatment
Sponsors: National Cancer Institute (NCI); Duke Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified October 2007
Diagnosis and Treatment of Leishmanial Infections

Condition: Leishmaniasis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2012
Genetic Analysis of Patients With Pseudoxanthoma Elasticum

Conditions: Pseudoxanthoma Elasticum; PXE
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Conditions: Breast Cancer; Neoplasm Metastasis
Interventions: Other: Standard supportive care (packed RBC transfusion); Drug: epoetin alfa + packed RBC transfusion
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer

Condition: Neoplasms, Breast
Intervention: Drug: lapatinib + capecitabine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Expanded Breast Cancer Registry and Tissue Repository

Condition: Breast Cancer
Intervention:
Sponsors: New Mexico Cancer Care Alliance; New Mexico Cancer Care Alliance
Recruiting - verified April 2012
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Condition: Breast Cancer
Intervention: Drug: Zometa® (zoledronic acid)
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Determining Disease Activity Biomarkers in Individuals With Polyarteritis Nodosa

Condition: Polyarteritis Nodosa
Intervention:
Sponsors: Boston University; Boston University; Office of Rare Diseases (ORD); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Rare Diseases Clinical Research Network
Recruiting - verified February 2012
Determining Disease Activity Biomarkers in Individuals With Giant Cell Arteritis

Condition: Temporal Arteritis
Intervention:
Sponsors: Boston University; Peter A. Merkel; Office of Rare Diseases (ORD); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Rare Diseases Clinical Research Network
Recruiting - verified February 2012
Determining Disease Activity Biomarkers in Individuals With Takayasu's Arteritis

Condition: Takayasu's Arteritis
Intervention:
Sponsors: Boston University; Boston University; Office of Rare Diseases (ORD); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Rare Diseases Clinical Research Network
Recruiting - verified February 2012
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: chemotherapy; Drug: exemestane; Drug: letrozole; Drug: tamoxifen citrate
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; American College of Surgeons; North Central Cancer Treatment Group; NCIC Clinical Trials Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified July 2011
Telephone-Based Genetic Counseling or Standard Genetic Counseling in Women at Risk of Carrying the BRCA1 or BRCA2 Mutation

Condition: Breast Cancer
Interventions: Genetic: mutation analysis; Other: counseling intervention
Sponsors: Georgetown University; Georgetown University; National Cancer Institute (NCI)
Recruiting - verified October 2011
Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Systemic Sclerosis

Condition: Scleroderma
Intervention: Biological: Hematopoietic stem cell transplantation
Sponsors: Northwestern University; Richard Burt, MD
Recruiting - verified April 2012
Quality of Life in African-American or Caucasian Female Breast Cancer Survivors

Conditions: Breast Cancer; Cancer Survivor; Depression; Fatigue; Sexual Dysfunction; Sleep Disorders; Spiritual Concerns
Interventions: Other: study of socioeconomic and demographic variables; Procedure: fatigue assessment and management; Procedure: management of therapy complications; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Indiana University Melvin and Bren Simon Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2007
Studies of Disorders in Antibody Production and Related Primary Immunodeficiency States

Conditions: Hyper-IgM Syndrome; Ectodermal Dysplasia
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012
Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Biological: sargramostim; Biological: therapeutic autologous dendritic cells; Biological: trastuzumab; Drug: vinorelbine ditartrate
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Precancerous Condition
Interventions: Biological: therapeutic allogeneic lymphocytes; Drug: busulfan; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: peripheral blood stem cell transplantation; Radiation: Total Body Irradiation (TBI); Drug: Granulocyte colony-stimulating factor (G-CSF); Drug: Phenytoin; Drug: Methotrexate
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified March 2012
Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients

Condition: Breast Cancer
Interventions: Drug: Taxotere; Drug: Adriamycin/Cytoxan; Drug: docetaxol; Drug: doxorubicin
Sponsors: Baylor Breast Care Center; Baylor Breast Care Center; Baylor College of Medicine
Recruiting - verified November 2011
Yoga-Based Cancer Rehabilitation Program

Conditions: Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms
Intervention: Behavioral: Yoga
Sponsors: Albert Einstein College of Medicine of Yeshiva University; Albert Einstein College of Medicine of Yeshiva University; National Cancer Institute (NCI); The Jacob and Valeria Langeloth Foundation
Recruiting - verified February 2012
Stem Cell Transplant for Hemoglobinopathy

Conditions: Sickle Cell Disease; Thalassemia; Severe Congenital Neutropenia; Diamond-Blackfan Anemia; Shwachman-Diamond Syndrome
Interventions: Drug: Busulfan, Fludarabine, ATG, TLI; Drug: Busulfan, Cyclophosphamide, ATG, GCSF; Drug: Campath, Fludarabine, Cyclophosphamide; Radiation: Total Body Irradiation; Procedure: Stem cell infusion
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota; National Marrow Donor Program
Recruiting - verified April 2012
Upstaging of ALH/LCIS Found on Core Biopsy Based on Subsequent Excisional Biopsy

Condition: Breast Neoplasms
Intervention:
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital
Recruiting - verified July 2011
Analysis of Lyme Disease Lesions

Conditions: Erythema Migrans Lesions; Erythema Migrans
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012
Doxorubicin, Cyclophosphamide, and/or Paclitaxel in Treating Women With Nonmetastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: AC regimen; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Duke Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified April 2008
Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer

Condition: Breast Cancer
Interventions: Radiation: 3-dimensional conformal accelerated partial breast irradiation; Radiation: brachytherapy; Radiation: whole breast irradiation
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Radiation Therapy Oncology Group; Southwest Oncology Group
Recruiting - verified May 2012
MRI Using Ferumoxytol in Patients With Primary Brain Cancer or Brain Metastases From Lung or Breast Cancer

Condition: Brain Neoplasms
Intervention: Drug: ferumoxytol
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI); National Institutes of Health (NIH)
Recruiting - verified March 2012
Retinoids for Minimal Change Disease and Focal Segmental Glomerulosclerosis

Conditions: Kidney Diseases; Glomerulosclerosis, Focal
Interventions: Procedure: Kidney needle biopsy; Procedure: DEXA Scan; Procedure: X-rays; Drug: Retinoids for Podocyte Disease
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified October 2011
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Myelodysplastic Syndromes; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Disseminated Neuroblastoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; High Risk Metastatic Gestational Trophoblastic Tumor; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Previously Treated Childhood Rhabdomyosarcoma; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage II Ovarian Epithelial Cancer; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Malignant Testicular Germ Cell Tumor; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Ovarian Epithelial Cancer; Stage III Small Lymphocytic Lymphoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Breast Cancer; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Ovarian Epithelial Cancer; Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: pentostatin; Biological: therapeutic allogeneic lymphocytes; Drug: mycophenolate mofetil; Drug: cyclosporine
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer

Condition: Breast Cancer
Interventions: Drug: paclitaxel; Genetic: microarray analysis; Procedure: biopsy; Procedure: neoadjuvant therapy; Drug: Paclitaxel
Sponsors: Georgetown University; Georgetown University; National Cancer Institute (NCI)
Recruiting - verified October 2011
Progression of Spinal Fusion in Ankylosing Spondylitis

Condition: Spondylitis, Ankylosing
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified January 2012
Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease

Conditions: Nervous System Malformations; Arthropathy, Neurogenic; Urticaria; Papilledema
Intervention: Drug: Anakinra
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified November 2011
Studies of the Natural History and Pathogenesis and Outcome of Neonatal Onset Multisystem Inflammatory Disease (NOMID/CAPS, DIRA, CRMO, Still's Disease, Behcet's Disease, and Other Undifferentiated Autoinflammatory Diseases)

Conditions: Urticaria; Arthropathy; Lymphadenopathy; Nervous System Anomalies
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified January 2012
Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study

Condition: Ankylosing Spondylitis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified February 2012
Clinically Important Changes in Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified February 2012
Study of Families With Twins or Siblings Discordant for Rheumatic Disorders

Conditions: Rheumatic Diseases; Rheumatoid Arthritis; Systemic Lupus Erythematosus; Scleroderma; Dermatomyositis; Myositis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Environmental Health Sciences (NIEHS)
Recruiting - verified November 2011
Cause and Natural Course of Pediatric-Onset Mastocytosis

Condition: Mastocytosis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012
Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum

Condition: Xeroderma Pigmentosum
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012
Study of Factors Regulating Mast Cell Proliferation

Condition: Mastocytosis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012
Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer

Conditions: Breast Neoplasms; Ovarian Neoplasms
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011
Cell Lines From High-Risk Breast Tissue

Condition: Healthy
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2011
Blood Component Collection From Patients With Rheumatic Disease and Healthy Volunteers

Conditions: Rheumatic Diseases; Healthy
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified January 2012
High-Risk Breast Duct Epithelium

Conditions: Breast Neoplasms; Healthy
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012
Cancer in Inherited Bone Marrow Failure Syndromes

Conditions: Fanconi's Anemia; Anemia, Diamond Blackfan; Dyskeratosis Congenital; Thrombocytopenia; Neutropenia
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012
Screening Patients for NCI Protocol Eligibility

Conditions: Cancer; HIV Infection; Skin Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012
Morbidity After Diagnosis and Treatment of Breast Cancer Patients

Condition: Breast Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institutes of Health Clinical Center (CC)
Recruiting - verified March 2012
Leptin to Treat Lipodystrophy

Condition: Lipodystrophy
Intervention: Drug: Metreleptin
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified November 2011
Natural History of Rheumatic Diseases in Minority Communities

Condition: Rheumatic Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified October 2011
Study of Mycobacterial Infections

Conditions: Atypical Mycobacterium Infections; Cystic Fibrosis; Job's Syndrome
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011
Adult and Juvenile Myositis

Conditions: Dermatomyositis; Polymyositis; Idiopathic Inflammatory Myopathy; Healthy
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Environmental Health Sciences (NIEHS)
Recruiting - verified September 2011
Study of Arthritis and Related Conditions

Conditions: Arthritis; Synovitis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified October 2011
Evaluation and Treatment of Patients With Dermatologic Diseases

Conditions: Connective Tissue Disease; Skin Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified May 2012
The Acquisition of Blood and Skin Samples From Normal Volunteers to Support Research Activities on Dermatologic Diseases

Conditions: Healthy; Skin Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified May 2012
Follow-up Protocol for Patients With Cancer/AIDS/Skin Disease

Conditions: Acquired Immunodeficiency Syndrome; Neoplasm; Skin Disease; HIV Infections
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012
Continuing Care and Treatment for Patients With Cancer/AIDS/Skin Disease

Conditions: Acquired Immunodeficiency Syndrome; Neoplasm; Skin Disease; HIV Infections
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012
Study and Treatment of Inflammatory Muscle Diseases

Conditions: Autoimmune Disease; Dermatomyositis; Inclusion Body Myositis; Myositis; Polymyositis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified August 2011
Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics

Condition: Periodic Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified April 2012
Study of Systemic Lupus Erythematosus

Conditions: Lupus Nephritis; Systemic Lupus Erythematosus
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified January 2012
Genetic Basis of Primary Immunodeficiencies

Condition: Immunologic Deficiency Syndrome
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified October 2011
Host Response to Infection and Treatment in Filarial Diseases

Conditions: Filariasis; Helminthiasis; Loiasis; Mansonelliasis; Onchocerciasis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012
Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy

Conditions: Cockayne Syndrome; Skin Neoplasm; Xeroderma Pigmentosum
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified June 2011
Clinical and Basic Investigations Into Hermansky-Pudlak Syndrome

Conditions: Albinism; Intestinal Disease; Kidney Disease; Myocardial Disease; Pulmonary Fibrosis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified August 2011
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex

Conditions: Cushing's Syndrome; Hereditary Neoplastic Syndrome; Lentigo; Neoplasm; Testicular Neoplasm
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified June 2011
Study of Mast Cell Precursors

Condition: Mastocytosis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2012